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 i 
Abstract 
 
γδ T-cells are unconventional lymphocytes hypothesised to act at the interface between innate 
and adaptive immunity. Emerging evidence indicates γδ T-cells play important, non-
redundant roles in lymphoid stress surveillance during infection and tumourigenesis, and γδ 
T-cell-focussed immunotherapy trials suggest their potential exploitation in cancer 
immunotherapy. However, the molecular basis of γδ TCR/ligand recognition is poorly 
understood. In this thesis I first focussed on ligand recognition by the LES TCR, which is 
derived from a Vδ2-negative T-cell and mediates TCR-dependent recognition of CMV-
infected cells and tumour cell lines by binding to Endothelial Protein C Receptor (EPCR). 
After producing LES TCR in a conformationally correct form, I used mutagenesis to map the 
LES TCR binding site on EPCR. Importantly, EPCR was recognised independently of bound 
lipid, suggesting it acts as a stress ligand rather than an antigen presenting molecule, and 
highlighting the importance of TCR-extrinsic factors in recognition. Secondly, I determined 
an NMR structure of Skint-1, a selecting ligand for mouse skin-resident DETC γδ T-cells that 
play important roles in immunoregulation and tumour immunosurveillance. This emphasised 
structural features unique to Skint-1, and suggested interaction with a separate ligand, such as 
the DETC TCR. Collectively, these studies improve understanding of γδ T-cell recognition.  
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CHAPTER 1 – 
GENERAL INTRODUCTION  
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Chapter 1: Introduction 
 
1.1 Vertebrate adaptive immunity 
The vertebrate immune system appears to have evolved mainly to fight infection and is 
composed of two major arms: the innate and adaptive immune systems. The innate immune 
system probably evolved as a mechanism to protect against infection with common 
pathogens. The primary activators of innate immunity are innate pattern recognition receptors 
(PRRs), which include toll-like receptors (TLRs) (Medzhitov et al, 1997). The TLRs on 
dendritic cells (DC) and monocytes sense pathogen-associated molecular patterns (PAMPs) 
(Yang et al, 1998) and initiate effector responses such as phagocytosis, cytokine production 
and activation of the adaptive immune system. The innate immune system also includes 
Natural Killer (NK) cells, which detect pathogen infected cells through activating and 
inhibitory receptors on the cell surface. 
 
The second arm to the immune system is the adaptive system, which evolved approximately 
350-400 million years ago in jawed vertebrates. While PRRs are crucial to efficient activation 
of the innate immune system, the adaptive immune system evolved to use somatic gene 
rearrangement to generate diverse repertoire antigen receptors capable of detecting foreign 
molecules. Cells expressing useful receptors are amplified by clonal selection, and can be 
committed to immunological memory to provide faster responses upon secondary infection. 
The cells mainly responsible for adaptive immunity are B lymphocytes and αβ T 
lymphocytes. Whereas B cells recognise antigen through their cell surface B cell receptor 
(BCR) T cells use a homologous receptor termed the T cell receptor (TCR) (Hedrick et al, 
1984a; Hedrick et al, 1984b). Most T cells use an αβ TCR, but there is a subpopulation of T 
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lymphocytes which express a different antigen receptor on the cell surface, a γδ T cell 
receptor (TCR). γδ T cells also use somatic rearrangement to generate their TCR, but the 
antigens recognised by the γδ TCR remain poorly understood. Also, since γδ T cells express 
many innate NK-like receptors, this potentially places them at the border of innate and 
adaptive immunity. This thesis focuses on molecular recognition by γδ T cells.  
 
1.2 Antigen receptors 
Adaptive immune cells possess the ability to recognise foreign molecules by the expression of 
unique antigen receptors expressed on their surface. The interaction of receptor with specific 
antigen initiates an intracellular signalling cascade which results in a variety of effector 
responses. In B cells, antigen binding to the B cell receptor (BCR) or surface immunoglobulin 
(Ig) leads to cellular differentiation and production of secreted Ig, or antibodies (Ab), while 
antigen recognition by T cells through their (TCR) leads to cytokine secretion or cytotoxicity. 
 
The antigen receptors expressed by B cells and T cells are multimeric proteins grouped within 
immunoglobulin superfamily (IgSF). Antibodies are composed of two Ig heavy chains (IgH) 
and two Ig light chains (IgL). Each IgH consists of four domains of 110 amino acids, while 
each IgL chain consists of two such domains. Each 110 amino acid domain is called an Ig 
domain, and folds into 7-9 β-strands that form two anti-parallel β-sheets, stabilised by a 
disulphide bond. Disulphide bonds link the IgL to the IgH, as well as linking the two IgH 
chains in each antibody. Antibodies can be cleaved with the enzyme papain to generate three 
fragments. Two contain the antigen binding site and are called the Fragment antigen binding 
(Fab), while the other fragment is called the Fragment crystallisable (Fc), as this fragment was 
found to crystallise easily.  
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The antigen binding region of the Fab is confined to the N-terminal Ig domains of IgH and 
IgL. These domains have high sequence variability and are termed Ig variable (V) domains. 
The Ig domains not involved in antigen binding are less variable and are classed as Ig 
constant (C) regions. The Fc region of the antibody contains two C domains and is important 
for interactions with Fc receptors on innate cells, and with the complement cascade, which 
lead to clearance of pathogens.  
 
Sequence variability within the V regions of IgH and IgL is focussed in three hypervariable 
regions in each chain (Wu and Kabat, 1970). These hypervariable regions correspond to the 
loop regions on the structure of a folded Ig protein. The three IgH hypervariable loops and 
three IgL hypervariable loops determine the antigen specificity, partly by establishing surface 
complementary to the antigen (Wilson et al, 1991), and therefore these loops were designated 
complementarity-determining regions (CDRs). The sequences in between the CDRs in the 
linear sequence are less variable and form the core β strands that provide the structure to the 
Ig fold, and are described as framework regions.  
 
The vast variability of foreign antigens might suggest an equally vast number of possible 
antigen receptors genes, and yet the genome cannot possibly separately encode antigen 
receptors for all possible antigens. Instead, a process of gene rearrangement has evolved that 
enables production of a highly diverse receptor repertoire from limited genetic material. 
Antigen receptor genes are recombined from individual gene segments, a process involving 
DNA rearrangement and described as somatic recombination (Hozumi and Tonegawa, 1976). 
This process requires V (D) J recombinase enzymes, especially the recombination activating 
genes RAG-1 and RAG-2. In B cells, IgH recombination involves the joining of any of 250-
 5 
1000 variable (VH) gene segments to one of ten diversity (DH) gene segments and to one of 
four joining (JH) gene segments (Table 1.1). The rearranged sequence is then spliced to the 
constant domain in the mRNA. These potential 40,000 V(D)J combinations can be further 
diversified by the addition of non-template nucleotides at regions of V(D)J joins by the 
lymphoid specific enzyme terminal deoxynucleotidyl transferase (TdT). The repertoire is 
increased further by the pairing of a rearranged IgH with a rearranged IgL. All these 
mechanisms result in the production of diverse antibody specificities which can recognise a 
plethora of different antigens. 
 
The structure of TCRs is similar to immunoglobulins (Hedrick et al, 1984b), and TCR 
domains are therefore included in the IgSF. However, TCRs, unlike Ig, exist only in a 
membrane bound form. The majority of T cells express a heterodimeric TCR that is made up 
of α and β chains, while a small percentage express a γδ TCR. Each TCR chain consists of 
two extracellular Ig domains, composed of a membrane-distal V domain and a membrane-
proximal C domain, as well as a transmembrane domain and short cytoplasmic tail. The two 
chains are connected by a disulphide bond located near the transmembrane domain. Amino 
acids in the transmembrane domain of the TCR chains facilitate association with the CD3 
signalling complex.  
 
The membrane distal domains of the TCR contain high sequence variation and are classed as 
IgV domains, while the membrane proximal domains do not vary in sequence and are classed 
as IgC domains. Similar to Ig, the variable domains of TCR chains each have three 
hypervariable regions which are also defined as complementarity determining regions (CDR), 
and the three CDR loops of TCRα combine with the three CDR loops of TCRβ to form the 
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antigen binding site. Like Ig, TCRs use gene rearrangement mediated by RAG-1 and RAG-2 
to generate diverse TCRs to recognise foreign antigen. The TCRα and β gene loci contain 
fewer V gene segments than IgH and IgL, but more J segments (Table 1.1). In addition, the 
TCRβ chain uses D gene segments as does IgH, and as with Ig, diversity can be increased by 
N-nucleotide addition (Davis and Bjorkman, 1988). 
 
1.3 Antigen recognition by conventional αβ T cells 
Unlike B cells, αβ T cells do not recognise intact antigen. Instead, as demonstrated initially by 
Zinkernagel and Doherty (Zinkernagel and Doherty, 1974), αβ T cells are able to recognise 
antigen in a way that is restricted by self-encoded molecules of the major histocompatibility 
complex (MHC), which are able to bind and present short peptide fragments derived from 
foreign antigens directly to T cells (reviewed in Townsend et al, 1989). In humans, the MHC 
locus is termed the Human Leukocyte Antigen (HLA) locus, while in mice it is referred to as 
the histocompatibility 2 (H-2) complex. The functional consequence of peptide-MHC binding 
depends on which type of MHC molecule is presenting antigen, and which class of T cell is 
activated.  
 
1.3.1 Conventional αβ T cell subsets  
Conventional T cells are classified by their expression of CD4 or CD8 coreceptors, and these 
cell types exhibit different effector functions. CD8 αβ T cells recognise peptides derived from 
intracellular pathogens presented by MHC class I molecules (HLA-A, B and C in humans), 
differentiate into cytotoxic T lymphocytes (CTLs), which are able to kill infected cells. CD4 
αβ T cells recognise peptides generated from extracellular pathogens presented by-MHC class 
II molecules, and can be subdivided further into subpopulations of T helper cells, based on the 
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profile of cytokines they produce (Mucida et al, 2010). TH1 cells develop in the presence of 
IL-12, and secrete IFN-γ and TNFα, which enhance the killing of NK and CTL, and the 
microbicidal properties of macrophages. TH2 cells develop in the presence of IL-4, and 
secrete cytokines which enhance B cell activation, differentiation and antibody secretion. 
TH17 cells are a recently described subset that develops in the presence of IL-6 and TGFβ and 
produces IL-17 and IL-22 upon activation (Korn et al, 2009). TH17 cells are crucial for the 
recruitment of innate cells such as neutrophils to the site of infection. Another important 
subset of T cells is the regulatory T cells (Tregs) (Vignali et al, 2008). These can be 
subdivided into natural Treg which develop in the thymus, or induced Treg which 
differentiate following infection in the presence of TGFβ and IL-2. When Treg cells recognise 
peptide antigen they suppress the activation of other specific T cells via production of 
immunosuppressive cytokines such as IL-10 and TGF-β, and also cell-cell contact-dependent 
mechanisms, so preventing autoimmune reactions or dampening down the immune response 
to prevent immunopathology. 
 
1.3.2 Molecular mechanisms underlying αβ T cell recognition 
Experiments by Townsend and colleagues proved that T cells recognise small protein 
fragments, peptides, which are directly presented by self MHC molecules on the cell surface 
(Townsend et al, 1989). This recognition of “altered self” is carried out by the TCR which can 
directly bind to pathogen derived peptides in the context of self-MHC molecules. The 
interaction of TCRs with pathogen peptide MHC complex leads to cell signalling which 
induces cellular responses such as proliferation, differentiation and cytokine secretion. T cell 
recognition is dependent upon a whole range of protein-protein interactions that occur 
between T cell and target cell (van der Merwe and Davis, 2003), culminating in efficient TCR 
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triggering. In addition to the TCR/MHC interaction itself, the simultaneous binding of 
coreceptor (CD4 or CD8) to the peptide-MHC molecule is crucial in enhancing the sensitivity 
of antigen recognition. The coreceptors are able to bind to the non polymorphic region of the 
MHC molecule, and these interactions are weaker than, and occur after, TCR interaction with 
the MHC. A number of other interactions, including CD2/CD48, LFA-1/ICAM1 interactions, 
and costimulatory receptor/ligand interactions are critical in these processes (van der Merwe 
and Davis, 2003). As a result, TCR triggering occurs, resulting in stimulation of intracellular 
signalling cascades. Several models have been proposed to explain how TCR triggering 
occurs, involving either receptor aggregation, receptor conformational change, or kinetic 
segregation of the TCR-CD3 complex. While these are still debated, a growing body of data 
support the idea that segregation of TCR/MHC complexes into zones of close contact that 
exclude the T cell phosphatase CD45 is important in initial triggering, a key point of the 
kinetic segregation model (Davis and van der Merwe, 2006). Following triggering, active 
rearrangement of the T cell/target cell interface culminates in formation of the immune 
synapse (Huppa and Davis, 2003), whereby some of the key cell surface molecules involved 
are separated into distinct zones at the interface. Although the function of the immune synapse 
is somewhat unclear, one possibility is that it facilitates targeted secretion of effector 
molecules to the target cell. 
 
1.3.3 Thymic selection of αβ T cells 
TCR gene rearrangement can produce a vast TCR repertoire up to 10
15
 unique αβ TCR 
sequence combinations, and up to 10
18
 unique γδ TCR sequence combinations, however many 
of these possible TCR combinations may not be able to recognise self MHC, rendering them 
useless, or may recognise self-peptide/MHC too strongly, potentially leading to autoimmune 
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disease. In order to prevent maturation of such ineffective or potentially dangerous 
specificities, T cells undergo positive and negative selection in the thymus during T cell 
development (Stritesky et al, 2012).  
 
Initially thymocytes are double negative for the expression of the coreceptors CD4 and CD8 
and the TCRβ locus undergoes rearrangement. After assembly of a productively rearranged 
TCRβ chain with the pre-TCRα chain and the CD3 signalling complex, proliferation of the T 
cell occurs and expression of both CD4 and CD8 coreceptors is upregulated, and at this stage 
the cell is defined as a double positive T cell. Double positive T cells then undergo positive 
selection for the ability to recognise self MHC complexes. The majority of TCRs generated 
cannot recognise self peptide-self MHC and so are not positively selected, eventually dying 
by neglect (Figure 1.1). The cells which are positively selected mature and express high levels 
of TCR. At this stage they cease to express one of the coreceptors based on TCR signal 
strength during positive selection, and become single positive CD4 or CD8 T cells. These 
single positive T cells express TCRs with a wide range of affinities for MHC molecules. T 
cells which express potentially high affinity TCRs will undergo negative selection, leading to 
death by apoptosis (Figure 1.1). This lowers the probability of autoimmune disease and 
allows survival of T cells that weakly recognise self MHC molecules (Figure 1.1) and have 
the potential for specificity for foreign antigens in a self-MHC context.  
 
The mature T cell pool is therefore composed of T cells that express TCRs of moderate 
affinity for self-MHC (Carreño et al, 2006). Positive and negative selection of γδ T cells will 
be discussed later. 
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Figure 1.1 Development of T cells is dependent on TCR-pMHC binding kinetics. The model 
proposed by Carreño et al, (2006) suggests that thymocyte positive selection occurs as a result 
of TCR/pMHC interactions within an intermediate range of half-lives. Short TCR/pMHC 
interaction half-lives that would prevent completion of TCR signaling due to lack of positive 
signals and hence thymocytes will die by neglect. However, TCR/pMHC interactions with 
prolonged half-lives would impede TCR serial engagement impairing TCR signalling, 
resulting in negative selection and thymocyte death by apoptosis. 
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1.3.4 Antigen presentation and MHC structure 
As mentioned earlier, there are two classes of MHC molecules, MHC class I and MHC class 
II, which interact with CD8 and CD4 T cells respectively. Importantly, these two classes of 
molecule are structurally distinct, and the peptides they present are derived from different 
intracellular locations.  
 
MHC Class I molecules are composed of a heavy or α chain associated noncovalently with a 
smaller β2-microglobulin (β2M) domain (Figure 1.2a). There are three MHC class I α chain 
genes in the human, HLA-A, B and C, and each gene is highly polymorphic, while β2M is 
nonpolymorphic. The α chains are transmembrane glycoproteins of approximately 31 kDa and 
are organised into three extracellular domains (α1, α2 and α3 domains), while the β2m protein 
is an Ig-like protein of approximately 12 kDa in size. The association of the heavy chain and 
β2M proteins is essential for expression of the MHC on the cell surface. Human MHC class I 
(specifically HLA-A2) was the first MHC structure to be solved (Bjorkman et al, 1987). The 
structure revealed two pairs of interacting domains, a membrane distal pair consisting of α1 
and α2 regions of the heavy chain and membrane proximal pair consisting of α3 region and 
β2M (Figure 1.2a). The α1 and α2 domains interact to produce a peptide binding platform 
which contains two α-helices which rest on a β-sheet, and form a groove in which the peptide 
is sited. This groove can accommodate a peptide up to ten amino acids in length. The α3 
domain and β2M are Ig-like domains of two anti-parallel β-sheets. In contrast to the α1 and α2 
domains, which are highly polymorphic, the α3 domain is relatively conserved across MHC 
class I molecules and is a key interaction site for the CD8 T cell coreceptor (Gao et al, 1997). 
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Figure 1.2 Overview of the crystal structures of MHC-I (HLA-A2) and MHC-II (HLA-DR4). 
a) Structure of HLA-A2 in complex with peptide derived from Influenza A matrix protein M1 
(PDB code 1HHI; Madden et al, 1993). The α1 and α2 domains (green) combine to form the 
antigen binding cleft (bottom) allowing peptide (red) presentation to CD8
+
 T cells. The α3 
domain (green) non-covalently associates with β2M (cyan). b) Structure of HLA-DR4 in 
complex with peptide derived from human collagen II (PDB code 2SEB; Dessen et al, 1997). 
MHC-II molecules are comprised of a polypeptide alpha (red) and beta (yellow) chain of 
approximately equal length. The α1 and β1 domains combine to form the antigen binding 
groove allowing peptide (green) presentation to CD4
+
 T cells. The groove of MHC-II is open 
at one end relative to MHC-I allowing accommodation of longer peptides (13-25).  
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The assembly of MHC class I molecules begins in the endoplasmic reticulum (ER), where 
newly synthesized MHC class I heavy chain and β2M assemble with each other in association 
with a large multiprotein complex termed the Peptide Loading Complex (PLC) (Pamer and 
Cresswell, 1998; Cresswell et al, 1999). The peptides which are loaded onto the MHC class I 
complex are generated in the cytosol from cytosolic proteins that have been degraded by a 
multi-subunit protease called the proteasome. The peptides generated by the proteasome are 
then transported into the ER by the transport associated with antigen processing (TAP) 
complex. Peptides that associate stably with the MHC class I- β2M dimers are ultimately 
transported to the cell surface (Pamer and Cresswell, 1998). 
 
MHC class II are structurally similar to MHC class I molecules, but consist of two 
polypeptide chains of approximately equal size, which are associated by noncovalent 
interactions (Figure 1.2b). The two chains consist of two domains each: α chain has α1 and α2 
domains and the β chain has β1 and β2 domains. The α1 and β1 domains fold together to form 
the peptide binding groove, analogous in structure to that of MHC class I, however the ends 
of the peptide binding groove are not constrained, and as a result, MHC class II proteins are 
able to bind longer peptides (Figure 1.2b). Nascent MHC class II molecules are initially 
assembled in the ER, as for MHC class I molecules (Watts, 1997). However, unlike MHC 
class I, the binding groove of MHC class II molecules is occupied at first by association with 
a portion of the Class II MHC invariant chain (Ii). This association prevents peptides in the 
ER from binding to the MHC class II molecule, and helps traffic the MHC class II molecule 
out of the ER towards the endocytic pathway, where it ultimately intersects with endosomal 
vesicles carrying antigen originating from outside the cell. In the low pH of these vesicles, the 
Ii chain is degraded by proteases, leaving the Class II-associated invariant chain (CLIP) 
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peptide bound to the MHC class II peptide binding groove. After fusion with endocytic 
vesicles, the CLIP peptide is displaced from the MHC class II groove by peptides derived 
from endocytosed antigens that have been similarly proteolytically degraded. Exchange of the 
CLIP peptide for antigenic peptide is catalysed by the class II-like molecule HLA-DM 
protein, after which mature MHC class II complexes are transported to the cell surface for 
presentation to T cells (Watts, 1997).  
 
1.3.5 Structural basis of TCR/MHC recognition 
Structural studies of TCRs and TCR/MHC complexes have shed light on how T cell 
recognition takes place at a molecular level (Rudolph et al, 2006). TCR structures have 
confirmed structural homology to antibody Fab fragments, with antigen binding site formed 
by the CDR loops protruding from the membrane distal ends of the Vα and Vβ domains. 
Generally, TCR/peptide-MHC structures have revealed a roughly diagonal orientation of the 
TCR relative to the long axes of the α1/α2 helices, with the Vα domain positioned over the N-
terminal portion of the peptide (and the α2 helix), and the Vβ domain positioned over the C-
terminal region of the peptide (and the α1 helix). In this orientation, the CDR3 loops of both 
chains are positioned over the centre of the antigen binding groove and dominate contacts to 
antigenic peptide, whereas contacts to α1 and α2 helices are dominated by the CDR1 and 
CDR2 loops of Vβ and Vα respectively. Importantly no gross conformational changes in 
either TCR or MHC have been noted upon binding, arguing against models of TCR triggering 
based on conformational change. Furthermore, crystallographic studies have shown that TCRs 
can accommodate altered peptide ligands of diverse stimulatory capacity with only minor 
conformational adjustments (Ding et al, 1999). Similarly, crystal structures have provided no 
evidence for TCR triggering models based on ligation-dependent dimerisation. Instead, both 
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binding studies and structural studies have highlighted relatively minor conformational 
alterations at the TCR/MHC protein-protein interface, particularly involving conformational 
changes in CDR loops upon binding (Willcox et al, 1999; Boniface et al, 1999; Rudolph et al, 
2006). Collectively, these data are arguably most consistent with models of triggering based 
on kinetic segregation (Davis and van der Merwe, 2006). 
 
1.4 Development of the adaptive immune response 
A wide range of studies provide support for a model of conventional adaptive responses based 
on initial activation of myeloid cells, followed by activation and recruitment of antigen 
specific lymphocytes, which takes place after a considerable delay (Hayday, 2009). After 
initial PRR stimulation, myeloid cells help to activate innate responses, but also upregulate 
antigen presentation molecules and migrate to local lymphoid tissues, where they present 
antigens to T cells. After initial priming, antigen-specific T cells have to proliferate, 
differentiate into effector T cells, and migrate to the affected site in order for their potent 
adaptive effector responses to be carried out. In addition, a portion of the effector cells are 
retained in a long-lived memory pool. In this way, subsequent exposure to the same 
antigen/pathogen enables rapid differentiation to produce a wave of effector cells that mount a 
quick secondary response (Hayday, 2009). While this system of adaptive immune initiation is 
clearly very powerful and can be sufficient to eliminate some pathogen infections, the time 
taken for initiation of antigen-specific lymphocyte responses suggests that in some cases, 
other arms of the immune response may be required to provide fast responses to microbial and 
non-microbial challenges. Increasing evidence suggests unconventional lymphocytes may 
fulfil this role (Hayday, 2000; Hayday, 2009).  
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1.5 Unconventional lymphocytes 
Additional subsets of T cells, classed as unconventional T cells, do not recognise self MHC 
molecules and peptides. These cells can express an αβ TCR and may recognise MHC-like 
molecules or unrelated antigens. A major class of unconventional αβ T cells recognises CD1 
molecules presenting antigenic lipids (Brigl and Brenner, 2004), while another class is 
specific for the MR1 molecule (Tilloy et al, 1999; Treiner et al, 2003) CD1 molecules are 
homologous to MHC class I molecules, but have evolved specialised hydrophobic antigen 
binding grooves, enabling presentation of lipid antigens to T cells (Figure 1.3a). In humans 
five CD1 genes are present, with CD1d (as in mouse) being recognised by Natural Killer T 
cells, which express a highly restricted αβ TCR and have potent immunoregulatory capacity. 
In contrast, the group 1 CD1 molecules (CD1a, b, c) present in humans are recognised by αβ 
T cells with diverse TCRs, and are implicated in responses to mycobacterial lipids (Willcox et 
al, 2007). In addition, muscosal associated invariant T cells (MAIT) have a highly restricted 
TCR usage, and recognise the class I MHC-like MR1 molecule, which has recently been 
shown to present a folic acid metabolite to αβ T cells (Kjer-Nielsen et al, 2012) (Figure 1.3b). 
In addition, γδ T cells undoubtedly represent one major class of unconventional T cell 
(Hayday, 2000), and these are discussed in greater detail in subsequent sections.  
 
Collectively, unconventional T cells, together with Natural Killer cells that also belong to the 
lymphocyte lineage, demonstrate the potential to respond rapidly to complement the 
conventional adaptive response, by responding rapidly to signs of either microbial challenge, 
or non-microbial stress such as cellular transformation. Collectively, these processes have 
been termed “lymphoid stress surveillance” (Hayday, 2009) and will be considered in more 
detail below in the context of γδ T cells. 
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Figure 1.3 Established ligands for unconventional αβ T cells. a) Crystal structure of CD1d 
bound to α-galactosylceramide (PDB code 1ZT4; Koch et al, 2005). The α1 and α2 domains 
(red) combine to form the antigen binding cleft (bottom) in which the lipid (ball and stick 
format) is presented to invariant natural killer T cells. The α3 domain (red) non-covalently 
associates with β2M (cyan). b) Crystal structure of MHC-I related molecule MR1 in complex 
with 6-formyl pterin (PDB code 4GUP; Kjer-Nielsen et al, 2012). The α1 and α2 domains 
combine to form the antigen binding cleft in which the microbial vitamin B9 metabolite (ball 
and stick format) is presented to mucosal-associated invariant T (MAIT) cells. The α3 domain 
(lime) non-covalently associates with β2M (cyan). c) For comparison the crystal structure of 
HLA-A2 in complex with peptide derived from Influenza A matrix protein M1 (PDB code 
1HHI; Madden et al, 1993) is shown. The α1 and α2 domains (green) combine to form the 
antigen binding cleft in which the peptide (ball and stick) is presented to CD8
+
 T cells. The α3 
domain (green) non-covalently associates with β2M (cyan). 
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1.6 An introduction to γδ T cells 
One important feature of the adaptive immune response, as outlined above, is the considerable 
time required from initial antigen encounter to generation of antigen-specific lymphocyte 
effector populations. This emphasises the requirement for a complementary arm of the 
immune system, to mount rapid and initial responses. In addition to innate immune responses, 
growing evidence suggests unconventional lymphoid subsets make key contributions at these 
early stages, acting to limit infection, initiate and regulate downstream responses, and 
preserve tissue integrity. Collectively, these early lymphoid-mediated responses have been 
referred to as “lymphoid stress surveillance” (Hayday, 2009). In addition to Natural Killer 
cells, γδ T cells are emerging as arguably the archetypal lymphocyte subset involved in this 
process.  
 
1.6.1 The discovery of γδ T cells 
The existence of γδ T cells as a third lineage of lymphocytes alongside conventional T cells 
and B cells was completely unanticipated, and stemmed from a serendipitous discovery. In 
their attempt to identify the α chain of the TCR, Saito et al instead cloned a TCR γ cDNA 
(Saito et al, 1984). A key subsequent step was to understand how the γ chain was encoded, 
and studies soon afterwards outlined the organisation of the γ locus on chromosome 13, which 
is arranged in four clusters, each containing one or more V segments, and both a single J 
segment and single C gene (Hayday et al, 1985; Vernooij et al, 1993). A second key question 
was whether the γ chain paired with another TCR chain to form a heterodimer, as for the αβ 
TCR. A number of biochemical studies, both in mouse and human systems, provided 
evidence that a fourth chain did indeed heterodimerise with γ (Brenner et al, 1986; Pardoll et 
al, 1987; Nakanishi et al, 1987). Subsequent work revealed that the murine Vδ locus was 
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embedded within the α chain locus, between the Vα and Jα segments, on chromosome 14 
(Chien et al, 1987). Interestingly, there are relatively few Vδ segments compared to Vα gene 
segments, however Vα genes can be utilised during γδ TCR recombination, increasing the 
potential diversity of the Vδ chain (Elliott et al, 1988). 
 
1.6.2 γδ TCR recombination and diversity 
A striking feature of the γδ TCR is the paucity of Vδ and Vγ gene segments compared to Vα 
and Vβ segments (Table 1.1). Furthermore, several γ and δ chains preferentially pair with 
each other. Although both of these features serve to limit combinatorial diversity for the γδ 
TCR and might suggest overall genetic diversity within the γδ TCR is also low, this is not the 
case. In fact, two features of TCR δ recombination have the effect of increasing diversity 
substantially relative to the αβ lineage (Davis and Bjorkman, 1988) (Table 1.1). Firstly, 
although diversity (D) regions are not utilised in recombination of the Vγ chain (as is also the 
case for the Vα chain), each δ chain can utilise more than one Dδ region, whereas TCR β 
chains use only one D region. Secondly, these Dδ segments can be read in any frame. As a 
result of these features, the potential diversity of the γδ TCR exceeds that of either the BCR 
repertoire or the αβ TCR. 
 
Molecular features of the TCR γ and δ chain also distinguish these from α and β TCR chains 
to an extent. One notable feature is that although human and mouse Vh, Vk, Vα, Vβ and Vδ 
gene segments can be separated into distinct families that each share relatively high homology 
at the nucleotide level (>75%), Vγ gene segments are by contrast genetically diverse. 
Although Vγ1 (human) and Vγ7 (mouse) exhibit >40% homology, other human and mouse 
Vγ genes are relatively distinct. In addition, it has been noted that although Vδ gene segments 
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are homologous to those of Vα segments, the “classical” Vδ segments used exclusively by Vδ 
chains (Vδ1, Vδ2, Vδ3 in humans, and Vδ1, Vδ4, Vδ5, and Vδ6 in mice), as opposed to those 
shared by Vα chains, bear key sequence features distinct from Vα genes (Arden et al, 1995a; 
Arden et al, 1995b; Clark et al, 1995). These include a characteristic increased length (by two 
amino acids) of CDR1δ and 2δ regions relative to CDR1α and 2α regions. In addition, 
detailed comparisons have revealed certain amino acids that are highly conserved in Vα genes 
such as glutamate 14 (hypothesised to be involved in contacting the Cα domain) and 
glutamine 37 (hypothesised to form contacts to the β chain) are not conserved in Vδ.  
 
 Immunoglobulin TCR α : β TCR γ : δ 
 H Κ α β γ δ 
Variable segments 250-1000 250 100 25 7 10 
Diversity segments 10 0 0 2 0 2 
Ds read in all 
frames 
Rare - - Often - Often 
N region addition V-D, D-J None V-J V-D, D-J V-J V-D1, D1-
D2, D1-J 
Joining segments 4 4 50 12 2 2 
V region 
combinations 
62,500 – 250,000 2,500 70 
J combinations ~10
11
 ~10
15
 ~10
18
 
Table 1.1 Sequence diversity in immunoglobulin genes and αβ/γδ TCRs (Davis and 
Bjorkman, 1988. 
 
1.6.3. Essential features of γδ T cell localisation and development  
γδ T cells can be separated into two subtypes. The first is systemic γδ T cells, which comprise 
1-10% of circulating T cells in both mice and humans. Secondly, tissue-associated γδ T cells 
are enriched within epithelia, and are termed “intraepithelial γδ lymphocytes” or IELs. Their 
prevalence at epithelial surfaces in particular suggests γδ T cells may act as a first line of 
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defense against infection (Hayday, 2000). In the mouse, IELs demonstrate restricted V-region 
usage and limited junctional diversity, with particular combinations characteristic of distinct 
anatomical sites. As examples, uterine γδ’s utilise an invariant Vγ6Vδ1 TCR, whereas 
intestinal γδ’s predominantly use Vγ7, and skin DETC γδ’s use an invariant Vγ5Vδ1 
combination (Figure 1.4a). In contrast, systemic γδ T cells are more diverse in chain usage 
and have higher junctional diversity. Although human γδ T cell subsets are less well 
characterised, the predominant peripheral blood γδ subset utilises Vγ9Vδ2. In contrast, tissue-
associated γδ T cells are predominantly Vδ2-negative, with use of Vδ1 highlighted in the 
intestine, and generally diverse Vγ chain usage (Figure 1.4b).  
 
In both mice and humans, γδ T cells are the first T cells to develop, suggesting important roles 
in neonatal immunity. In mice, their development occurs in waves, with DETC appearing 
first, followed by uterine and then other γδ T cell populations (Figure 1.5). The lack of 
junctional diversity in DETC and uterine populations can be explained in part by the fact their 
recombination occurs before terminal deoxynucleotide transferase (TdT) is expressed, 
however some studies also suggest canonical rearrangements may either be enriched by 
positive selection, or may occur at high frequencies due to homologous recombination 
directed by short nucleotide sequences flanking the V gene segments. For the DETC TCR, 
evidence for positive selection derives from disruption of the Vγ5 gene used by DETCs 
(Mallick-Wood et al, 1998). In normal mice, the canonical DETC TCR Vγ5/Vδ1 is 
recognised by the 17D1 antibody, which does not recognise either Vγ5 or Vδ1 paired with 
other chains. In the skin of Vγ5-/- mice, DETCs were present but they bore TCRs comprising a 
replacement Vγ1 chain paired with the canonical Vδ1 chain. Interestingly, in Vγ5-/- mice a 
significant proportion of the replacement DETC were reactive against the 17D1 antibody, 
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Figure 1.4 γδ gene usage in mouse (a) and human (b). In each case γδ T cells show limited V 
region usage at particular anatomical sites. 
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Figure 1.5 Vγ gene segment usage is developmentally regulated in the murine thymus. The 
first wave of thymocytes produced in the embryonic thymus rearranges Vδ5 and migrates to 
the skin, while the next wave rearranges Vδ6 and homes to the lung and uterus. αβ T cells and 
peripheral and intestinal γδ cells, which are more diverse, undergo rearrangement and 
selection following birth (Janeway et al, 2005). 
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indicating that many Vγ1Vδ1 TCRs could adopt a conformation similar to that of the 
canonical Vγ5Vδ1 DETC TCR, and suggestive of thymic positive selection events based on 
recognition of a ligand that may be also present in the skin.  
 
An important difference between γδ and αβ T cell development that is highly relevant to the 
points above, relates to the pre-TCR. Whereas in αβ T cell development, functional 
expression of a pre-TCR is required to rescue cells from apoptosis at the DN stage 
immediately prior to the DP CD4
+
CD8
+
 stage, there is no evidence of a functional pre-TCR 
checkpoint for γδ T cells, the majority of which mature as DN cells. The assumption is that 
like the pre-TCR (Yamasaki et al, 2006), the majority of γδ TCRs can signal independently of 
thymic ligands sufficiently to effect maturation. Recent evidence in mice supports this idea, 
indicating that most Vδ chains can substitute for the pTα chain. Importantly, the one 
exception to this observation was the Vδ1 DETC TCR chain, consistent with the idea that 
interaction of the canonical DETC TCR with a thymic ligand is an essential positive selection 
step (Jensen et al, 2008).  
 
Finally, whereas negative selection of αβ T cells strongly reactive against self-MHC is well 
established, this is not generally thought to occur with γδ T cells. The most convincing 
evidence for this comes from studies on mouse γδ T cells reactive against the non-classical 
class I MHC molecules T10 and T22. Although early studies involving mice transgenic for 
the G8 TCR that recognises T10/T22 favoured both positive and negative selection (Dent et 
al, 1990; Bonneville et al, 1990; Perreira et al, 1992; Wells et al, 1991), the use of T10/T22-
specific tetramers detected comparable frequencies of T10/T22-specific γδ T cells was also 
found in β2M
-/-
 mice, excluding negative (and positive) selection playing a major role 
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(Crowley et al, 2000). Although this is somewhat surprising given the relatively high affinity 
of some γδ TCR/T10-T22 interactions, the observation that there is an unexpectedly high 
threshold for activation in spite of this may provide an explanation. Instead, in the T10/T22 
system, the presence or absence of TCR ligand in the thymus is suggested to affect TH1/TH17 
phenotype bias, with thymic selection in the presence of ligand inducing a TH1 phenotype, 
and vice-versa (Jensen et al, 2008). Moreover, in humans, results from next generation 
sequencing analyses comparing frequencies of in-frame and out-of-frame Vγ genes have been 
used to suggest that only low levels of negative selection may occur (Sherwood et al, 2011). 
In summary, there is strong evidence against negative selection playing a dominant role in 
shaping the γδ T cell repertoire, unlike for αβ T cells. The implications of this are highly 
significant. Firstly, they suggest that mature γδ T cells may have the potential to recognise 
self antigens, even if these are expressed in the thymus. Secondly, they raise the key question 
of how γδ T cell tolerance to self-antigens is maintained in the absence of negative selection. 
 
1.6.4. Key γδ T cell subsets 
Much of the research on γδ T cells has been focussed on key γδ T cell subsets. A brief 
summary of some key γδ subsets is provided below. 
 
Vγ9Vδ2 T cells are restricted to humans and primates and are the predominant population in 
human peripheral blood. Known to expand rapidly in a range of infections, including 
mycobacterial infection, salmonella, listeria, toxoplamosis, and malaria, Vγ9Vδ2 have been 
described to be activated by small non-peptidic phosphorylated compounds derived from 
bacterial-specific isoprenoid biosynthetic pathways, commonly referred to as phosphoantigens 
(Pfeffer et al, 1990; Constant et al, 1994; Tanaka et al, 1994). The most potent of these, 
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HMB-PP, could potentially be considered a PAMP, as it is an essential metabolite for most 
pathogenic bacteria such as Mycobaterium tuberculosis, and is produced via the non-
mevalonate pathway of isoprenoid synthesis absent in higher eukaryotes. Therefore, Vγ9Vδ2 
T cells may play an important role in sensing infection by HMB-PP-producing pathogens. 
Importantly, host-produced phosphoantigens such as isopentenyl pyrophosphate (IPP) are 
able to stimulate Vγ9Vδ2 cells, these are 104-107-fold less potent than HMB-PP, which has a 
bioactivity of 0.1nM (Eberl et al, 2003). Conceivably, molecules such as IPP may promote 
recognition of stressed or cancerous cells, supported by in vitro reactivity of Vγ9Vδ2 T cells 
to transformed tumour cell lines. In addition, studies by Moser et al highlight the potential for 
Vγ9Vδ2 cells to act as antigen presenting cells to αβ T cells, following phosphoantigen 
stimulation (Moser et al, 2006). The direct anti-tumour reactivity of Vγ9Vδ2 cells is 
potentially manipulable in the therapeutic setting, as aminobisphosphonates (e.g. zoledronate 
and pamidronate) used clinically to decrease bone loss (e.g. in myeloma) stimulate Vγ9Vδ2 T 
cells by inhibiting enzymes of the classical mevalonate pathway, leading to IPP accumulation 
(Hewitt et al, 2005). A number of clinical trials have used aminobisphonates to elicit γδ T 
cell-mediated anti-tumour responses, with some evidence of efficacy (Wilhelm et al, 2003 
Dieli et al, 2003). Both for HMB-PP and IPP, the mode of recognition is unclear, however a 
species-specific antigen-presentation molecule is hypothesised (Hewitt et al, 2005).  
 
Human Vδ2-negative γδ T cells are more poorly characterised than the Vδ2+ peripheral blood 
subset. Although they are predominantly tissue-associated, Vδ2-negative cells are present in 
the peripheral blood at relatively low frequencies (typically <2% of circulating T cells), and 
expand upon certain infections, including HIV, Lyme disease, and CMV. The response to 
CMV is arguably best characterised, and involves diverse TCR chain usage, that varies from 
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patient to patient and involves clonotypic expansions (Déchanet et al, 1999). In addition, 
expanded populations of CMV-specific Vδ2-negative cells bearing an effector memory 
phenotype persist post-infection, highlighting similarities to adaptive responses (Pitard et al, 
2008). Within the Vδ2-negative subset, Vδ1+ cells have been most extensively studied, and 
their reactivity to epithelial tumour cells emphasised (Groh et al, 1998; Groh et al, 1999). 
Moreover, CMV-reactive Vδ2-negative cells can exhibit a dual reactivity against tumour 
cells, suggesting reactivity towards self stress antigens (Halary et al, 2005). In both cases, the 
effector functions of the Vδ2-negative cells include cytokine production and cytotoxicity. The 
ligands recognised by Vδ2-negative are unknown, although they are clearly distinct from the 
phosphoantigens that stimulate the Vγ9Vδ2 subset. One suggested TCR ligand is the class I 
MHC-like protein MICA (Li et al, 1999; Wu et al, 2002) (Figure 1.6), however this remains 
controversial, particularly as these cells universally express NKG2D, a high affinity ligand for 
MICA. The Vδ2-negative population is discussed more extensively below. 
 
A key population in mice is the skin-resident intra-epithelial lymphocyte population known as 
dendritic epidermal T cells, or DETC (Hayday, 2000). These cells express a highly invariant 
Vγ5Vδ1 TCR, and in the steady state, adopt a dendritic morphology, contacting numerous 
keratinocytes in the epidermal layer. DETC are able to respond to keratinocytes in vitro, and 
this is augmented by exposing keratinocytes to stress stimuli such as heat shock. The 
responses induced include production of IL-2, cytotoxicity, production of keratinocyte growth 
factor, and secretion of chemokines (e.g. lymphotactin) that can recruit CD8
+
 T cells. 
Consistent with this, studies in mice support a role for DETC both in promoting epithelial 
tissue repair, and also in cutaneous tumour immunosurveillance. DETC are discussed in 
greater detail below. 
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Figure 1.6 Established ligands for unconventional γδ T cells. a) Crystal structure of murine 
T22 (PDB code 1C16; Wingren et al, 2000). The α1 and α2 domains (orange) combine to 
form a MHC-I like antigen binding groove. The α3 domain (orange) non-covalently 
associates with β2M (cyan). b) Crystal structure of murine T10 (PDB code 1R3H; Rudolph et 
al, 2004). The α1, α2 domains (pink) combine to form a MHC-I like antigen binding groove. 
The α3 domain non-covalently associates with β2M (cyan). Both T10 and T22 are recognised 
by γδ T cells in the absence of endogenous/exogenous ligands. c) Crystal structure of MHC 
class I polypeptide-related sequence A (MICA) (PDB code 1B3J; Li et al, 1999). The α1, α2 
and α3 domains are highlighted in blue. MICA serves as stress inducible ligand that is 
recognized by a subset of γδ T-cells (expressing Vδ1) independent of β2M and bound 
peptides. d) For comparison the crystal structure of HLA-A2 in complex with peptide derived 
from Influenza A matrix protein M1 (PDB code 1HHI; Madden et al, 1993) is shown. The 
heavy chain (α1, α2 and α3 domains) is shown in green β2M in cyan). 
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γδ T cell reactivity to the mouse class IB (ie non-classical) MHC molecules T10 and T22 was 
first defined in two alloreactive T cell hybridomas, G8 and KN6. T10 and T22 are highly 
related (sharing 94% identity), and associate with β2-microglobulin (Figure 1.6), although 
neither binds an antigen (Wingren et al, 2000). As is the case for MICA, T10/T22 expression 
is increased on activated cells, and a threshold of T10/T22 is required for G8/KN6 activation. 
While the physiological significance of T10/T22 recognition is unclear, the T10/T22 system 
has proven a valuable system in which to examine in particular γδ T cell selection (described 
above), and γδ TCR ligand recognition (discussed in more detail below). 
 
1.7 Functional roles of γδ T cells 
1.7.1 Evolutionary conservation and the lymphoid stress surveillance response 
The γδ T cell subset appears to have co-evolved alongside αβ T cells and B cells, since early 
in vertebrate evolution, which is around 400 million years ago, around the time when jawed 
vertebrates emerged. This suggests a critical and fundamental role for γδ T cells in vertebrate 
immunity, and one that is likely to be complementary to conventional αβ and B cell responses 
(Hayday, 2000). Consistent with such a fundamental role, to date no humans have been 
observed that specifically lack γδ T cells. However, the key reasons underlying this 
evolutionary conservation have until recently, remained unclear. This is illustrated by the 
observation that many γδ T cell knockout models are unremarkable in terms of the phenotypes 
observed. Despite this, their enrichment at epithelia surfaces fits well with a potential role for 
γδ T cells in the “first line of defense”, a role that would complement adaptive immunity. 
Consistent with this, a wealth of evidence (summarised below, with important contributions 
from animal model studies), now suggests that γδ T cells play key and in some cases essential 
roles in immune responses to both microbial and non-microbial stress, and illustrate many of 
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the key features of lymphoid stress surveillance. To understand these processes it is useful to 
consider the effector responses γδ T cells can carry out. 
 
1.7.2 Effector responses of γδ T cells  
γδ T cells exhibit a diverse range of effector functions, as for αβ T cells. These include 
cytotoxicity, consistent with their expression of cytolytic effector molecules such as perforin, 
granzymes, and Fas/FasL (Hayday, 2000). Cytokine production is another key function, with 
IFNγ and TNFα being prevalent. Previous studies have characterised γδ T cells as either TH1 
(as defined by IL-2 and IFNγ production) or TH2 (as defined by IL-4, IL-5, IL-6. IL-10 
production) in phenotype, with the majority conforming to the TH1 phenotype, and the TH2 γδ 
T cell subset correlating with rare expression of CD4 (Wen et al, 1998; Wen et al, 1997). 
Importantly, comparisons of the transcriptome of mouse intestinal γδ IELs versus αβ IELs 
suggested a TH1-skewed “activated but resting” phenotype, comprising naive expression of a 
range of cytolytic markers, chemokines, chemokine receptors, and adhesion molecules (Shires 
et al, 2001). In contrast to αβ T cells, these γδ cells expressed various proteins that inhibit 
proliferation. More recently, IL-17-producing γδ T cells have been described (Roark et al, 
2008). In some model systems, such as bacterial infection, γδ T cells can provide an innate, 
rapid, substantial and potentially protective source of IL-17 prior to generation of classical 
adaptive αβ TH17 cells (Lockhart et al, 2006, Umemura et al, 2007, Martin et al, 2009; Sutton 
et al, 2009). In addition, IL-17-production by γδ T cells has been highlighted as playing a 
critical role in chemotherapy-induced anti-cancer immune responses (Ma et al, 2011). Finally, 
a third important effector function of some γδ T cells is production of key growth factors, 
exemplified by skin-resident Vγ5Vδ1 DETC, which make keratinocyte growth factor upon 
activation (Boismenu and Havran, 1994). 
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1.7.3 Immunoprotection from infection 
Observations that expansions of γδ T cells occur in a diverse range of pathogen infections (as 
detailed above), combined with in vitro analyses of effector function, provide strong but 
circumstantial evidence for their importance in immunoprotection against infectious challenge 
(Hayday, 2000). Complementary to these approaches are γδ T cell knockout studies in mice, 
which have directly addressed the importance of γδ T cells in various infectious models. 
These studies have highlighted some examples (detailed below) where γδ T cells provide 
essential contributions to anti-pathogen immunity. In other cases their effector responses are 
either insignificant, or redundant (as in Eimeria infection of the gut), whereby deficiency in 
the γδ T cell subset in adults can be compensated for by αβ T cells (Hayday et al, 2000; 
Ramsburg et al, 2003). Therefore collectively, published data in this area highlight that the 
relative contribution of γδ T cells to immunoprotection against infection is dependent on the 
exact pathogen involved.  
 
A key example of an essential role for γδ T cells is infection of the lung with Nocardia 
asteroids, an intracellular Gram
+
 bacteria (King et al, 1999). In wild type animals, which all 
survived infectious challenge, bacteria were cleared from infected airway epithelial cells by 
an inflammatory response driven by neutrophils. However, all γδ negative mice died, due to a 
failure to develop inflammatory infiltrates. This highlights the potential role of γδ T cells in 
protection of an epithelial barrier, and their importance in orchestrating downstream 
inflammatory responses (King et al, 1999). A second example is lung infection with the Gram 
negative bacteria Klebsiella pneumonia (Moore et al, 2000). In this case, γδ negative mice 
have considerably higher mortality compared to wild type mice. Although, initial bacterial 
clearance in the lung is similar, a disseminated infection results, correlating with lower IFNγ 
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and TNFα levels, and resulting in liver damage. Consequently, γδ T cells are critical in this 
model for early production of IFNγ and TNFα; in contrast, αβ negative mice are no more 
susceptible to infection than wild type mice. A third example is Listeria monocytogenes, 
where knockout studies support a role for γδ T cells in primary infection, as γδ-/- mice have 
massively enhanced bacterial titers. Their key role in this scenario appears to be early 
production of IFNγ, which, by stimulating monocytes to produce TNFα, acts to enhance the 
NK IFNγ response. This example illustrates the potential of γδ T cells to orchestrate 
downstream innate immune responses. Collectively, these examples illustrate the principles 
that γδ T cells can play critical roles in host immune defence against pathogens, and these 
functions are most critical early in infection, where their rapid responses serve to protect 
epithelial surfaces, and initiate and shape downstream innate and adaptive responses.  
 
In contrast to the models described above, other systems highlight γδ T cell contributions that, 
while potentially important, are compensated for by the presence of αβ subsets, and therefore 
in the αβ replete setting, redundant. One example is HSV-1 infection, where both αβ negative 
and γδ negative animals are mostly immunocompetent, whereas infection is fatal in β negative 
δ negative animals, implying reciprocal compensation by each subset (Sciammas et al, 1994). 
A second example is CMV infection, where recent data highlight a similar scenario, with both 
the γδ and αβ compartments providing equally potent protection from MCMV infection in the 
absence of the other (Déchanet-Merville, unpublished observations). Such systems are 
potentially highly relevant to clinical scenarios involving infection in immunosuppressed 
individuals, whereby γδ T cells may be able to compensate for a deficiency in the αβ T cell 
compartment. Two of the most obvious examples include the post-transplant setting, and in 
neonatal immunity, both scenarios where αβ T cell responses can be highly compromised. 
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With these scenarios in mind, I will briefly outline the evidence that Vδ2-negative γδ T cells 
play an important role in immunoprotection from CMV infection in humans.  
 
Strong evidence for involvement of γδ T cells in human CMV comes from the setting of renal 
transplantation, where immunosuppressed recipients frequently develop acute CMV infection. 
Déchanet et al first reported large expansions of Vδ2-negative γδ T cells in this setting, which 
correlated with CMV infection, and persisted for years (Déchanet et al, 1999a; Déchanet et al, 
1999b). These involved expansions of Vδ1+ and Vδ3+ cells with evidence for oligoclonal 
expansions focussed on CDR3 regions of restricted length and bearing specific sequence 
motifs. In addition, relative to cells in uninfected patients, these populations demonstrated 
increased expression of activation markers, and expression of other surface markers 
(CD45RA, downregulation of CD28) consistent with an effector memory phenotype, 
analogous to CD8
+
 αβ T cells (Pitard et al, 2008). Subsequent studies have strengthened the 
argument that these cells help control CMV. Expansion of the Vδ2-negative population is 
associated with resolution of viraemia, consistent with a protective role (Lafarge et al, 2001). 
In addition, Vδ2-negative γδ T cells displayed robust TNFα production and cytotoxicity 
towards target cells infected with CMV (but not other viruses), and could also limit CMV 
propagation in vitro. Moreover, they frequently expressed homing receptors for the intestine, 
a key site of CMV infection in vivo (Halary et al, 2005). Importantly, Vδ2-negative γδ T cells 
bearing similar phenotypic markers and with equivalent functional abilities exhibited durable 
expansions outside the transplant setting in healthy CMV
+
 individuals, although to more 
modest levels (Pitard et al, 2009). Collectively these data strongly suggest that γδ play an 
important role in protection from acute CMV infection, particular in the immunosuppressed 
state. Two independent clinical scenarios confirm this conclusion. Firstly, similar expansions 
 34 
of CMV-reactive Vδ2-negative γδ T cells have been observed after stem cell transplantation, 
where patients are also immunosuppressed (Knight et al, 2010), and also in patients receiving 
tyrosine kinase inhibitors, where αβ responses are thought to be impaired (Dr David Lewis, 
unpublished data). In addition, foetal responses to congenital CMV infection involved major 
Vδ2-negative γδ T cell expansions with comparable anti-CMV reactivity, and featured a 
dominant clonotype expressing a public Vγ8Vδ1-TCR, suggestive of antigen-driven 
expansion (Vermijlen et al, 2010). This highlights the probability that Vδ2-negative γδ T cells 
play a key role in protecting the individual from CMV infection in the immunosuppressed 
setting, including in utero, when conventional adaptive responses are immature. The fact such 
Vδ2-negative populations exhibit dual reactivity to tumour cells (discussed below) provides 
important clues as the fundamental role of these cells, and the molecular mechanisms 
underlying their antigen recognition (Halary et al, 2005). 
 
1.7.4 Tumour immunosurveillance and potential application in cancer immunotherapy 
Prevalence of γδ T cells at epithelial surfaces, combined with their potent effector responses 
and the idea that γδ T cells may recognise self encoded stress-induced ligands, suggests the 
possibility that γδ T cells may play a role in tumour immunosurveillance. Studies in certain 
mouse models of tumourigenesis support this possibility. Firstly, Girardi et al demonstrated 
that mice lacking γδ T cells were highly susceptible to multiple regimens of cutaneous 
carcinogenesis (Girardi et al, 2001). Interestingly, whereas the presence of αβ T cells either 
inhibited or promoted tumours depending on the model, γδ T cells universally inhibited 
tumour development, consistent with a non-redundant contribution of γδ T cells to tumour 
immunosurveillance. Similarly, a study on colon carcinogenesis in mice detected a higher 
frequency of carcinoma and dysplastic crypt architecture in TCR δ negative mice, whereas 
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depletion of the αβ T cell subset had little effect. Again, these results are consistent with a role 
for γδ T cells in the suppression of epithelial tumourigenesis (Matsuda et al, 2001). Finally, 
CMV-induced expansions of Vδ2-positive cells in renal transplant patients were found to 
correlate with lower rates of post-transplant skin cancer, consistent with the dual reactivity of 
such Vδ2-positive γδ T cells to both CMV and tumour cells (discussed below) (Couzi et al, 
2007).  
 
In keeping with the above findings, there is considerable interest in the use of γδ T cells in 
immunotherapy approaches targeted at cancer. Several phase 1 or phase 2 clinical trials have 
been conducted, focusing on exploiting the anti-tumour properties of the Vγ9V2 subset of 
phosphoantigen-reactive γδ T cells in the context of either haematological malignancies 
(Wilhelm et al, 2003) or solid cancers (Dieli et al, 2007; Meraviglia et al, 2010). In each case 
objective clinical responses correlate with the potency of the γδ T cell response. In addition, 
studies in mice have shown γδ T cells can critically enhance chemotherapy induced anticancer 
immune responses (Ma et al, 2011), suggesting potential for combining chemotherapy and γδ 
T cell immunotherapy in humans. Finally, the fact that CMV-induced expansions of human 
Vδ2-negative γδ T cells correlate with lower rates of post-transplant malignancies (Couzi et 
al, 2010) suggest the potential for future vaccination/immunotherapy strategies to enhance γδ 
T cell-mediated immunoprotection. Together, these studies imply the ability of γδ T cells to 
respond to tumour cells may be exploited in the clinic in novel cancer immunotherapy 
approaches.  
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1.7.5 Immunoregulation and maintenance of tissue integrity 
Although mice deficient in γδ T cells do not show obvious signs of autoimmunity or gross 
immune dysregulation in the steady state, in the context of pathogen infection or challenge 
with non-microbial stress the same models highlight key roles for γδ T cells in both 
immunoregulation and in the maintenance of tissue integrity. A good example is the 
protozoan Eimeria, which infects intestinal epithelial cells. In this system, γδ T cell negative 
mice exhibit excessive damage to intestinal villi during primary infection, and a heavy 
neutrophil infiltration, a phenotype reduced by γδ T cell adoptive transfer. Importantly, this 
excessive inflammation is not observed in TCR β negative δ negative mice, indicating the 
capacity of γδ T cells to regulate the αβ T cell response that results in immunopathology 
(Roberts et al, 1996). Comparable effects are found in Listeria infection (Thoma-Uszynski et 
al, 1997). Mycobterium tuberculosis infection of mice highlights the potential of γδ T cells to 
shape the downstream response, as γδ T cell effector responses are required for promoting 
appropriate cytokine and chemokine signals necessary for protective granuloma formation 
(D’Souza et al, 1997). Beyond infection, an orchitis model demonstrated exaggerated 
inflammation in the absence of γδ T cells, again suggesting the ability to shape the 
downstream response (Mukasa et al, 1999). In addition, in the MRL lpr mouse model of 
lupus, γδ T cell deficiency led to increased mortality, correlating with increased 
autoantibodies, CD4 T cells, and Ig deposition in the kidney (Peng et al, 1996). Finally, 
studies on DETC (Jameson et al, 2002) highlighted this population recognizes damaged or 
stressed keratinocytes, and produces keratinocyte growth factors (KGF) and chemokines. In 
the absence of DETC, defects in keratinocyte proliferation and tissue epithelialisation are 
observed, and wound healing in DETC-deficient skin can be restored by adoptive transfer of 
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DETC or KGF. This suggests a role for DETC in the recognition of injured keratinocytes and 
subsequent production of factors that directly promote wound repair. 
 
1.8 Molecular basis of γδ T cell regulation 
Our molecular understanding of γδ T cell recognition is less advanced than that of αβ T cells. 
However, I will briefly describe some of the key immune receptors involved in γδ T cell 
recognition, and summarise our current knowledge of TCR ligands, before focussing on the 
two populations most relevant to the work outlined subsequently. 
 
1.8.1. Key receptors on the γδ T cell surface 
As for αβ T cells, γδ T cell recognition is dependent upon an array of different cell surface 
receptors, engaging with counter-receptors on the surface of the target cell. Three classes of 
receptor are worthy of particular attention. Firstly, γδ T cells express a range of NK-like 
receptors, including both inhibitory (Boullier et al, 1998) and activatory receptors (Bauer et 
al, 1999). These include members of the KIR (Lafarge et al, 2005), CD94/NKG2, and also 
activatory NK receptors such as NKp44/46, suggestive of a phenotype intermediate between 
NK cells and αβ T cells (Pont et al, 2012). Most notably, the activatory receptor NKG2D has 
been highlighted as an important axis influencing γδ T cell activation. NKG2D, expressed on 
NK cells, CD8 T cells, and γδ T cells, binds to a range of class I MHC-related ligands, in 
humans comprising MICA, MICB, and ULBP1-6, and in mice RAE1, MULT1, and H60 
(O’Callaghan et al, 2001; Mistry et al, 2007). NKG2D ligands are normally tightly controlled, 
but can be upregulated by viral infection and in epithelial tumours, and it is notable that both 
viruses (e.g. CMV) and tumours have evolved ways to evade NKG2D-mediated immune 
responses (Mistry et al, 2007). In the context of tumour immunity, NKG2D negative mice 
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have defective tumour immunosurveillance in spontaneous models of prostate cancer and 
lymphoma (Guerra, 2008). In relation to γδ T cells, NKG2D receptor/ligand binding triggers 
γδ T cell activation and cytotoxicity towards the target cell. Consistent with this, upregulation 
of Rae1 in the skin initiated altered organisation of DETC population, and resulted in a rapid 
immunosurveillance response, resulting in infiltration by unconventional αβ T cells (Strid et 
al, 2008). In addition to NK receptor expression, a recent study suggests CMV-reactive γδ T 
cells commonly express a second class of innate receptor, the Fc receptor CD16 (FcγRIIIA), 
which is normally associated more closely with NK cells and myeloid cells. CD16 expression 
enables γδ T cells to produce IFNγ in response to IgG-opsonised virions (Couzi et al, 2012). 
Thus, by expressing NK receptors and Fc receptors, γδ T cells bear some similarities to innate 
immune subsets. 
 
Despite some evidence for TCR independent effector capacity (Couzi et al, 2012; Kapsenberg 
et al, 2009), there is also ample evidence that the TCR is a critical determinant of γδ T cell 
function. Firstly, transfection of Vγ9Vδ2 TCRs into recipient T cells confers reactivity to 
relevant phosphoantigens (Bukowski et al, 1995). In this subset, NKG2D ligand interactions 
appear to provide costimulatory signals rather than independently stimulate effect functions 
(Nedellec et al, 2010). In Vδ2-negative T cells reactive to CMV, it appears that 
NKG2D/ligand interactions do not exert a major role on stimulation, since blocking of either 
NKG2D or NKG2DL had no effect on target cell recognition. In contrast, anti-CD3 antibodies 
effectively blocked target cell recognition, and in addition TCR down modulation was 
observed on antigen recognition (Halary et al, 2005). Furthermore, transfection of individual 
Vδ2-negative TCRs conferred recognition of key target cells (Willcox et al, 2012). These data 
argue strongly that human γδ T cells, comprising both the Vγ9Vδ2 and also Vδ2-negative 
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subsets, depend heavily on TCR ligation to initiate activation. In mice, recent imaging studies 
suggest the steady-state contacts between skin-resident DETC γδ T cell population and 
keratinocytes which take place in intercellular contact zones termed “phosphotyrosine-rich 
assemblies located on projections” or PALPs, are highly likely to involve TCR/ligand 
interactions (Chodaczek et al, 2012). Moreover, although T10/T22-reactive γδ T cells can 
survive thymic selection in the absence of the T10/T22 ligands and mature into IL-17-
producting effectors, their stimulation once mature is dependent on the TCR (Jensen et al, 
2008). Therefore, not surprisingly, the γδ TCR, which arose in parallel with the αβ TCR ~450 
million years ago, is thought to be a key regulator of γδ T cell function. However, how γδ 
TCR/ligand interactions take place is largely uncertain. 
 
1.8.2. γδ TCR structures 
Given the critical nature of the TCR to γδ T cell function, there are considerable efforts 
underway to understand the structural basis of γδ TCR recognition. A number of 
crystallographic studies have shed light on this issue. An initial structure of a human Vγ9Vδ2 
TCR outlined some distinctive features of the heterodimer relative to αβ TCR and Fab 
fragments (such as the interdomain angles and architecture of the C domains), and also 
highlighted a potential phosphoantigen binding site, comprising an intriguing electropositive 
patch formed by the CDR loops (Allison et al, 2001). Although this has not been verified, this 
is perhaps not surprising as phosphoantigen recognition is hypothesised to involve an 
unknown antigen presenting molecule and to involve all CDR loops (Wang et al, 2010). 
 
Studies on the mouse non-classical class I MHC molecules T10/T22 system led to a crystal 
structure of the G8 γδ TCR in complex with T22 (Adams et al, 2005). G8 interacted with T22 
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in an orientation different to that of αβ TCR/MHC interactions, which was intriguing in that 
involved mainly the CDR3δ loop. A subsequent study extended this mode of recognition to 
the KN6 clone, and established that grafting of their CDR3δ loops into αβ TCRs was 
sufficient to confer recognition with wild-type affinity, confirming it was truly CDR3δ-
autonomous (Adams et al, 2008). While these studies potentially outline an important mode 
of γδ TCR reactivity, involving only somatically recombined regions (ie CDR3 regions) of the 
TCR, it remains to be seen how widely applicable this recognition mode is, and clearly 
involvement of CDR1/2 regions is also possible (Wang et al, 2010).  
 
Finally, a recent study details the structure of a human VγVδ1 TCR reported to be specific for 
the MHC class I related MIC (although these data remain controversial). The structure, which 
was of the TCR alone rather than in complex with MIC, revealed the CDR loops formed a 
relatively flat putative binding surface (Xu et al, 2011).  
 
1.8.3 γδ TCR ligands and their recognition 
The enrichment of γδ T cells at epithelial surfaces suggests the possibility that they act as a 
first line of defence against epithelial infection, injury or stress. Moreover, based on their 
restricted V-region usage, one possibility is that γδ T cells primarily engage self-encoded 
stress ligands, rather than microbial ligands, which are likely to be much more diverse 
(Janeway et al, 1988). However, due to the considerable diversity in their CDR3 regions, the 
possibility that γδ TCRs recognise foreign antigens to a significant extent cannot be excluded, 
especially in light of the exclusively CDR3-mediated recognition of T10/T22 by the G8 TCR. 
Despite ample evidence for TCR dependent recognition of target cells, the ligands bound 
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directly by γδ TCRs have remained largely unidentified. A summary of putative ligands, in 
rare cases confirmed by direct binding studies, is given below. 
 
Host-encoded whole protein antigens 
Various whole protein antigens have been suggested as direct ligands for the γδ TCR. One of 
the earliest classes highlighted were heat shock proteins (hsps), which are extremely abundant 
in the cell, upregulated upon cellular stress, and highly conserved across species. In particular, 
mycobacterial hsps and GroEL (mycobacterial hsp58/60) were suggested as ligands for both 
mouse and human γδ TCRs. To date, no direct binding data have been derived that confirm γδ 
TCR/hsp interaction. In addition, one complicating factor in this area has been the proven 
ability of hsps to directly bind peptide antigens and deliver it to antigen processing cells 
(Srivastava, 2002), and the prospect that this kind of mechanism underlies their stimulatory 
capacity rather than an ability to directly bind the γδ TCR.  
 
 
MHC and MHC-like proteins 
Despite acceptance that γδ T cells do not generally recognise MHC proteins, an alloreactive 
mouse T cell line, LBK5, has been shown to recognise the class II MHC protein I-E
k
 (Matis et 
al, 1989; Schild et al, 1994; Hampl et al, 1999). Mutational studies suggested a binding mode 
distinct from αβ TCRs that recognise I-Ek (Schild et al, 1994; Hampl et al, 1999), and 
hypothesised to be low affinity, although direct binding was not shown. Importantly, the 
significance of alloreactivity for γδ T cell recognition in general is unclear, but conceivably it 
could mimic recognition of foreign proteins by γδ T cells (see below). Of relevance to this 
idea, comparison of γ and δ TCR genes with those of αβ TCRs highlights CDR1 and CDR2 
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lengths that are longer compared to TCRα and β, and the CDR3s of TCRδ sequences are 
thought to be more similar to IgH CDR3s (Rock et al, 1994). Therefore, instead of the 
relatively flat surface of the αβ TCR where CDR loop lengths appear to be constrained in 
order to enable MHC binding, the longer CDRs of γδ TCRs may suggest the ligands 
recognised are not so constrained.  
 
Despite these arguments, non-classical MHC antigens have long been suspected to be γδ TCR 
ligands. The limited V-region usage of the γδ T cell population is consistent with a limited 
number of presenting molecules (Davis and Bjorkman, 1988). Moreover, the ability of γδ T 
cells to use Vδ regions that can also be used by the αβ repertoire suggests, at least for part of 
the γδ T cell repertoire, that some MHC-like molecules may be involved – particularly as the 
Vα domain is thought to play an important role in forming the TCR/MHC interface (Rudolph 
and Wilson, 2002). The first direct evidence in favour of this hypothesis was the discovery 
that the mouse non-classical MHC molecules T10 and T22 were ligands were recognised by 
murine γδ T cell clones (Teitell et al, 1994). Although highly related to each other, they are 
regulated differently – with T22 expressed by most cells, whereas T10 is restricted to 
splenocytes, thymocytes and macrophages (Ito et al, 1990). Notably, neither T10 nor T22 are 
thought to bind peptide, as the structure of T22 revealed a disrupted binding groove that is too 
narrow to accommodate peptide antigen (Wingren et al, 2000) (see Figures 1.6). Importantly, 
T22 was the first γδ TCR ligand to be directly confirmed in a biochemical assay (Crowley et 
al, 2000). A tetramer of T22 was found to stain 0.4% of γδ T cells in the blood, and a similar 
proportion of IEL γδ T cells. BIAcore analysis highlighted an affinity for T22 of 0.1µM, 
considerably higher than many αβ TCR/MHC interactions. Subsequent structural (Adams et 
al, 2005) and functional (Adams et al, 2008) studies have indicated that that the G8/T22 
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interaction relies entirely on residues in CDR3δ. One of the more important points emerging 
from these studies is that γδ T cell recognition of T10/T22 is not dependent on antigen 
presentation, and instead is likely to be affected by increases in T10/T22 expression under 
certain conditions, such as cellular activation.  
 
Another potentially important group of potential γδ TCR ligands is the CD1 family, of which 
5 members exist in humans, CD1a,b, c, d, and e (Brigl, M., and Brenner, M.B. 2004; Willcox 
et al, 2007). CD1 molecules are related to class I MHC proteins in structure, although they 
possess highly specialized hydrophobic antigen binding grooves, enabling presentation of 
lipid antigens to T cells, whereby the aliphatic lipid tails are buried inside the CD1 molecules, 
and the hydrophilic head group is solvent accessible for recognition by the TCR. Whereas 
CD1d, the only group 2 CD1 molecule, is recognized by Natural Killer T (NKT) cells, the 
group 1 CD1 molecules comprising CD1a, b and c are known to present a range of pathogen 
derived (in many cases mycobacterial) lipid antigens (Willcox et al, 2007). While the T cells 
that recognize group 1-CD1-restricted T cells have previously been defined as αβ lineage with 
diverse TCR V-region usage, there is evidence that γδ T cells may also be involved. Human 
γδ T cells generated by culturing with CD1-expressing DCs pulsed with mycobacterial 
extracts were found to recognize CD1c without addition of exogenous antigen (Spada et al, 
2000). Reactive Vδ1-expressing clones proliferated, secreted cytokines, and killed target 
CD1c-positive cells. Although responses were blocked by anti-γδ TCR antibody, and CD1c-
reactivity could be conferred by transduction of CD1c-specific TCRs, direct recognition of 
CD1c by the γδ TCR has not been established.  
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Another set of MHC-like proteins proposed as direct ligands for the γδ TCR are the MHC-
class I-related (MIC) genes, comprising MICA and MICB (see Figure 1.6). Studies from the 
Spies group suggested human intestinal γδ T cells were able to recognise MICA (Groh et al, 
1998). MICA is attractive as a candidate host-endoded stress antigen, as it is upregulated by 
heat shock and also during tumourigenesis (Groh et al, 1996; Groh et al, 1999). In support of 
these suggestions, Vδ1+ cells from the intestine were found to kill MICA transfectants, and 
this could be blocked by anti-MIC and anti-TCR antibodies. However, this has remained a 
highly controversial area, as subsequent work showed MICA/B were ligands for NKG2D, 
which is expressed by γδ T cells (Bauer et al, 1999; Diefenbach et al, 2000; Cerwenka et al, 
2000). Wu et al, aimed to resolve this, by transfecting TCR chains from MICA-responsive 
and non-responsive clones into an NKG2D-negative T cell line (Wu et al, 2002). 
Transfectants that expressed TCRs from MICA-responsive clones were found to bind MICA 
tetramers effectively, whereas those from unresponsive clones did not. Although detection of 
direct binding via SPR would provide final confirmation, recent data purporting to highlight 
this seem unconvincing (Xu et al, 2011). 
 
Low molecular weight antigens 
The small non-peptidic “phosphoantigens”, either host or pathogen-derived, found to activate 
human peripheral blood subset of γδ T cells are candidate ligands for the Vγ9Vδ2 TCRs 
expressed by these cells. In support of this, recognition of these compounds can be conferred 
by TCR transfection, as transfection of a Vγ9Vδ2 TCR into Jurkat T cell line conferred 
reactivity to isopentenyl pyrophosphate (Morita et al, 1995). In addition, reactivity to 
phosphoantigens has been reported to be dependent on the CDR3 regions of the TCR 
(Bukowski et al, 1998), and was sensitive to small changes in the structure of the antigens 
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(Morita et al, 2001), consistent with TCR-mediated recognition. Moreover, the structure of a 
Vγ9Vδ2 TCR indicated an electropositive patch, forming a putative phosphoantigen binding 
site. Despite this, no direct binding data has demonstrated binding of phosphoantigens to the 
γδ TCR, and it seems likely that an antigen presentation molecule may be involved. In 
addition to being dependent upon cell-cell contact, presenting cells must be human in origin, 
consistent with a species-specific antigen presentation molecule (Hewitt et al, 2005). 
Secondly, recent mutagenesis studies highlight all 6 CDR loops are involved in recognition, 
consistent with a sizeable interface with ligand, and therefore with involvement of an antigen-
presentation molecule. Finally, it is difficult to envisage how molecules as small as the 
phosphoantigens could induce TCR signalling in the absence of a presenting molecule. 
Clearly further work is needed in this area. 
 
Pathogen-encoded protein antigens 
Although γδ T cells use a restricted range of V regions, the high level of diversity in their 
CDR3 regions suggests that recognition of foreign antigens cannot be discounted. Two lines 
of evidence suggest this may be the case. Firstly, the TgI4.4 γδ T cell clone, derived from a 
mouse infected with Herpes Simplex Virus-1, was reported to recognise unprocessed HSV-1 
glycoprotein I (gI) (Johnson et al, 1992; Sciammas et al, 1994). To date, no direct binding 
data has been obtained to support this. Secondly, recent data from Chien’s laboratory has 
defined both mouse and human cells capable of recognising the model antigen phycoerythrin 
(Zeng et al, 2012). Direct binding studies convincingly showed reactivity was TCR 
dependent, and comparison of relevant γδ TCRs suggested conserved CDR3 motifs were 
crucial for recognition, and could mediate recognition in the context of different V regions 
(Zeng et al, 2012). Although this study focuses on phycoerythrin as a model (rather than 
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physiological) antigen, they demonstrate that γδ TCR recognition of intact pathogen-derived 
proteins may be a feature of γδ T cell responses. 
 
1.8.4 Molecular basis of ligand recognition by the human Vδ2 negative subset 
As noted above, several studies, originally from the laboratory of Dr Julie Déchanet-Merville, 
have noted substantial and long-lasting expansions of human Vδ2-negative T cells during 
acute CMV infection, which frequently occurs as a complication of immunosuppression 
following renal transplantation (Dechanet et al, 1999). Importantly, these expansions were in 
parallel with resolution of CMV viraemia, consistent with a protective antiviral role (Lafarge 
et al, 2001). In addition, they involved multiple V regions and evidence for clonotypic 
selection, suggestive of antigen-driven expansion in vivo (Dechanet et al, 1999). In addition, 
Vδ2-negative T cells induced in CMV infection have an effector memory phenotype (Pitard et 
al, 2008), display strong reactivity to CMV-infected target cells (cytotoxicity, cytokine 
production) and also were able to limit CMV propagation in vitro (Halary et al, 2005), 
supporting the idea they play an important role in anti-CMV responses after renal 
transplantation. 
 
A landmark publication by Halary et al gave important clues to how Vδ2-negative recognition 
of CMV infection took place. Firstly, use of anti-CD3 blocking antibodies and evidence of 
TCR downmodulation during recognition strongly supported a key role for the TCR in 
recognition of CMV-infected target cells. Secondly, CMV-reactive Vδ2-negative T cells were 
also found to have a dual reactivity, against various epithelial tumour lines. While this was 
consistent with previous observations that Vδ1-derived cells are able to recognise transformed 
epithelial cell lines (Groh et al, 1998), in this case involvement of NKG2D/ligand interactions 
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was excluded. These findings, and in particular the dual reactivity towards CMV infection and 
cellular transformation, suggested the possibility of host-encoded ligands stress ligands that 
were induced in both infection and transformation. Consistent with this possibility, 
subsequent work showed that renal transplant patients with CMV-induced expansions has 
lower rates of post-transplant malignancy, suggestive of an immunosurveillance role for this 
subset (Couzi et al, 2010). Clearly the nature of the targets recognised by the γδ TCR in these 
responses are of great interest.  
 
1.8.5 Molecular basis of ligand recognition by murine DETC 
Although the DETC subset of mouse skin-resident γδ T cells has been discussed in part 
above, and is also covered more extensively in Chapter 5, included here are a few points 
regarding how they function at a molecular level. As noted above, studies on DETC have 
provided strong evidence for roles in immune regulation, maintenance of epithelial integrity, 
and tumour immunosurveillance. Their epithelial localisation, ability to respond to diverse 
stress stimuli, and ability to affect downstream responses are characteristic features of γδ T 
cells in general, and provide strong motivation for understanding these roles at a molecular 
level. Despite this, and despite the recognised importance of NKG2D/ligand interactions in 
influencing DETC functions, the exact role of the γδ TCR in these processes, as for Vδ2-
negative T cells, is unclear. As outlined more fully in Chapter 5, likely to be of key 
importance is a molecule termed Skint-1, which is required for thymic development of DETC, 
and is a candidate ligand expressed constitutively on keratinocytes (Lewis et al, 2006) and in 
the thymus (Boyden et al, 2008). Consistent with this possibility, recent imaging data suggest 
that DETC TCRs may constitutively recognise unknown ligands on keratinocytes even in the 
absence of stress stimuli (Chodaczek et al, 2012). Although these findings highlight Skint-1 
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as potentially crucial molecule for DETC γδ T cells both in their selection and function in the 
periphery, our molecular knowledge of Skint-1 and related family members is poor.  
 
1.9 Aims of this thesis 
The γδ T cell receptor was identified at approximately the same time as the αβ T cell receptor. 
Whereas the ligands bound by αβ TCRs are well known, and how they are recognised is well 
understood, in contrast our knowledge of the ligands recognised by γδ TCRs remains poor. As 
outlined above, a number of ligands have been proposed, many based on cellular activation 
assays utilising γδ T cell clones or by use of γδ TCR transfected lines. However in many cases 
a direct binding interaction between the TCR and ligand has not been convincingly 
demonstrated.  
 
This thesis aimed to progress our understanding of γδ ligand recognition, and focussed on two 
systems. Firstly, focussing on Vδ2-negative γδ T cell recognition in the context of CMV 
infection, I developed a line of research based on identification of Endothelial Protein C 
Receptor by Dr C. Willcox as a ligand recognised by a Vδ2-negative γδ TCR. This γδ TCR 
derived from a T cell clone (LES) induced in acute CMV infection that displayed a dual 
reactivity against CMV-infected target cells and transformed tumour cell lines, properties 
typical of the Vδ2-negative subset as a whole. Partly to help validate this putative ligand, I 
first generated soluble γδ TCR for direct binding studies (Chapter 3). To understand the 
binding mode of the interaction, I carried out an extensive mutagenesis study of the EPCR 
molecule (Chapter 4). Based on the similarity of EPCR to CD1d, it seemed likely that the 
LES γδ TCR recognised the α1α2 lipid-binding platform of EPCR, analagous to recognition 
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of CD1d by the NK TCR. The results had significant implications for understanding how γδ T 
cell recognition of EPCR might take place in the immune response. 
 
In a second line of investigation, I carried out structural studies on Skint-1, a selecting ligand 
and putative TCR ligand for the murine DETC subset of γδ cells, as well as a prototypic 
member of a family of related molecules. In Chapter 5, I describe production of the soluble 
Skint-1 molecule and both X-ray crystallographic and NMR-based approaches I adopted to 
define its structure. Following successful determination of a partial structure of the Skint-1 
ectodomain, I carried out a comprehensive structural analysis, which is described in Chapter 
6.  
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Chapter 2: Materials and Methods 
 
2.1 Molecular Cloning 
2.1.1 Expression Plasmids 
pET23a (Novagen) and pGMT7 (Invitrogen) plasmids were used in the prokaryotic 
expression of Skint-1 and LES γδ TCR. The eukaryotic S2 Drosophila plasmid vector, 
pMT/BiP/V5-His (Invitrogen), was used to express LES γδ TCR, MAU γδ TCR, endothelial 
protein C receptor (EPCR) and EPCR site directed mutants. The pMT/BiP/V5-His vector 
contains a metallothionein (MT) promoter for high level, metal-inducible expression of the 
target gene in S2 cells and a poly-histidine (6xHis) tag for detection and purification of the 
target protein. The selection plasmid pCoHygro (Invitrogen), consisting of the bacterial 
hygromycin B phosphotransferase gene under the control of the constitutive Drosophila 
Copia 5′-LTR promoter, was used for stable transformation. The linear maps of plasmids used 
in this thesis are shown in Figures 2.1 and 2.2. 
  
2.1.2 Primers 
Custom primers were designed and then purchased from Invitrogen 50nmol scale. Desalted 
primers were reconstituted in 10mM Tris pH8/1mM EDTA and stored at -20°C. Primer 
sequences are listed in Table 2.1. DNA amplification for the gene of interest was performed 
using proofreading polymerases including Pfu Turbo (Agilent), Phusion (New England 
Biolabs) and Velocity (Bioline). Polymerase chain reaction (PCR) mixtures typically 
consisted of 200nM dNTPs (Invitrogen), 20 pmoles of each primer, 1x polymerase buffer, 2.5 
units of polymerase enzyme, 200ng of DNA template and made up to 50μl with molecular 
grade water (Sigma). All thermal cycling experiments were performed using a 2720 thermal 
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Figure 2.1. Linear plasmid maps highlighting the restriction sites used to clone TCR γ and δ 
in Drosophila (a-b).   Linear plasmid map used to express EPCR in Drosophila (c). 
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Figure 2.2. Linear pET23a plasmid maps highlighting the restriction sites used to clone LES γ 
and δ TCR chains (a), Skint-1 IgV-IgC and Skint-1 IgV (b). 
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cycler (Applied Biosystems). PCR thermal cycling conditions consisted of 95°C for 3 minutes 
followed by 30 cycles of 95°C for 30 seconds (denaturation), 55°C for 30 seconds (annealing) 
and 72°C for 1 minute per kilobase (extension), followed by a final extension step of 72°C for 
10 minutes. 
Primer identification Sequence 
Skint-1 Ectodomain 5’ 5’ggg aat tc cat atg agt tca gaa cca ttt ata gtt aat ggt 
tta gaa ggg ccag tcttggc 
Skint-1 Ectodomain 3’ 5’ggcctc gag cta ttt cca aat cct att cca tga aaa aaa tg 
Skint-1 IgV SDM 5’ 5’ cagag gtc aag atc aca tag gcc ata aac tta cagg 
Skint-1 IgV SDM 3’ 5’ cctgtaagtttatggc cta tgt gat ctt gac ctctg 
Skint-1 CCLQ second C SDM to S 5’ 5’ cttccagaaagtcatttgttctcttcagaaccctctaac 
Skint-1 CCLQ second C SDM to S 3’ 5’ gttagagggttctgaagagaacaaatgactttctggaag 
LES γ TCR baculo zipper construct 5’ 5’ tcccccgggtcttccaacttggaagggagaacgaagtc 
LES γ TCR baculo zipper construct 3’ 5’ cgtctagagcaactgtctttgggatccactgtggtgacatctg 
LES δ TCR baculo zipper construct 5’ 5’ cgggatccgaccagcaagttaagcaaaattcacc 
LES δ TCR baculo zipper construct 3’ 5’ cgtctagagcagctctttgaaggttgctttgtg 
LES γ TCR + zipper into Drosophila 
construct 5’ 
5’gaagatcttcttccaacttggaagggagaacgaagtcagtcatcagg 
LES γ TCR + zipper into Drosophila 
construct 3’ 
5’ ggccaccggtctgagccagttccttttccagtgcttgcaactc 
LES δ TCR + zipper into Drosophila 
construct 5’ 
5’ gaagatctgaccagcaagttaagcaaaattcaccatccctgagc 
LES δ TCR + zipper into Drosophila 
construct 3’ 
5’ggccaccggtctgggcgagtttcttcttgagggcttgaagtttcc 
Baculovirus zipper sequencing primer 
residues E H T S K M 
5’ g gaa cac aca agc aag atg 
 
Sequencing forward primer Acid/base 
zipper residues LLAAAAH 
5’ ctt ttg gcg gcg gcg gcg cat tc 
Sequencing forward primer Acid/base 
zipper residues LLAAAAH 
5’ ctt ttg gcg gcg gcg gcg cat tc 
Sequencing reverse primer Acid/base 
zipper 3C protease region 
5’ cc ctg gaa cag aac ttc cag 
Sequencing forward primer Acid/base 
zipper 3C protease region LEVLFQG 
5’ ctg gaa gtt ctg ttc cag gg 
Sequencing Basic/Acid Baculo zipper 
reverse primer QERIRS 
5’ c cag gaa agg atc aga tct g 
Drosophila primer 5’ N-terminal end 5' caatgtgcatcagttgtg 
Drosophila primer 5’ C-terminal end 5' catgtctggatcctcgatc 
Reverse TCR δ chain-basic zipper primer 
to BirA tag 
5’ ggcctt ctc gag ctg ggc gag ttt ctt ctt gag g 
 
EPCR 5’ Drosophila primer 5’ ggt ccatgg agccaagacgcctcagatggc 
EPCR 3’ Drosophila primer 5’ gg ctcgag cgaagtgtaggagcggcttgtttgg 
Table 2.1. Primers used in amplification and sequencing of Skint-1, LES γδ TCR and 
EPCR. 
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2.1.3 Restriction enzyme digest 
Restriction enzymes (obtained from Roche and New England Biolabs) were used with the 
appropriate buffer at manufacturer’s recommended concentration. Restriction digests were 
carried at the suggested temperatures for a minimum of 1 hour. To improve downstream 
experiments many of the digestion experiments were purified using the PCR purification kit 
(Qiagen). 
 
2.1.4 DNA agarose gel electrophoresis and gel purification 
DNA samples prepared in 1x loading dye (40% sucrose, 0.5% bromophenol blue) were 
analysed by agarose gel electrophoresis at the required percentage (0.6% to 1.2%) run in TBE 
buffer (89 mM Tris base, 89 mM Boric acid and 2 mM EDTA) at 80V. DNA was visualised 
by the addition of ethidium bromide. Ethidium bromide intercalates into DNA and fluoresces 
in ultraviolet light. DNA fragment sizing was carried out by measuring amplified DNA 
against DNA ladders of the appropriate size (100bp and 1kb ladders; Invitrogen). Agarose gel 
and solution purification of digested vectors and PCR amplified inserts were carried out with 
the QIAquick Gel Extraction Kit (Qiagen). Digital images of agarose gels were recorded 
using the Syngene documentation system and quantified with the Gene Snap software 
(Syngene). 
 
2.1.5 DNA Ligation 
To obtain the most efficient ligation the digested vectors were treated with alkaline 
phosphatase (Roche) at 37°C for 30 minutes, to prevent self-ligation of the vector and 
promote the insert DNA ligating into the vector. DNA ligations were carried out at differing 
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vector to insert ratios overnight using T4 DNA ligase (Roche) as per manufacturer’s 
guidelines. 
 
2.1.6 Lysogeny broth media and pouring LB agar plates 
Lysogeny broth (LB) media consisting of 10g bactotryptone, 10g NaCl and 5g of yeast were 
mixed in a litre of deionised water and autoclaved. For LB agar plates, 15g of agar was added 
to LB media and autoclaved. The flask was allowed to cool in a water bath (50-55°C) for 30 
minutes before adding the antibiotic at the appropriate concentration (e.g. chloroamphenicol 
35 μg/ml, kanamycin 50 μg/ml or ampicillin 100 μg/ml). The LB-agar media was poured into 
plates and left to cool at room temperature for 60 minutes before storing at 4°C. 
 
2.1.7 Transformation of bacteria 
TOP10 chemically competent E. coli cells (Invitrogen) were thawed on ice. To the thawed E. 
coli cells (50 µl) 10-50ng of plasmid DNA were added and incubated on ice for 30 minutes. 
After the incubation period cells were heat shocked for 30 seconds at 42°C in a water bath. 
Immediately following heat shocking, 250 μl of SOC medium was added and then incubated 
at 37°C for 1 hour at 200 rpm to allow for the resistance gene to be incorporated into the host 
genome. The final transformation mix was then plated (100 µl) onto a pre-warmed LB 
ampicillin agar plates (supplemented with appropriate antibiotic) and incubated overnight at 
37°C. 
 
2.1.8 DNA miniprep isolation 
A single colony from a freshly transformed E. coli plate was selected and inoculated into 5ml 
of LB medium (e.g. 100 μg/ml ampicillin) and grown overnight in an orbital rotating shaker at 
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37°C/200 rpm. In the following morning, bacterial cell cultures were harvested by 
centrifugation (13,000 rpm) using a bench top centrifuge (Heraeus Biofuge Fresco 21) to 
recover the bacterial pellet. Miniprep plasmid isolation was conducted with the QIAprep Spin 
Miniprep kit (Qiagen) using the manufacturer’s guidelines. To obtain higher yields of plasmid 
DNA, a Maxiprep was undertaken using a Plasmid Maxi kit (Qiagen). The DNA yield and 
purity were assessed by agarose gel electrophoresis. Successful DNA cloning was confirmed 
by test digestion of plasmid DNA followed by a final confirmation through DNA sequencing. 
 
2.1.9 Dideoxy terminator sequencing 
DNA sequencing was conducted by the Functional Genomics service (University of 
Birmingham) utilising the Bigdye terminator sequencing kit (Applied Biosystems). 
 
2.2 Prokaryotic protein production 
Bacterial protein expression was undertaken using the bacterial transformation protocol as 
described previously but using a strain of E. coli that is modified to express protein 
(BL21(DE3)pLyS; Novagen), the pLyS is deficient in the ion and ompT proteases which 
increases the stability of expressed proteins. These cells were transformed with an expression 
plasmid as described previously and induced by adding 500μM isopropyl β-D-1-
thiogalactopyranoside (IPTG) to the culture during the exponential growth phase of the 
bacteria which then allowed inducible expression of the target protein.  
 
2.2.1 Small-scale test protein expression 
Typically, 0.5-1µl of the expression plasmid DNA was transformed overnight into 20 µl of 
chemically competent BL21(DE3)pLysS E. coli cells at 37°C. A single colony was inoculated 
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into 5 ml of LB culture medium (containing appropriate concentrations of antibiotic). The E. 
coli cells were then cultured by shaking at 37°C until an optical density of 0.4-0.6 OD600 was 
achieved. At this point, a 100 µl aliquot of the pre-induced culture was retained and stored at 
4°C. The culture was then induced with IPTG to a final concentration of 0.5mM, after 3-4 
hours post-induction, another 100 µl aliquot was retained for comparison with the pre-induced 
sample using SDS-PAGE. Both samples were subjected to centrifugation for 5 minutes at 
13,000 rpm to pellet cells. The pre and post induced pellets were resuspended in 10 µl and 20 
µl water, respectively. Reduced loading dye (containing DTT) was added to samples and 
heated at 95°C for 5 minutes. After heating, samples were vortexed and centrifuged before 
loading onto the SDS-PAGE gel (8 µl for pre-induced sample and 5 µl for post-induced 
sample) as described in section 2.3.  
 
2.2.2 Large-scale expression and inclusion body preparation 
Large scale expression of protein was conducted in 3-4 litres of LB media cells were grown to 
O.D. 0.4 to 0.6 and induced with IPTG for 3-4 hours. The bacterial cell pellet was harvested 
by centrifugation at 5000 rpm for 20 minutes in a Beckman Avanti 25 centrifuge. Harvested 
cells were resuspended in 50mls of PBS and lysed by sonication with a Misonix 3000 
sonicator using 5 x 45s sonication pulses (power level 8) with 15s cooling between pulses. 
The sonicated preparation was then subjected to centrifugation at 15000rpm for 30 minutes 
using a Beckman centrifuge (Avanti J-26 XP) to isolate the protein inclusion bodies. The 
protein inclusion fraction was then subjected to three detergent wash steps to remove 
contaminants, membrane components and cellular debris. This encompassed homogenisation 
of the inclusion pellet in 25 ml of Triton containing buffer (500 mM Tris-HCL pH 8, 0.5 % 
Triton X-100, 200 mM NaCl, 10 mM EDTA, 0.1% (w/v) Na Azide, 2 mM DTT) followed by 
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centrifugation at 13500 rpm for 15 minutes to recover inclusion body pellet from bacterial 
lysate. After the three Triton washes, a resuspension wash was conducted (500 mM Tris-HCL 
pH 8, 200 mM NaCl, 10 mM EDTA, 0.1% (w/v) Na Azide, 2 mM DTT) to remove residual 
detergent and salt from the protein inclusions. At this point the purified inclusion bodies were 
solubilised into denaturant buffer (8M Urea, 50 mM MES pH 6.5, 10 mM EDTA, 2 mM 
DTT) and incubated overnight at 4°C on a 3D gyratory rocking platform shaker (Stuart 
Scientific). Protein concentration was evaluated using a Bradford dye-binding assay 
(BioRad). Briefly, 5µl of protein sample (diluted appropriately) was added to 1ml of diluted 
Bradford reagent (1:5) in a non-UV cuvette and mixed. The spectrophotometer (Eppendorf) 
was calibrated with a blank and the OD595 of the protein sample was measured. The 
concentration of the test protein sample is determined by comparison against a series of 
bovine serum albumin (BSA) standards known to reproducibly demonstrate a linear 
absorbance profile in this assay. The equation below demonstrates how to determine protein 
concentration. 
  
Protein concentration (μg/ml) = Protein OD reading x dilution factors /0.05 (BSA) standard 
reading 
 
2.2.3 Oxidative refolding of denatured protein 
In vitro refolding of inclusion bodies was performed using the Garboczi oxidative dilution 
refolding method (Garboczi et al, 1992), utilising ~30mg of protein in 500ml refold mixture 
(100 mM Tris-HCl pH8, 400 mM L-arginine, 2 mM EDTA, 5 mM reduced glutathione, 
0.5mM oxidised glutathione and 0.1 mM PMSF) overnight at 4°C. Protein was added in a 
drop wise manner to reduce protein aggregation. The refolded mixture was then concentrated 
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to ~10ml using an ultrafiltration unit (Amicon) under nitrogen pressure (50 psi), with an 
appropriate sized molecular weight cut-off membrane (10 kDa). An alternative oxidative 
refolding method (Willcox et al, 1999) was also attempted to enhance refolding yields. This 
method used a high concentration of denaturant in the refold mixture (5M Urea, 100mM Tris-
HCl pH8, 400mM L-arginine, 2mM EDTA, 5mM reduced glutathione, 0.5mM oxidised 
glutathione and 0.1mM PMSF) and was left to stir at 4°C overnight. The refolded protein was 
then dialysed overnight at 4°C to reduce the denaturant levels (1:10 ratio dialysis in 100mM 
urea). A secondary dialysis step was performed to decrease the concentration of Tris in the 
refold mixture (1:10 ratio, 100mM Urea, 10mM Tris-HCl pH8 at 4°C). The dialysed protein 
mixture was then concentrated down and purified by ion exchange (section 2.2.4) and/or size 
exclusion chromatography (section 2.2.5). 
  
2.2.4 Ion exchange Chromatography 
Ion exchange was carried out on a BioCAD

/SPRINT Perfusion Chromatography system 
(Perseptive Biosystems). The dialysed protein mixture was loaded onto a POROS 10HQ 
analytical anion exchange columns (Perseptive Biosystems), pre-equilibrated with 0.1M Bis 
Tris propane pH 8.3 at a flow rate of 5 ml/min. In total, 7 x 200 ml aliquots were loaded, and 
for each run bound protein was eluted with a linear gradient of NaCl (0-400 mM) over 50 
column volumes. Peak eluted fractions were initially analysed by SDS-PAGE, pooled and 
stored at -20°C. 
 
2.2.5 Size exclusion chromatography  
The refold mixture containing renatured protein was filtered using 0.45µm filter disc. The 
mixture was purified by size exclusion chromatography on a Superdex 200 column pre-
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equilibrated with 20mM Tris-HCL pH 8 and 50mM NaCl, using an AKTA FPLC (fast protein 
liquid chromatography) (GE Healthcare). This purification step was carried out at room 
temperature at a flow rate of 3 ml/min, and the eluate was collected in 5 ml fractions. The 
elution profiles were analysed by using the Unicorn (version 4) software (Amersham 
Biosciences). Fractions corresponding to discrete elution peaks were analysed by SDS-PAGE 
(section 2.3). 
 
2.2.6 TCA protein precipitation 
All experimental procedures were performed on ice unless otherwise stated. To a protein 
solution, pre-cooled trichloroacetic acid (TCA) was added at a final concentration of 10% 
(v/v). This solution was mixed and incubated on ice for 5 minutes, after which the sample was 
centrifuged for 5 minutes at 4°C with a speed of 13000 rpm (Heraus Biofuge). Following 
centrifugation the supernatant was discarded and the pellet was resuspended with pre-chilled 
acetone solution. This mixture was centrifuged for 2 minutes at 4°C with a speed of 13000 
rpm and the supernatant discarded. The latter step was then repeated and the sample tube was 
then air dried to remove residual acetone. The pellet was re-suspended with 10-20μls of water 
and analysed by SDS-PAGE. 
 
2.3 SDS-PAGE  
Denaturing protein gels were carried out according to the method described by Schagger and 
Von Jagow, 1987. Protein purity and quantification was evaluated using the mini protean 3 
multi casting chamber system (BioRad). Briefly, SDS-PAGE resolving acrylamide gels of 12-
15% (0.765M Tris pH8.8, 0.2% SDS), 5ml 30% acrylamide (Geneflow), 0.1% ammonium 
persulphate (stock concentration 10%) and 4μl TEMED (Sigma) were mixed and then 
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pipetted into a 1mm BioRad gel cassette. To level the resolving gel and minimise air bubbles, 
1ml of isopropanol was added. Whilst the resolving gel was setting the stacking gel was 
prepared (150mM Tris pH6.8, 0.12% SDS, 0.1% ammonium persulphate and 4μl TEMED). 
Once the resolving gel had set the isopropanol was removed and the stacking gel was added 
on top followed by insertion of a 1.0mm 10-well comb. Protein samples were prepared by 
mixing ~1-20μl of protein with 2-4μl of 5x loading buffer (containing 125mM Tris pH8, 8M 
urea, 10% glycerol, 6% SDS, bromophenol blue and +/- 200mM DTT) and made up to a final 
volume of 10-20μl with deionised water. Samples were vortexed, boiled at 80°C for 5 
minutes, centrifuged for 30 seconds before loading onto the SDS-PAGE gel. 10 x SDS-PAGE 
running buffer (0.1% w/v SDS, 90g Tris, 183g Glycine) was diluted 10-fold and poured into 
the SDS-PAGE tank. Protein samples were resolved by applying an electric current across the 
acrylamide gel at constant 100V for electrophoresis through the stacking gel and then 
subsequently increased to 185V for migrating through the resolving gel. Once the coomassie 
dye had migrated to the bottom of the gel, the gel was stained in coomassie blue stain 
(Brilliant blue 0.5g, 250 ml methanol and 50 ml acetic acid) for 30 minutes and de-stained 
overnight in destain buffer (10% acetic acid, 30% methanol) to visualise protein bands. SDS-
PAGE gel images were recorded utilising the Syngene gel documentation system (Syngene). 
 
2.4 Eukaryotic protein production  
2.4.1 Expression in S2 Drosophila cell line 
Protein expression vectors encoding the proteins of interest (pMT/BiP/V5-His) and selection 
plasmid pCoHygro conferring Hygromycin B resistance were co-transfected into the S2 
Drosophila cell line. The cells were grown in a selecting medium (Schneider’s Drosophila 
medium, modified with L-glutamine, Lonza) consisting of 10% fetal bovine serum 
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incorporated with 0.3mg/ml Hygromycin B. Every 4-5 days, cells were subcultured into fresh 
medium containing 5-10% conditioned medium. Small volumes of culture (15-20 ml) were 
seeded at a density of 1x10
6
cells/ml into T-75 flasks and incubated at 27°C, enabling the cells 
to grow semi-adherently. For expression, cells were adapted to shaking cultures and were 
seeded at a density of 1.2x10
6
cells/ml, with 0.05% Pluronic F-68 surfactant (Gibco) to 
prevent large-scale cell clumping. The flasks were incubated at 27°C at constant shaking rate 
of 80rpm. Once cells reached log phase protein expression was induced by adding copper 
sulphate (500 µM) once cells reached a density of 4-10x10
6
cells/ml. After five days the cell 
supernatant was harvested by centrifugation (two spins; first at 50 rpm for 10 minutes and 
second at 2500 rpm for 10 minutes) and following the addition of 0.02 % of Sodium-Azide, 
stored at 4°C until purification. Expression of Drosophila expressed target proteins were 
analysed by Western Blot.  
2.4.2 Western Blot/Dot Blot 
Protein samples were first separated by SDS-PAGE as described previously. All separated 
proteins were transferred (Towbin et al, 1979) onto a PVDF membrane (Hybond LFP, GE 
Healthcare) for one hour (300V/400mA) using a transfer buffer (10% Methanol, 190mM 
Glycine, 25 mM Tris). The PDVF membrane was incubated for one hour or overnight at 4°C 
in blocking buffer (5% milk) in order to minimize non-specific antibody binding. The 
membrane was subsequently washed three times with 20mM Tris pH 7.5, 150mM NaCl 
(1xTBS) + 0.1 % Tween-20 (Sigma) for five minutes. The membrane was incubated with the 
primary antibody diluted in 1xTBS + 0.1% Tween + 3% BSA (mouse anti-C terminal HIS 
(Invitrogen) 1:5000 dilution) for 1 hour at room temperature. The membrane was then washed 
three times, each for 5 minutes, with 1xTBS + 0.1 % Tween-20. The secondary antibody 
(HRP-conjugated, anti-mouse, goat mAb 1:20000 dilution, Sigma) was added in 5% milk + 
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1xTBS + 0.1% Tween and incubated for 1 hour at room temperature. Antibody binding and 
fluorescence was visualized by using the “EZ-ECL Chemiluminescence Detection Kit for 
HRP” (Biological Industries). Briefly, this involved mixing 500 µl of solution A with 500 µl 
solution B and then incubating for five minutes at room-temperature. This mixture was added 
onto the membrane and incubated for five minutes at room-temperature. The membrane was 
placed into a cassette and taken to a dark-room, where a light sensitive film (Amersham 
Hyperfilm
TM
 MP, GE Healthcare) was placed for 10 or 20 seconds on the membrane before 
the film was developed.  
2.4.3 Nickel-NTA Chromatography 
S2 supernatant was placed into dialysis tubing (10 kDa cut-off size, Sigma) and dialysed 
against PBS buffer (1:10 ratio) overnight at 4°C to remove amino acids which compete for 
binding to nickel beads. 1ml of Nickel-beads (Ni-NTA agarose stored in 20% ethanol, 
Qiagen, binding capacity of 25mg/ml) was added to an Econo column (BIO-RAD) and 
equilibrated in 1x PBS + 10 mM Imidazole. The dialysed S2 supernatant was passed over the 
beads by gravity flow at 4°C overnight at approximately 1ml/min. On the next day, the 
column was washed with 1x PBS + 10 mM Imidazole to remove the majority of non-specific 
proteins. The levels of eluted non-specific proteins were evaluated by measuing the optical 
density of the wash through at OD280 at several time points. Once all non-specific proteins had 
been eluted, the column was filled with 1x PBS + 250 mM Imidazole (~10 ml) and left for 30 
minutes. After this period the target His-tagged proteins were collected in 1ml fractions, 
quantified by measuring optical density at 280 nm and stored at -20°C. Target proteins utilised 
for binding and structural studies were further purified by size exclusion chromatography. 
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2.5 Deglycosylation assays 
Proteins expressed in Drosophila S2 cell lines were utilized in these assays. For analytical 
samples the deglycosylation experiments with either PNGase F (Roche) or Endonuclease H 
(New England Biolabs) were performed according to the manufacturer's instructions. Prior to 
enzymatic treatment, samples were denatured by boiling for 10 minutes in the presence of 
denaturing buffer (50 mM sodium phosphatase, pH 7.5, 0.02% SDS, 10 mM 2-
mercaptoethanol). One unit cleaves 10μgs of protein at 37°C for 1 hour then the cleavage 
reaction was stopped by heating to 100°C for 5 minutes and deglycoslated protein was 
evaluated against native protein by SDS-PAGE analysis. For functional experiments, proteins 
were treated with PNGase F (10ugs protein per unit enzyme) in PBS for one hour at 4°C 
before surface plasmon resonance analysis.  
2.6 3C Cleavage of TCR 
Cleavage of purified gamma/delta TCRs, containing a 3C protease cleavage site following the 
C-terminal cysteine of each chain, was performed using Human RhinoVirus 3C protease 
enzyme (Novagen) at a concentration of 1U/100μg protein. Cleavage reactions were 
incubated for 2 hours at 4°C. Removal of excised acid/base zipper and 3C protease enzyme 
was undertaken by incubating with 200μl of Ni-NTA beads overnight at 4°C with constant 
mixing. On the following day, confirmation of the cleavage reaction was assessed by SDS-
PAGE.  
 
2.7 Surface Plasmon Resonance 
2.7.1 Biotinylation of Proteins 
Soluble proteins purified by Ni-NTA and/or size exclusion chromatography were buffer 
exchanged into biotinylation buffer (100mM Tris pH7.5, 20mM NaCl, 5mM MgCl2) using 
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PD10 desalting columns (GE Healthcare). The PD10 column was initially equilibrated three 
times with 3.5 ml of biotinylation buffer. Following priming with the biotinylation buffer, 
soluble protein sample (~3 ml) was loaded onto the PD10 column and then eluted with 
biotinylation buffer (~3 ml). Biotinylation reactions were carried previously (O’Callaghan et 
al, 1999) using 0.56mM Biotin (Sigma), 1mM ATP (Sigma), 1x protease inhibitors (25x 
concentrated, Roche) and BirA enzyme (In house product) incubated at 24°C for 1 hour and 
then at 4°C overnight. The following day excess biotin was removed from the protein sample 
by size exclusion chromatography as described previously.  
 
2.7.2 Experimental Procedure 
Protein-protein binding studies were carried out at 25°C with the University of Birmingham 
BIAcore 3000 machine (BIAcore, GE Healthcare) using HBS-EP as running buffer (10mM 
HEPES pH 7.4, 150mM NaCl, 3.4mM EDTA, 0.005% surfactant P20). A new CM5 sensor 
chip was docked and the system primed with water. Then 500μl of BIAnormalising solution 
was injected at a flow rate of 10μl/min to normalise the instrument signal. Streptavidin was 
immobilized onto CM5 binding chips using standard amine coupling chemistry at pH 5.0. 
Briefly, equal volumes (50µl + 50µl) of 0.2M N-ethyl-N5 (3-diethylaminopropyl)-
carbodiimide (EDC) and 0.5M N-hydroxysuccinimide (NHS) were mixed, and immediately 
injected at 10μl/minute to activate the sensor chip. The next step consisted of injecting 60μl of 
streptavidin (dissolved in 10mM Sodium Acetate pH 5.5 at final concentration of 0.5 mg/ml) 
over surface of all four flow cells. This was followed by a third injection with 70μl of 1M 
ethanolamine pH 8.5 to block the remaining active carboxyl-esters on the surface. Finally 
500μl of Glycine-HCl pH2.5 was injected to remove any uncoupled streptavidin. The levels 
of streptavidin immobilised to each flow cell were calculated in response units, using the 
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BIAevaluation software. Biotinylated protein samples (in PBS buffer) were diluted in HBS-
EP buffer and immobilised to streptavidin at a flow rate of 5μl/min. The remaining flow cells 
were injected either with control protein, irrelevant protein or left blank. Each flow cell was 
immobilised with similar levels of protein. Analytes were incubated on ice and centrifuged at 
13,000 rpm prior to injections to remove any aggregates formed. Analytes were serially 
injected over each flow cells at a flow rate of 10μl/minute. For test injections, 30μl was 
injected. Equilibrium affinity measurements were performed by calculating the analyte/ligand 
binding response interaction following serial dilutions of analyte (100μM-1.25μM) in HBS-
EP at a flow rate of 10μl/minute. The affinity studies were performed in both orientations. 
Data were collected at 10Hz. Data was analysed with the BIAevaluation software (BIAcore 
AB) and Origin Pro 8 software (OriginLab Corporation). 
 
2.8 X-ray Crystallography 
2.8.1 Crystallisation Trials 
Prior to crystallisation trials, protein samples purified by Ni-NTA or size exclusion 
chromatography were concentrated to 5-10 mg/ml using a microcon centrifugal filter device 
(Millipore) with a YM-10 cut-off membrane. The purity and homogeneity of the concentrated 
protein samples were assessed by SDS-PAGE under reducing and non-reducing conditions. 
Initial crystallisation screening involved using the hanging drop vapour diffusion method with 
the Mosquito nanolitre crystallisation robot (TTP LabTech). The preliminary crystallisation 
conditions were identified using commercially available sparse matrix screens from 
Molecular Dimensions (JCSG
+
, Pact, MIDAS, ProPlex), Hampton Research (PEG/Ion I and II 
and Index) and Emerald Biosystems (Wizard I/II and III). The hanging drops were obtained 
by pipetting 100 nl of protein sample with 100 nl of crystallisation reagent onto a ViewDrop 
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II 96-well plate seal (TTP LabTech). This was suspended over a 96-well plate (Iwaki) 
containing 100 µl of reservoir solution, then sealed and allowed to equilibrate by vapour 
diffusion at 23°C. After 3-4 days each drop was assessed for crystal growth using a light 
microscope (Leica). The most promising initial crystallisation hits were optimised by varying 
the pH, incubation temperature, protein concentration, and incorporating additive (Molecular 
Dimensions) and detergent (Hampton Research) screens. Larger diffraction-grade crystals 
were grown by manually setting up larger drops using 24-well Linbro plates (Molecular 
Dimensions). Briefly, equal volumes of protein sample were mixed with crystallisation 
reagent (usually 1+1µl drops) on a cover slip that was inverted onto a greased well containing 
1 ml of the reservoir solution. The drops were then allowed to equilibrate by vapour diffusion 
for several days before they were viewed for crystal growth as described previously.  
 
2.8.2 X-ray Data Collection and Processing 
Prior to data collection, crystals were selected using cryoloops and soaked in reservoir 
solution supplemented with increasing concentrations of ethylene glycol or glycerol 
cryoprotectant (5% to 20% in 5 % increments) before being flash-cooled in liquid nitrogen. 
All crystals were stored in a cryogenic dewar (Molecular Dimensions) prior to X-ray 
diffraction experiments. All X-ray diffraction studies were carried out using the University of 
Birmingham Macromolecular X-ray Facility which houses a Micromax 007HF rotating anode 
X-ray generator (Rigaku) and Saturn charged coupled device. All data collection 
manipulations were performed using the CrystalClear (Rigaku) software. Intensity data were 
integrated, scaled and merged using programs of the XDS suite (Kabsch, 2010).  
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2.8.3 Structure Determination  
The determination of initial phase information for Skint-1 was calculated with molecular 
replacement. Prior to molecular replacement calculations, solvent content calculations were 
performed with the CCP4 suite to determine the number of molecules per asymmetric unit. 
Molecular replacement calculations were performed with MOLREP (Winn et al, 2011) and 
Crystallography & NMR System (CNS) (Brünger et al, 1998). The sequence of the target 
protein was input into BLAST (basic local assignment search tool) 
(http://blast.ncbi.nlm.nih.gov) to identify putative search models for molecular replacement. 
 
2.9 Nuclear Magnetic Resonance (NMR)  
NMR experiments and analysis were performed in collaboration with Dr Timothy J Knowles 
using the Henry Wellcome Building for Biomolecular NMR Spectroscopy Facility 
(University of Birmingham). 1D, 2D and 3D backbone assignment spectra were recorded 
using Agilent Direct Drive 600, and Inova 800 and 900 MHz spectrometers equipped with 
HCN 5mm z-PFG cryogenic probes with enhanced 13C, 1H and 15N sensitivity. Machine 
calibration was performed using the external standard, DSS (4,4-dimethyl-4-silapentane-1-
sulfonic acid). 
 
2.9.1 1D Experiments 
Unlabelled Skint-1 at a concentration of 0.2mM in 20mM MES, 50mM NaCl pH 6.5 
(90%H2O, 10%D2O) was analysed in an Agilent direct drive 600MHz spectrometer equipped 
with HCN 5mm z-PFG cryogenic probes with enhanced 
13
C, 
1
H and 
15
N sensitivity. The 
standard Biopack (Agilent) 1D water experiment was used, with a pulse width of 8.775 µs, 
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spectral width of 13008 Hz and 4096 points. The spectrum was Fourier transformed, baseline 
corrected and analysed using MestraNova (Mestrelab). 
 
2.9.2 Heteronuclear single quantum coherence spectroscopy (HSQC) 
15
N-labelled Skint-1 at a concentration of 1mM in 20mM MES, 50mM NaCl pH 6.5 
(90%H2O, 10%D2O) was analysed in an Agilent direct drive 600MHz spectrometer equipped 
with HCN 5mm z-PFG cryogenic probes with enhanced 
13
C, 
1
H and 
15
N sensitivity. The 
standard Biopack (Agilent) fast nitrogen HSQC method was used, gNfhsqc, with a pulse 
width of 9.0 µs, spectral widths of 8397 Hz and 1944 Hz, and 1024 and 128 points in the 
proton and nitrogen dimensions respectively. The spectrum was apodized, zero filled to 2048 
and 256 points, respectively, Fourier transformed, phased, baseline corrected and analysed 
using NMRPipe software (Delaglio et al, 1995). 
 
2.9.3 Hydrogen-deuterium exchange 
Hydrogen-deuterium exchange experiments were performed on a 0.2mM 
15
N-labelled sample 
of Skint1 in 20mM MES, 50mM NaCl pH 6.5. The sample was divided equally between two 
standard 5mm NMR tubes (Wilmad), rapidly frozen in liquid nitrogen, then freeze dried using 
a lyophiliser (Thermo Heto PowerDry LL1500). To one sample H2O was added to the same 
volume as the sample prior to freeze drying. This sample was used for HSQC set up, a 
standard HSQC was taken as reference. Immediately prior to using, D2O was added to the 
second sample. Using the calibration performed for the H2O sample, HSQC experiments were 
performed within 5 minutes of D2O addition and then every 10 minutes for 2 hours. 
Following analysis, those amide resonances remaining after 1 hour were deemed to be 
involved in hydrogen bonding. 
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2.9.4 Backbone assignments 
Three dimensional backbone experiments were performed on a 1mM sample of 
13
C
15
N-
labelled sample of Skint-1 in 20mM MES, 50mM NaCl pH 6.5 in 90% H2O/10% D2O. 
Experiments included standard BEST versions of HNCA, HN(CO)CA, HN(COCA)CB, 
HNCACB, HNCO, and HN(CA)CO (Biopack, Agilent). All experiments were performed 
with pulse widths of 9.85 µs, spectral widths in the proton and nitrogen dimensions of 8869 
Hz and 2430 Hz respectively at 25
o
C. HNCA and HN(CO)CA experiments were performed 
with a spectral width in the carbon dimension of 5174 Hz. HN(COCA)CB and HNCACB, 
with a spectral width of 13025 Hz, and HNCO and HN(CA)CO experiments with a spectral 
width of 2454 Hz. Side chain assignments were performed on the same sample using the 
following experiments: H(C)CH-TOCSY (spectral widths of 6983, 6983 and 5880 Hz 
respectively in the 
1
Hx, 
1
Hy and 
13
Cz dimensions respectively) , HC(CO)NH (spectral widths 
of 6757, 8013 and 2000 Hz respectively in the 
1
Hx, 
1
Hy and 
15
Nz dimensions respectively), 
C(CO)NH (spectral widths of 6757, 7768 and 2000 Hz respectively in the 
1
Hx, 
13
Cy and 
15
Nz 
dimensions respectively) and HBHA(CO)NH (spectral widths of 6757, 3600 and 2000 Hz 
respectively in the 
1
Hx, 
1
Hy and 
15
Nz dimensions respectively). NOESY experiments were 
performed to provide restraints for structural characterisation. The following experiments 
were performed: 
15
N-edited NOESY-HSQC (τmix = 100ms, spectral widths of 8407, 10000 
and 2400 Hz respectively in the 
1
Hx, 
1
Hy and 
15
Nz dimensions respectively), 
13
C-edited 
NOESY-HSQC (τmix = 100ms, spectral widths of 9000, 9000 and 7840 Hz respectively in the 
1
Hx, 
1
Hy and 
13
Cz dimensions respectively) and 
13
C-edited aromatic-NOESY-HSQC (τmix = 
100ms, spectral widths of 7558, 8000 and 8000 Hz respectively in the 
1
Hx, 
1
Hy and 
13
Cz 
dimensions respectively). All spectra were apodized, zero filled to double the points, phased, 
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linear predicted, baseline corrected and analysed using NMRPipe (Delaglio et al, 1995) and 
SPARKY 3 (Goddard and Kneller, 2004) software. 
  
2.9.5 Data processing and analysis 
Data processing was conducted using the NMRPipe program (Delaglio et al, 1995), protein 
backbone assignments were conducted using the program SPARKY 3 (Goddard and Kneller, 
2004). Secondary structure prediction was conducted using backbone assignment data (CA, 
CB, CO, HA, HN, and N chemical shifts) implemented into the TALOS web server 
(Cornilescu et al, 1999). Proton distance constraints for the structure calculation were 
obtained through the analysis of three-dimensional 
15
N-edited and 
13
C-edited NOESY-HSQC 
spectra. Cross peaks were manually selected and the peak intensities measured using 
SPARKY 3 (Goodard and Kneller, 2004).  
 
The 3D structure was determined using the CANDID/CYANA package with the automated 
NOE cross-peak assignment and structure calculation with torsion-angle dynamics 
implemented (Güntert, 2004). The CYANA protocol consisted of seven iterative cycles of 
NOE assignment and structure calculation. The first cycles starts from 200 random 
conformers with 10,000 torsion-angle dynamic steps performed per conformer in each cycle 
with the results being used as input in the following cycle. The seven cycles were followed by 
a final structure calculation where 20 conformers with the lowest CYANA target function 
were chosen as representative. The final water minimisation was performed with ARIA1.2 
(Linge et al, 2001). A total of 894 NOES, 38 hydrogen bonds and 182 dihedral-angle 
restraints were fed in the final calculation. Structures were analysed using PROCHECK-NMR 
(Laskowski et al, 1993). The final structural statistics of the Skint-1 D1 ensemble are 
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highlighted in Table 4.2 (Chapter 4). The RMSD values from the average structure were 
calculated using the MOLMOL program (Koradi et al, 1996).  
 
Homologous structures were identified using the Dali server 
(http://ekhidna.biocenter.helsinki.fi/dali). Electrostatic surface maps were calculated with 
DELPHI (Rocchia et al, 2002) and viewed in PYMOL (http://www.pymol.org/). Protein-
protein interactions were analysed with programs of the CCP4 suite (http://www.ccp4.ac.uk/). 
Potential models were generated using one-to-one threading function with PHYRE 
(www.imperial.ac.uk/PHYRE). Putative protein-ligand docking sites were calculated using 
the SPPIDER web server (http://sppider.cchmc.org/). All molecular graphic figures were 
produced with PYMOL. 
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Chapter 3: Production of Soluble Vδ2-negative γδ T cell receptor 
 
3.1 Potential utility of soluble receptor for analysing γδ TCR ligand recognition  
 
Studies of αβ T cell recognition have benefited greatly from the availability of soluble T cell 
receptors (TCRs) and MHC molecules which has enabled analysis of TCR interaction with 
specific ligand. Early cell-based blocking experiments demonstrated that TCR affinity was in 
the µM range, several orders of magnitude lower than that of antibodies for their antigens 
(Matsui et al, 1991). Subsequently, production of soluble TCRs has enabled comprehensive 
biophysical analysis of ligand engagement by the receptor, using various different 
experimental approaches. Studies carried out using surface plasmon resonance (SPR) to 
analyse protein-protein binding, as well as structural examination using X-ray crystallography 
have clarified the molecular features of TCR/peptide-MHC interactions (Garbozci et al, 1996; 
Garcia et al, 1996). A wealth of structural studies published over the past 15 years have 
established a binding mode which places the hyper-variable loops of the CDR3α/β regions of 
TCR chains directly over the centre of the bound peptide, with CDR1α and CDR1β frequently 
contributing to peptide recognition by binding over the amino-terminal and carboxyl-terminal 
peptide regions. The germline encoded CDR1/2 loops of the αβ TCR predominantly contact 
the alpha helical regions of the MHC molecule (Wucherpfennig, 2010). Direct protein-protein 
binding assays, chiefly involving SPR; have established the range of TCR/pMHC affinities 
and indicated TCR binding typically involves slow association/dissociation kinetics and 
characteristic thermodynamic properties (Garcia et al, 1997; Boulter et al, 2007). In many 
cases it is believed these properties reflect conformational flexibility at the TCR binding site, 
particularly focused on the CDR loops, and are consistent with a model whereby where the 
unbound state of the receptor is dynamic but stabilised upon binding (Choudhuri K and van 
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der Merwe, 2007; Willcox et al, 1999). Conformational flexibility at the TCR/pMHC 
interface is likely to increase the potential number of peptide-MHC ligands TCRs bind.  
 
Historically soluble TCR production has been fraught with problems, although several TCR 
expression systems have emerged. Of these, one method of soluble TCR production involved 
prokaryotic protein expression and in vitro refolding (Figure 3.1) (Garbozci et al, 1996). 
Additional techniques were devised to produce soluble TCR D10 from insect cells (Reinherz 
et al, 1999). The two systems used for insect cell expression are the baculovirus expression 
method which allows for expression of glycosylated protein in a reasonable quantity. 
However the gene is not expressed continuously due to the host cell under going lyses and 
eventual death after infection (Steele et al, 2003). The other insect cells expression method 
incorporates a non lytic expression system where the insect Schneider 2 cells are stably 
transfected and do not lyse, therefore can undergo several rounds of replication. Although 
both systems have been used successfully to express TCR proteins, each has advantages and 
limitations in terms of the quality and quantity of soluble TCR expressed (Garcia et al, 1999). 
Insect cell expression provides folded, glycosylated soluble TCR but in limited yields. 
Prokaryotic expression can yield the highest levels of protein but the method will require the 
expressed protein refolded in vitro into the native state, a step that is frequently problematic 
(Hans Peter Sorensen, 2010). 
 
Our understanding of γδ TCR ligand recognition is at an infant stage compared with the field 
of αβ TCR-peptide MHC recognition. Historically work on αβ TCRs has demonstrated the 
ligand restriction and the molecular pattern for recognition by αβ TCRs. In contrast, 
experiments for determining γδ TCRs ligands are still considerably low in numbers. 
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Figure 3.1 Overview of recombinant TCR production in E. coli. The γ and δ chains are 
individually expressed in Rosetta cells as inclusion bodies and renatured by using an 
oxidative in vitro dilution protocol. Following refolding, the mixture is purified by anion 
exchange and size exclusion chromatography.  
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Nevertheless the production of soluble γδ TCR will be a valuable tool to help identify key 
target ligands for relevant γδ TCRs. Two γδ TCRs have been produced and utilised in 
structural studies. Allison, et al, (2001), used a prokaryotic system and then in vitro refolding 
of the TCR. This resulted in the structure of a human γδ TCR. Another technique was 
published by Crowley et al, 2000 using an insect cell expression approach. This technique 
allowed the characterisation of the interaction for the G8 murine γδ TCR with its non-classical 
MHC molecule ligands, T10/T22 (Crowley et al, 2000) and the solution of the G8 TCR 
structure in complex with T22 ligand (Adams et al, 2005).  
 
3.2 Selection of Vδ2-negative TCRs for soluble production 
γδ T cells are known to expand in many different infections and have also been shown to 
recognise tumour cells lines. Vδ2 negative cells in particular expand in CMV, HIV and other 
infections (Halary et al, 2005; De-Maria et al, 1992; Haregewoin et al, 1989), and dramatic 
expansions are often seen in immunosuppressed solid organ transplant patients with acute 
CMV infection (Déchanet et al, 1999). Furthermore individual γδ T cell clones from these 
patients were shown to have a dual recognition capability by responding to HCMV infected 
cells and tumour cell lines (Halary et al, 2005). The Vδ2-negative γδ T cells responded to 
HCMV infected cells and were unable to recognise cells that were infected with other viruses. 
The dual reactivity of these γδ T cells suggested recognition of host ligands induced under 
conditions of cellular stress, including CMV infection and cell transformation. In particular, 
two T cell clones were characterised extensively. The LES Vγ4Vδ5 T cell clone was isolated 
from a patient who received a lung transplant and who developed recurrent acute CMV 
infections (Lafarge et al, 2005), whereas MAU Vγ9Vδ1 T cell was isolated from a renal 
transplant patient. The TCR genes for these two T cell clones were isolated and transfected 
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into the TCR deficient jurkat 3 (JRT3) cell line. The JRT3 LES and MAU transfectants were 
stimulated by the very same cell lines that stimulated the T cell clones (Table 3.1). 
Cell Line LES MAU 
HT29   
K562  X 
U937  X 
HUTU80 X X 
HUH7 X X 
U373 X  
293T X  
HeLa EV2 X X 
HeLa PF X  
SKMES X  
Table 3.1. Analysis of different tumour cell lines for γδ TCR recognition. Cell lines which 
stimulate the relevant γδ clone or JRT3 transfectant (tick) compared to those that do not 
stimulate (cross). The LES and MAU γδ clones shows variable suggesting the two clones 
recognise independent antigens (Halary et al, 2005).  
 
Crucially, Halary et al, (2005) also demonstrated that TCR engagement was an important 
component of target cell recognition by LES and MAU γδ T cell clones. Use of anti-CD3 and 
anti-Cδ blocking mAbs to inhibit T cell activation of γδ T cell clones in response to CMV 
infected foreskin fibroblasts (FSF), suggested a requirement for TCR ligand recognition 
(Halary et al, 2005). Furthermore, specific TCR down regulation was highly suggestive of 
TCR involvement in T cell activation. In contrast, blocking NKG2D/ligand interactions 
illustrated that NKG2D was not pivotal in activating the T cell clones. These experiments 
strongly implied that cell activation was mediated by TCR/cognate antigen recognition 
(Halary et al, 2005). Collectively, these studies suggest that the LES and MAU γδ TCRs 
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mediate interactions with novel cognate antigens on the surface of tumour/CMV-infected 
cells, and emphasised these TCRs as interesting candidates for molecular analysis of human 
γδ TCR. To characterise the molecular interaction binding properties of LES and MAU γδ 
TCRs, collaboration with the Déchanet-Merville laboratory was undertaken. 
 
3.3 Production of soluble TCR utilising the Prokaryotic expression system 
Of the several different soluble TCR expression methods developed, prokaryotic expression 
systems have been the most widely used. Large numbers of αβ TCRs have been produced 
from protein purified from E. coli cells (Garboczi et al, 1996; Simpson et al, 2011). Such 
methods have advantages over insect cell expression in terms of speed, cost-effectiveness and 
yields (Hans Peter Sorensen, 2010). In addition, E. coli expression approaches were 
successfully used to express, refold and crystallise the G115 Vγ9Vδ2 TCR and determine its 
structure, providing an important precedent for prokaryotic production of human γδ TCR 
(Allison et al, 2001). Finally, there was considerable experience within the Willcox laboratory 
with respect to recombinant TCR production using E. coli cells and in vitro refolding methods 
(Willcox et al, 1999; Nicholls et al, 2009; Simpson et al, 2011). The strategy devised by 
Willcox et al, for promoting correct refolding of the TCR, consisted of incorporating the 
heterodimer domain of the c-Jun and v-Fos transcription factors onto the C terminal end of the 
α and β chains, respectively. Hence during the renaturation process, the Fos and Jun peptides, 
via their Leucine zipper moieties, facilitated formation of the TCR heterodimer without the 
requirement of a covalent linkage (Figure 3.2) (Willcox et al, 1999).  
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Figure 3.2 Schematic representation of the prokaryotic γδ TCR construct. Leucine zippers 
derived C-Jun and C-Fos were cloned onto the C terminal regions of the gamma and delta 
chains, respectively. Leucine moieties were incorporated to facilitate heterodimeric γδ TCR 
chain association (Willcox et al, 1999). 
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3.3.1 Cloning of LES and MAU TCR Leucine Zipper contructs 
In order to employ the Leucine zipper approach to generate LES γδ TCR, the Vγ4 and Vδ5 
chains were initially amplified by PCR from plasmid constructs supplied from the Déchanet-
Merville laboratory, using 5’ and 3’ primers enabling cloning into a prokaryotic expression 
vector, pET23a (see Figure 2.1). Each TCR expression construct contained an optimised 5’ 
region incorporating synonymous nucleotide alterations to improve expression. Pfu amplified 
PCR products were digested with NdeI and XhoI and purified to enable efficient cloning into 
pET23a expression vector digested with corresponding restriction enzymes. For the LES 
Vγ4Vδ5 TCR, the Leucine zipper constructs where cloned using restriction enzymes NdeI 
and PvuII for the γ chain and NdeI and BglII for the δ chain. A similar cloning strategy was 
undertaken for the production of the MAU Vγ9Vδ1 TCR zipper chains.  
 
3.3.2 Test Expression and Inclusion body preparation of LES and MAU TCR chains 
Having successfully cloned LES TCR zipper chains into pET23a, the Vγ4 and Vδ5 chain 
constructs were transformed into BL21 (DE3) pLys E. coli cells but unfortunately did not 
over-express protein in sufficient quantities. Hence, Rosetta E. coli cells, which are BL21 
derivatives and are designed to enhance expression of eukaryotic proteins that possess codons 
that are rarely used in E. coli, were utilised. Over-expression of the LES zipper constructs was 
verified by SDS-PAGE; test expression experiments indicated a clear induced band for each 
chain migrating to ~30 kDa, consistent with the predicted sequence derived molecular weight 
of the γ (~31.6 kDa) and δ (~30.2 kDa) chains, respectively (Figure 3.3a). However, there was 
a discrepancy in terms of the mobility of the δ chain through the SDS-PAGE gel. Although 
the predicted sequence derived molecular weight for the δ chain is ~30.2 kDa, an induced 
band was observed migrating approximately at 34-35 kDa. This deviation from the expected 
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Figure 3.3 a) SDS–PAGE analysis of LES γ and δ TCR chain test expressions in Rosetta E. 
coli cells. Molecular weight standards are shown in Lane 1, with masses indicated in kDa. 
Lanes 2 and 3 show pre (-) and post (+) induction samples of the γ chain (predicted weight 
31.7 kDa), respectively. Lanes 4 and 5 highlight pre (-) and post (+) induction samples of the 
δ chain (predicted weight 30.2 kDa), respectively. b) SDS-PAGE analysis of LES γ and δ 
inclusion bodies solubilised in 8M Urea. The δ chain is shown in Lanes 2, 3 and 4 (loaded 
13μg, 6.5μg and 0.1μg, respectively), whereas the δ chain is highlighted in Lanes 5, 6, 7 and 8 
(loaded 11μg, 5.5μg, 2.75μg and 0.55μg, respectively). 
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migration on SDS-PAGE could be attributed to the overall fold and charge of the TCR δ 
chain or due to the number of bound dodecyl sulphate to the protein and finally post 
translational modifications (Shi et al, 2012). Large scale expression and inclusion body 
preparation of LES γ and δ chains demonstrated that high yields were being produced. For 
example, typically from a 1L culture, 60-120 mgs of each chain were expressed as inclusion 
bodies based on the Bradford assay (Figure 3.3b). However, despite such high yields, the 
purity levels were poor relative to previous E. coli derived TCR expressed chains (Nicholls et 
al, 2009; Simpson et al, 2011). Indeed, previous studies have highlighted that poor purity of 
the inclusion body material can adversely affect the refolding process.  
 
MAU γδ TCR chains were also expressed in BL21 cells in this case the MAU γ and δ chains 
were expressed at high levels. SDS-PAGE analysis of purified inclusion bodies highlighted 
the MAU γδ TCR chains were considerably more pure (Figure 3.4). Notably, the only 
difference between the two TCRs is that the Rosetta strain was used for the expression LES γ 
and δ chains, whereas the BL21 strain were used for the production of the MAU chains.  
 
3.3.3 In vitro Refolding and Purification of LES and MAU TCR  
Attempts were made to refold equimolar amounts of LES Vγ4 and Vδ5 chains using a 
previously described method (Allison et al, 2001). The refolding buffer consisted of an 
additive in the form of L-arginine and a strong denaturant 5M urea. In addition, to help form 
stable disulphide bridges reduced and oxidised glutathione was included into the refolding 
buffer. After twenty four hours of refolding at 4°C the mixture was dialysed into 100 mM 
urea for 1 day then a second dialysis into 100 mM urea with 10 mM Tris-HCL pH8 was 
carried out. The dialysis step aided in generating preferential disulphide bonds that were the 
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Figure 3.4 SDS–PAGE analysis of MAU γ and δ TCR chains inclusion body expression in 
BL21(DE3) pLys E. coli cells, solubilised in 8M Urea. Molecular weight standards are shown 
in lane 3, with masses indicated in kDa. lanes 1 and 2 show MAU δ chain (7μg, 1.5μg) 
(predicted size 32.1 kDa) and lanes 4 and 5 depict MAU γ (3μg, 14μg) (predicted size 33.6 
kDa). 
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most stable. Purification of refold protein was carried out by anion exchange chromatography 
using a Porous HQ 10 column with a HPLC Perfusion BioCad system. Historically, αβ TCR 
purified on a Porous HQ 10 column elute as a single peak at approximately 25% of the elution 
gradient (Nicholls et al, 2009; Simpsons et al, 2011). However, for the LES γδ TCR the 
resulting elution profile was vastly different to previous TCR based studies, displaying an 
extremely broad peak which encompassed the whole elution gradient. Furthermore, the 
recovery yields for the LES γδ TCR were 90% less than that of αβ TCR using the same 
refolding strategies (Figure 3.5a). Nevertheless, the eluted fractions were screened by SDS-
PAGE to evaluate the quality of refolded protein. From the SDS-PAGE analysis it was clear 
that both chains were visible under both reducing and non-reducing conditions, with a higher 
mobility under non-reducing conditions, suggesting formation of internal disulphide bonds 
(Figure 3.5b). However, the γ and δ chains were non-stoichiometric, as there was generally an 
excess of δ chain relative to γ chain (Figure 3.5b). Additional purification with size exclusion 
chromatography provided an elution profile with multiple peaks (Figure 3.6a). SDS-PAGE 
analysis of fractions corresponding to the elution peak at 190 ml revealed LES γδ TCR, albeit 
in relatively small yields (Figure 3.6b). The recovery yields of soluble LES γδ TCR were 
extremely low (less than 2%), and reproducibility of the refolding procedure was poor. 
Broadly similar results were obtained for the MAU γδ TCR highlighting an extremely low 
yield (data not shown). Collectively, these refolding experiments indicated the methods 
developed by Allison et al for the production of a Vγ9Vδ2 TCR did not result in robust 
production of the Vδ2-negative LES and MAU TCR heterodimers.  
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Figure 3.5 a) Anion exchange elution profile for the LES γδ TCR using the 10HQ porous 
column. Fractions 1-27 (0.5 ml each) are highlighted in green. 200 mls of dialysed LES γδ 
TCR refold mixture was loaded. b) SDS-PAGE analysis of TCA precipitated fractions 10-23 
combined with 25-36 (Lanes 2 and 4) and fraction 24 (Lanes 3 and 5) under reducing and 
non-reducing conditions. Molecular weight standards are shown in Lane 1, with masses 
indicated in kDa. The refolded LES γδ TCR is non-stoichiometric. 
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Figure 3.6 a) Size exclusion elution profile of LES γδ TCR following purification using the 
Superdex 200 column. Fractions eluted from the anion 10HQ anion exchange column were 
pooled and loaded onto the size exclusion column. The elution peak observed at ~190 ml (~60 
kDa) corresponds to LES γδ TCR (shown at *). b) SDS-PAGE analysis of TCA precipitated 
peak fraction (Lane 2) highlights low level recovery of the LES γδ TCR. Molecular weight 
standards are shown in Lane 1, with masses indicated in kDa.  
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3.4 TCR Production using the Drosophila expression system 
An alternative method to express heterodimeric γδ TCR was required as expression with the 
prokaryotic system coupled with in vitro dilution refolding strategies failed to yield the 
quantities and purity sufficient for downstream binding and structural studies. This led to 
attempts at expressing the LES and MAU γδ TCRs using the Drosophila cell expression 
system. The protocol required the transfection of S2 Drosophila melanogester cells with both 
γ and δ TCR chains cloned into separate pMTBiPV5His vectors along with a hygromycin 
expression vector to select transfectants. The expression system is controlled by the 
Drosophila metallothionein promoter, which allows high level inducible expression of the 
gene of interest by addition of copper sulphate.  
 
3.4.1 Generating TCR γδ constructs for Drosophila 
To express protein in the Drosophila expression system the cDNA for each TCR chain was 
cloned separately into the pMTbipV5his vector. Polymerase chain reaction (PCR) of the LES 
γ chain and δ chain was carried out to amplify the variable and constant region of each chain, 
enabling cloning into a shuttle vector which contained an acid or base zipper which is 
approximately 6 kDa in size. The purpose of the zippers was to facilitate correct pairing of the 
γ and δ chains. Upstream from the acid/base zippers was an addition of a Human Rhinovirus 
3C protease cleavage site sequence. This would enable the removal of the zippers after 
purification. Once correct sequences for the shuttle vectors were confirmed, a secondary PCR 
was undertaken to amplify the individual chains and corresponding zipper to allow transfer 
into a S2 Drosophila expression vector pMTBiPV5His using restriction sites BglII and AgeI. 
The S2 expression plasmid vector for each individual chain also contained a V5His tag 
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sequence to allow purification of the γδ TCR from S2 supernatant by nickel chelate 
chromatography (For schematic of constructs see Chapter 2 Figure 2.2). 
 
3.4.2 Transfection of LES and MAU γδ TCRs into the Drosophila system 
In order to express heterodimeric LES γδ protein it was necessary to co-transfect S2 
Drosophila cells with the expression plasmids containing individual γ and δ chains. Previous 
evidence has highlighted TCR β chains as having the ability to form β chain homodimers 
(Garcia et al, 1996), therefore it is possible that γ or δ chains could also form homodimers. 
Hence, single chain transfectants were generated along side γδ co-transfectants. Using the 
calcium phosphate transfection protocol, each chain was transfected independently or co-
transfected with the γ and δ chains as well as the pCoHygro plasmid which contained the 
hygromycin resistance gene. Transfectants were selected for hygromycin resistance and 
evaluated for expression of single chains or TCR homodimers following induction by copper 
sulphate. 
 
Verification of LES γδ TCR expression by the S2 Drosophila cells was undertaken. Briefly, 
the expression levels of LES and MAU γδ TCR heterodimers as well as single chains were 
examined by western blot analysis of culture supernatant using a mouse anti-His antibody as a 
probe (Figure 3.7). Western blot analysis demonstrated that LES and MAU γδ TCRs were 
expressed by S2 cells. Unsurprisingly, both γ and δ chains were required for optimal 
expression and folding. Dot blot analysis of native culture supernatants using an antibody 
specific for the acid/base zipper also confirmed TCR chain pairing only in the co-transfected 
cells (Figure 3.8).  
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Figure 3.7 Western blot analysis of S2 supernatant following single chain and dual 
transfections. The blot was probed with an anti-His mAb to validate expression of 
heterodimeric γδ TCR. LES γ chain displays weak expression relative to the reduced LES γδ 
transfection which show a double band with increased expression of protein. The non reduced 
LES γδ band highlights disulphide bond formation between the two TCR chains. MAU 
indicates similarly high expression levels with dual transfection compared to the single chain 
transfection.  
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Figure 3.8 Verification of heterodimer TCR expression by dot blot. The dot blots probed with 
2H11 antibody demonstrate expression of heterodimeric TCR in cells with dual transfections. 
S2 cells transfected with single chain highlight no expression.  
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3.4.3 Expression, optimisation and large scale expression  
As previously discussed the expression of LES γδ TCR was verified by western blot analysis 
using an anti-His antibody. To determine the optimal time point for harvesting TCR following 
copper sulphate induction, cells were induced and supernatants harvested at the indicated time 
intervals (Figure 3.9). These time course experiments revealed that the expression levels of 
protein from S2 Drosophila cells remained constant after day three (Figure 3.9). Supernatants 
were generally harvested on day four after induction. 
 
3.4.4 LES and MAU γδ TCR purification by Ni-NTA chromatography  
Recombinant LES and MAU γδ TCRs from S2 Drosophila cultures was purified by nickel 
chelating chromatography. This setup enabled efficient isolation of His-tagged proteins from 
large volumes of crude S2 culture supernatant. The first step in achieving optimal binding of 
His-tagged proteins to the Ni-NTA column entailed removing free amino acids such as 
glycine and glutamine from the supernatant by dialysis against phosphate buffered saline 
solution stirring overnight at 4°C. The dialysed S2 supernatant was then loaded onto a Ni-
NTA column overnight. After washing the column bed with PBS + 10mM imidazole to 
remove non-specifically bound proteins, the bound TCR was eluted with a higher 
concentration of imidazole (250 mM). Typically from a 1L S2 culture approximately 3 mgs of 
LES γδ TCR were generated and 2 mgs MAU γδ TCR. SDS-PAGE analysis of the Ni-NTA 
eluted LES γδ TCR revealed two prominent bands at approximately 45 kDa, corresponding to 
the LES γ and δ chains (Figure 3.10). This difference in predicted size and protein mobility 
visualised on the SDS-PAGE gel could be due to protein glycosylation, as the γ chain has 
three N-linked glycosylation sites and δ chain has two N-linked glycosylation sites. In 
addition, there were several higher molecular weight proteins visible suggesting sub-optimal 
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Figure 3.9 Western blot analysis evaluating heterodimeric LES and MAU γδ TCR expression 
levels at different time points of transfection in S2 Drosophila cells. Based on these results 
day 5 was deemed optimal for harvesting S2 cells. The blot was probed with an anti-His mAb. 
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Figure 3.10 SDS-PAGE analysis of purified LES γδ TCR. Molecular weight standards are 
shown in Lane 1, with masses indicated in kDa. Lane 2 represents LES γδ TCR purified from 
Drosophila supernatant by Ni-NTA chromatography.  
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purity of the LES γδ TCR following Ni-NTA chromatography (Figure 3.10). MAU γδ TCR 
demonstrated similar results to LES when analysed by SDS-PAGE (data not shown). 
Although at this stage the sample was deemed unsuitable for crystallisation trials, the next 
step involved verifying the correct conformation of the LES and MAU γδ TCR using BIAcore 
technology.  
 
3.5 Validation of specific heteromeric TCR by BIAcore analysis  
SPR was utilised to confirm that LES Vγ4Vδ5 and MAU Vγ9Vδ1 TCRs were 
conformationaly intact. This was carried out by coupling biotinylated LES and MAU γδ TCRs 
to a BIAcore CM5 chip coated with streptavidin and injecting a pan-anti-γδ TCR antibody 
(11F2) over the surface (Figure 3.11). The 11F2 γδ antibody demonstrated specific binding to 
LES and MAU γδ TCRs relative to the control αβ TCR that was also expressed in the 
Drosophila expression system. In addition, injection of anti-Vδ1 monoclonal antibody over 
the surface of a flow cell immobilised with LES and MAU TCR demonstrated specific 
binding to MAU Vγ9Vδ1 TCR relative to LES Vγ4Vδ5 TCR (Figure 3.12a). Also, injection 
of anti-Vγ9 monoclonal antibody over the surface of a flow cell immobilised with LES and 
MAU TCR highlighted specific binding to MAU γδ TCR in comparison to LES γδ TCR 
(Figure 3.12b). At this time point in the experiments there was no specific antibodies against 
Vγ4 or Vδ5 to further validate the confirmation of the LES γδ TCR. However, utilising the 
LES γδ TCR the collaborators in the Déchanet-Merville laboratory were able to derive a LES 
specific antibody. This was later used in SPR experiments to validate the LES γδ TCR by Dr 
Carrie Willcox (data not shown). Collectively, these observations confirmed the correct 
association of LES and MAU γδ TCR chains as well as validating the functionality of 
recombinant TCRs generated by the Drosophila expression system in vitro. Indeed, the MAU 
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Figure 3.11 Verification of the correct conformation of LES and MAU γδ TCR using surface 
plasmon resonance. The pan-TCR γδ antibody, 11F2, was injected over the surface of flow 
cells immobilised with LES γδ TCR, MAU γδ TCR and control αβ TCR. The pan-TCR γδ 
antibody, 11F2, demonstrates specific binding to LES and MAU γδ TCRs relative to the 
control αβ TCR. 
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Figure 3.12 Verification of the correct MAU TCR chain conformation using surface plasmon 
resonance. a) Injection of anti-Vδ1 monoclonal antibody over the surface of a flow cell 
immobilised with LES and MAU TCR. The anti-Vδ1 antibody demonstrates specific binding 
to MAU TCR (Vγ9/Vδ1) relative to LES TCR (Vγ4/Vδ5). b) Injection of anti-Vγ9 
monoclonal antibody over the surface of a flow cell immobilised with LES and MAU TCR. 
The anti-Vγ9 antibody demonstrates specific binding to MAU TCR (Vγ9/Vδ1) relative to 
LES TCR (Vγ4/Vδ5).  
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γδ TCR was used for downstream ligand identification experiments together with 
characterising/validating candidate MAU TCR/ligand interactions using SPR and alpha 
screen technology. Moreover, the LES γδ TCR was utilised for functional (see Chapter 4) and 
structural studies (see sections 3.6 and 3.7). 
 
3.6 Structural studies of LES γδ TCR with X-ray Crystallography 
3.6.1 Overview of X-ray crystallography  
X-ray crystallography is a powerful technique used to determine the three dimensional 
structures of proteins. Structural information can highlight how protein molecules bind to and 
recognise their ligands as well as to ascertain their function. This technique, however, is 
heavily dependent on the protein of interest crystallising and diffracting X-rays to a sufficient 
resolution such that significant structural information can be gleaned (Figure 3.13). In 
addition, the quality of structural data that can be extracted from a protein structure is 
extremely reliant on the quality of the crystal.  
 
3.6.1.1 Protein Expression and Purification 
For maximal chances of crystallisation, usually high concentrations of relatively pure protein 
are required. Hence the protein of interest is introduced into an optimal expression system 
(Prokaryotic or Eukaryotic) that allows high quantities of protein to be expressed. Following 
expression, conventional protein purification approaches are undertaken, which involves 
separating proteins based on their differences in charge, size or whether they possess a 
specific tag (e.g. poly-His tag, GST). The sample is then subjected to a series of preliminary 
assays to evaluate protein purity and homogeneity using SDS-PAGE and dynamic light 
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Figure 3.13 Overview of X-ray crystallography. The target protein is over-expressed in a 
suitable expression system and purified using conventional methods to allow the initial 
crystallisation trials. Once crystals of a suitable size are grown they are exposed to an X-ray 
beam and the resulting diffracted X-rays are recorded on a detector in the form of spots or 
reflections. From the diffraction pattern the data is processed to provide information about the 
unit cell, space group. In addition, the intensity of each reflection is also measured and 
converted to amplitude. The phase for each reflection is estimated and when combined with 
amplitudes an electron density map is calculated. The electron density map is a map showing 
the distribution of electrons and can be interpreted to enable the molecular structure to be 
modelled. 
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scattering. It is important that the protein is devoid of contaminants and exists as a 
homogeneic species otherwise it can severely hinder the subsequent crystallisation process.  
 
3.6.1.2 Protein Crystallisation theory and practice 
Once the protein has been fully evaluated and fulfils the recommended criteria for successful 
crystallisation, the protein is concentrated to high levels and subjected to crystallisation trials. 
Crystals are grown by bringing the protein solution to a supersaturated state. This process 
occurs in three key stages. Firstly, is the nucleation phase in which well ordered aggregates 
called nuclei (micro crystals) are formed. Secondly, with the growth phase, protein molecules 
are recruited to the growing faces of the crystal. Finally, in termination phase, cessation of 
crystal growth occurs due to growth defects, presence of contamination or protein depletion. 
This supersaturated state forces protein molecules in solution to interact with each other in a 
specific manner which initiates nucleation and crystal formation, achieved through reducing 
the solubility of the protein (Li and Ismagilov, 2010). 
 
There are several factors that influence the solubility of a protein. One of the most important 
parameters is pH, since the solubility of a protein is at the lowest at the isoelectric point (i.e. 
the pH at which the protein has no net overall charge). Another key factor is ionic strength as 
introduction of salts (e.g. sodium chloride) have a dehydrating effect on the protein as it 
competes with protein molecules for water. Moreover, polymers such as poly ethylene glycol 
reduce the dielectric constant of the solution as well restructuring the drop by volume 
exclusion which in turn forces protein molecules to interact with each other. Collectively, the 
overall crystallisation strategy with the use of buffers, salts and precipitants is to reduce 
protein-solvent interactions whilst enhancing protein-protein interactions (Bergfors T, 2007). 
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These are commercially available as screens. The most common method used to crystallise 
proteins is the hanging drop vapour diffusion method. This involves mixing equal volumes of 
protein and crystallisation reagent onto a cover slip, which is inverted on a greased well 
containing the crystallisation reagent. The hanging drop is sealed to form an enclosed system. 
By creating differences in crystallisation reagent concentration between the drop and the 
reservoir solution, water molecules diffuse out of the hanging drop by a process called vapour 
diffusion until equilibrium is achieved. During this process, the protein reaches a 
supersaturated state and protein molecules are forced to interact with one another and if this 
interaction is specific, nucleation begins and then leads to crystal growth. The identification of 
crystallisation conditions optimal for crystal growth is largely a multi-dimensional search by 
trial and error and often represents one of the biggest obstacles in X-ray crystallography.  
 
Once a preliminary crystallisation hit has been identified, it is optimised to grow larger 
crystals for subsequent X-ray diffraction experiments. Prior to this the crystal is selected and 
soaked into the reservoir solution supplemented with cryoprotectant for two reasons. Firstly, it 
serves as anti-freeze and prevents the solvent surrounding the protein from forming ice 
crystals and secondly protects the crystal from X-ray radiation damage.  
 
3.6.1.3 X-ray Diffraction Theory and Data Collection 
Since individual atoms in protein molecules typically span a range from 0.01-10 nm, they can 
only be visualised with X-rays as they fall within a similar wavelength (0.01-10 nm range). 
The crystal is exposed to an X-ray beam, and the electrons surrounding the protein atoms 
within the crystal diffract X-rays that are recorded by an X-ray detector in the form of a 
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distinct array of black spots called a diffraction pattern. From the diffraction pattern it is 
possible to extract information that is necessary for determining the protein structure.  
 
Each diffracted X-ray represents a simple wave that consists of three parameters (frequency, 
amplitude and phase), and when defined, it can lead to determining the three dimensional 
structure of the protein. The frequency of the wave can be calculated from the wavelength of 
the X-ray source used to conduct the X-ray diffraction experiment. The amplitude of the wave 
specifies the height of the crests and troughs and can be determined by measuring the 
intensity of each spot and converting to amplitude. The phase of each wave specifies the 
position of the wave with respect the origin of the co-ordinate system on which the wave is 
plotted. During X-ray data processing it is possible to measure the amplitude of each 
reflection but not the phase information and this is in crystallographic terms is referred to as 
the ‘phase problem’. 
 
3.6.1.4 Techniques for Calculating Phase Information 
There are several methods available for calculating initial phase information, but the most 
common method used is molecular replacement (Evans and McCoy, 2008). With molecular 
replacement phases from a known structural homologue (e.g. phasing model) are used as 
initial estimates for the target structure. Importantly, since phases are sensitive to position of 
the atoms, before meaningful phase information can be extracted, the phasing model is 
initially superimposed onto the target structural data. This superimposition is heavily 
dependent on the sequence/structural homology between the phasing model and the target 
structure. The more homologous the phasing model, the easier it is to superimpose the two, 
enabling the extraction of phase information and solving the target structure.  
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However, if there is no structural homologue available, as is the case for most novel 
structures, phases must be determined experimentally. One method used for this purpose is 
multiple isomorphous replacement (MIR) and this relies on finding the positions of a few 
heavy atoms (atoms that are electron dense). Compounds that contain heavy atoms have a 
significantly higher atomic scattering factor because they possess more electrons in their outer 
shells which can interfere with the X-rays and this in turn affects the intensity of the 
reflections. The scattering contribution of these heavy atoms in combination with the 
knowledge of their positions can be used to calculate phases. The first step involves 
crystallising the target protein (native) and collecting a complete X-ray data. The native 
crystals are then soaked in solutions containing heavy atom compounds to generate 
derivatised crystals. The idea is that the heavy atoms will soak into crystal via the solvent 
channels and bind to specific amino acids of the target protein crystal. Importantly, the type of 
heavy atoms used is dependent on the amino acid sequence of the target protein. For example, 
mercury (Hg), gold (Au) and platinum (Pt) are highly reactive towards Cysteine, Histidine 
and Methionine residues. In contrast, heavy atoms such as the lanthanides and actinides bind 
to negatively charged residues such as glutamic acid and aspartic acid (Blundell and Johnson, 
1976). 
 
The native crystal is soaked in solution containing the heavy atom compound to generate an 
isomorphous derivative protein crystal (e.g. the unit cell parameters of the derivatised crystal 
must remain similar to the native crystal). This can be very difficult to achieve as often 
crystals soaked in heavy atoms can lead to crystal cracking or dissolving. If the crystal 
survives the heavy atom soaking process, the derivatised crystal is exposed to X-rays and an 
X-ray data set is collected. By subtracting the derivatised data from the native data, it is 
 105 
possible to find the positions of the heavy atoms and this in turn can lead to determining 
initial experimental phase information. It is important to highlight that by generating a second 
isomorphous derivative crystal using a different heavy atom, it is possible to calculate more 
accurate experimental phase information. The advantage of using MIR is that it is a powerful 
tool for generating phases of novel structures. The disadvantages include that it is extremely 
time consuming, the user is exposed to toxic compounds and finally there is no guarantee that 
heavy atoms will bind the crystal after soaking.  
 
The final technique used to calculate experimental phases is multi-wavelength anomalous 
dispersion (MAD). At the absorption edge of an element X-rays are absorbed and re-emitted 
with altered phase (anomalous dispersion). These altered phases can provide useful phase 
information that can be used to solve structures (Hendrickson WA, 1991). The most common 
heavy atom used for MAD is selenium which is incorporated into the target protein prior to 
crystallisation. This can be achieved by transforming target plasmid cDNA into methionine 
auxotrophic strain and then growing the cells in presence of selenium (selenium substitutes 
for methionine). Notably, with this approach the heavy atom is already incorporated into the 
target protein thus relieving the need for preparing multiple derivatised crystals as in MIR. 
The seleno-Met substituted protein is then purified by conventional methods similar to the 
native protein and subjected to crystallisation trials. The MAD experiment is then performed 
at a synchrotron radiation source, as the absorption edge of selenium is at wavelengths 
generated by a synchrotron. Furthermore, to obtain meaningful MAD data, it is desirable to 
collect at three different wavelengths (to maximise anomalous differences) and this requires a 
tuneable X-ray source such as a synchrotron (Hendrickson WA, 1991).  
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3.6.1.5 Electron Density Maps, Refinement, Verification and Structural Analysis 
An electron density map is a map showing the distribution of electrons. Since the electrons 
surround the nuclei of atoms it is possible for the atoms of the protein molecule to be fit into 
the electron density. This is known as model building and is usually performed on a computer 
graphics display. Once a round of model-building has been performed the model is then 
refined. The refinement software adjusts the model so that it best fits the data and ensures that 
the model is stereo-chemically correct (i.e. appropriate bond lengths and angles). Following 
this alternate cycles of model building and refinement are performed resulting in the final 
structure been determined which is then ready for structural analysis. 
 
3.6.2 Cleavage of LES TCR acid/base zipper moiety 
As mentioned beforehand, the levels of purity for the LES γδ TCR following Ni-NTA was 
insufficient for crystallisation trials. In addition, previous studies have highlighted that TCR 
crystallisation has not been successful with zipper chains attached to the corresponding TCR 
chains (Garboczi et al, 1992; Adams et al, 2005). It was highly likely that the presence of the 
flexible acid/base zippers would interfere with crystal packing and prevent crystal formation. 
This necessitated the removal of the acid/base zippers by cleaving with HRV 3C protease 
followed by additional purification before crystallisation screening trials could be attempted. 
The first stage in this process involved pooling together fractions eluted from the Ni-NTA 
column and buffer exchange into a buffer that was most suitable for the cleavage reaction, in 
this case 150 mM NaCl and 5mM Tris pH 8. 
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The ideal time point and concentration of 3C protease required to facilitate complete cleavage 
of the acid/base zippers from the corresponding individual chains were evaluated by carrying 
out replicate digests with differing protease concentrations. The resulting TCR digests were 
analysed by SDS-PAGE and the mobility of the TCR chains over different concentrations 
showed that the 1:50 dilution of protease enzyme was optimal for effective 3C protease 
cleavage activity (data not shown). The optimal digestion time was also calibrated by means 
of digesting the TCR protein and collecting analytical samples at differing time points which 
were then analysed by SDS-PAGE. Based on the gel, the optimal time for enzymatic 
digestion was determined to be two hours as protein mobility was unchanged after this time 
interval (Figure 3.14). 
 
3.6.3 Crystallisation Trials of LES γδ TCR 
Crystallisation trials of concentrated LES γδ TCR were carried out by using the commercial 
spare matrix kits and a mosquito nanolitre robot, with experiments performed at 23°C. The 
experimental method used was hanging drop vapour diffusion with the TCR concentration at 
8.5-10 mg/ml. The purity of HRV 3C protease cleaved LES γδ TCR was evaluated by SDS-
PAGE analysis after concentration and before crystallisation trials were undertaken (Figure 
3.15). This approach led to the identification of two initial hits obtained with the PEG/ion 
(Figure 3.16) and Structure (Figure 3.17) screens. Unfortunately, these initial hits were 
difficult to reproduce due to the instability of LES γδ TCR in solution. Furthermore, 
continuous freeze thawing of LES γδ TCR sample exacerbated protein solubility resulting in 
loss of protein due to aggregation. Due to these problems, reproduction or optimisation of 
preliminary crystallisation hits was not possible. 
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Figure 3.14 HRV 3C protease cleavage of LES γδ TCR sample analysed by SDS-PAGE. 
Time point analysis of 3C cleavage was performed over a period of 24 hours. Following 
protease cleavage with HRV 3C there is a significant downward shift of the TCR chains 
(Lanes 3-8) relative to undigested TCR (Lane 2), indicating removal of the acid/base zippers 
(6 kDa). After 24 hour incubation with the HRV 3C protease degradation of the TCR chains 
are observed (Lane 8).  
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Figure 3.15 SDS-PAGE analysis of purified LES γδ TCR used for crystallization trials. 
Following cleavage with HRV 3C protease the acid/base zipper fragments were removed by 
Ni-NTA depletion and the LES γδ TCR purified by Ni-NTA beads. Lanes 2 and 3 represent 
concentrated forms of LES γδ TCR at 8.5 and 10 mg/ml, respectively. Molecular weight 
standards are shown in Lane 1, with masses indicated in kDa.  
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Figure 3.16 Generation of LES γδ TCR micro-crystals. Micro-crystals of LES γδ TCR (black 
arrows) were identified using the PEG Ion screen (Hampton Research). The drop was set up 
by mixing LES γδ TCR (8.5mg/ml in 150mM NaCl/5mM Tris pH8 buffer) with an equal 
volume of reservoir solution (condition number G4, 0.2M Sodium formate pH7, 20% PEG 
3350). Micro-crystals were grown using the hanging drop vapour diffusion method and 
appeared after 14 days at room temperature.  
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Figure 3.17 Generation of LES γδ TCR micro-crystals. Micro-crystals of LES γδ TCR (black 
arrows) were identified using Crystal Screen 2 screen (Hampton Research). The drop was set 
up by mixing LES γδ TCR (10mg/ml in 150mM NaCl/5mM Tris pH8 buffer) with an equal 
volume of reservoir solution (condition number H7; 0.2M Ammonium phosphate monobasic, 
0.1M Tris pH8.5, 50% MPD). The micro-crystals were grown using the hanging drop vapour 
diffusion method and appeared after 14 days at room temperature.  
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3.7 Discussion 
As touched on briefly earlier there were several reasons for using the prokaryotic expression 
system to generate LES and MAU γδ TCRs. Firstly, recombinant production using the E. coli 
expression system is relatively inexpensive relative to insect cell derived protein. Secondly, 
there are considerable differences in terms of the time-frame required to produce expressed 
proteins within the two expression systems. For example, recombinant expression with 
Drosophila can take approximately several weeks, whereas protein expression within the E. 
coli system can be achieved within three days. Finally, the protein yields from E. coli far 
exceed those than generated by Drosophila. Despite the obvious advantageous properties 
conferred the E. coli system, there was a requirement to refold the LES and MAU γδ TCRs 
back to their native conformation. This is partly due to the fact that the prokaryotic expression 
machinery is not fully equipped (e.g. lacking key post translational modification enzymes and 
chaperones) to refold complex human proteins and as such the TCRs were expressed as 
insoluble inclusion body aggregates. Indeed, previous studies have highlighted several 
strategies that have successfully been employed to correctly refold αβ (Simpson et al, 2011) 
and γδ (Garboczi et al, 1996) TCRs back to their native heterodimer conformation in yields 
sufficient for structural and binding applications.  
 
In this study use of similar approaches provided limited success in refolding LES and MAU 
γδ TCR. Although, it was possible to generate significant levels of LES and MAU TCR 
inclusion body material (typically 100 mgs of each chain were produced per litre of LB 
culture), the yields following purification by anion exchange chromatography were extremely 
low for downstream functional and structural studies. One possible reason for low recovery 
yields was attributed to the fact that the initial inclusion body protein material, particularly for 
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the LES TCR γ and δ chains, was impure which may have interfered with the renaturation 
process. One solution for circumventing such a problem is to further purify the inclusion 
bodies, but past experiences have led to the conclusion that although such strategies can 
provide pure protein, the recovery yields are extremely low. Furthermore, the variation in 
protein purity levels between inclusion body preparations may have exacerbated the 
inefficient refolding of the γδ TCR. Another major problem associated with the generation of 
TCR using the prokaryotic system is the lack of TCR stoichiometry observed following 
refolding. Indeed, SDS-PAGE analysis of the γδ TCR refolded by in vitro dilution methods 
frequently revealed higher levels for the δ chain relative to the γ chain, raising considerable 
doubts as to whether the recombinantly derived γδ TCR is conformationally functional. One 
possible strategy for achieving correct stoichiometry of the TCR is supplementing the refold 
buffer with excess quantities of the γ chain relative to the δ chain. This may then provide 
sufficient levels of refolded γ chain in the refold mixture for pairing with the δ chain and 
facilitate stoichiometric association of the two chains. Collectively, these observations 
suggested that use of the prokaryotic expression system to generate recombinant γδ TCRs for 
structural and functional studies was impractical given the time constraints of this study. 
 
Due to the huge number of technical obstacles encountered in generating large amounts of 
heterodimeric γδ TCR protein with the prokaryotic system, an alternative approach with the 
Drosophila S2 cells was utilised. Indeed, the Drosophila expression system provided 2 mg of 
LES and MAU heterodimer TCR. Despite the lower yields subsequent dot blot analysis 
confirmed correct pairing of each TCRs by using the 2H11 antibody that specifically bound to 
the acid/base zipper moieties. The fractions eluted following Ni-NTA purification proved to 
be highly promising with two prominent bands observed, corresponding to each chain. There 
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was however several larger molecular weight bands present suggesting that the Ni-NTA 
purification protocol was sub-optimal. In the future it may be possible to improve the 
recovery yields by modifying the wash step to more efficiently remove non-specific proteins 
bound to the Ni beads. For instance, by washing with PBS buffer containing 20 mM 
imidazole (rather than 10 mM) there is an increased likelihood of generating purer TCR 
reagents for the subsequent cleavage step with 3C protease. Alternatively, if this proves to be 
unsuccessful it may be possible to remove the contaminants by including an additional 
analytical procedure following Ni-NTA chromatography such as size exclusion 
chromatography.  
 
Nevertheless, despite these issues it was possible to generate sufficient amounts of 3C cleaved 
LES γδ TCR for preliminary crystallisation trials. Although the screening process yielded 
several crystallisation hits, they were deemed very poor suggesting that considerable 
optimisation was required in order to produce diffraction grade crystals. Optimizing all of the 
most obvious parameters which included pH, salt and protein and precipitant concentration 
continued to produce crystals displaying poor size and morphology. A review of the 
procedures used before and after crystallization trials has highlighted several issues, that when 
addressed, may lead to enhanced crystal growth. Firstly, the stability of the LES γδ TCR was 
relatively poor in that it displayed an increased propensity to aggregate following multiple 
freeze thaw cycles, particularly at high concentrations, which was necessary for promoting 
nucleation. These stability issues most likely stemmed from the choice of the storage buffer 
used for the LES γδ TCR. Indeed, recent studies have demonstrated that incorporating thermal 
melting assays into the crystallization screening experiments enhanced the number of initial 
crystallization leads (Ericsson et al, 2006). A similar approach could be applied to LES γδ 
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TCR to identify a more stable storage buffer suitable for crystallization experiments. 
Secondly, future crystallisation trials could encompass using other physical techniques 
including dialysis and batch. Although both methods can induce the protein solution to 
achieve super-saturation, the underlying principles of these techniques vary. The 
batch method crystallisation technique consists of mixing concentrated protein solution with 
crystallisation reagent in a closed vessel to produce a final supersaturated concentration, 
which may ultimately lead to crystallisation. In contrast, dialysis techniques exploit diffusion 
and equilibration of small precipitant molecules through a semi-permeable membrane as a 
manner of gradually approaching the desired concentration at which protein crystallizes. 
Thirdly, it is clearly evident that the Drosophila derived LES γδ TCR is heavily glycosylated 
as there were significant shifts in migration observed for both chains relative to their sequence 
derived molecular weight. The glycosylation associated phenomenon observed for LES γδ 
TCR is unsurprising given that there are 2 γ chain and 3 δ chain predicted N-linked 
glycosylation sites for the gamma and delta chain, respectively. Indeed, it is a well established 
that the chemical and conformational heterogeneity of the carbohydrate moieties can inhibit 
protein crystallisation, thereby providing a rationale for intransigent crystallisation of the LES 
γδ TCR. However, there are several approaches that could be employed to overcome the 
glycosylation problem and enhance crystallisation of the LES γδ TCR. One possibility is the 
use of PNGase F or Endonuclease H to completely deglycosylate the LES γδ TCR sample 
prior to the crystallisation trials.  
 
A second approach involves expressing the LES γδ TCR transiently in insect cells with N-
glycosylation processing inhibitors such as tunicamycin. This approach has been successful in 
facilitating the crystallisation and structural determination of G8 γδ TCR in complex with 
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T22, which was treated with tunicamycin (Adams et al, 2005). This may allow the TCR to 
fold correctly, but more importantly the protein is likely to be increasingly sensitive to 
enzymes, such as endoglycosidase H, that reduce the N-glycans to single uniform residues, 
and thus enhance crystallization. Strikingly, these and similar strategies have been employed 
in a number of structural biology consortium initiatives (Chang et al, 2007; Adams et al, 
2005). Finally, proteins that are refractory to crystallization are more likely to crystallise in 
the presence of their ligands as it allows the protein to adopt a more stable form in solution 
(Warke and Momany, 2007). Indeed, the validity of co-crystallization has been highlighted by 
other members within the Willcox laboratory. For example, it has been possible to 
circumnavigate crystallisation of intransigent HLA-A2-peptide complexes with the 
incorporation of its natural ligand, LILBR1 (personal communication Dr Fiyaz Mohammed). 
With this in mind, attempting the co-crystallisation of the LES γδ TCR with its cognate 
ligand, EPCR (more details in chapter 4), could stabilise the structure in solution and enhance 
crystallisation.  
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Chapter 4: Molecular characterisation of a human γδ T cell receptor ligand 
 
4.1 Introduction 
As described in Chapter 3, the Déchanet-Merville group generated a panel of Vδ2neg γδ T cell 
clones from immunosuppressed solid organ transplant patients with acute CMV-infection and 
determined their reactivity to CMV-infected cells and tumour cell lines, with the goal of 
identifying the ligands recognised by this population of γδ T cells. At present, there are 
several strategies that could be used to identify potential TCR ligands, including transfection 
of non-target cell lines with a cDNA library to induce expression of the TCR ligand; 
transfection of target cell lines with an siRNA library to inhibit expression of the TCR ligand; 
or generation of blocking antibodies which would bind the TCR ligand and inhibit T cell 
activation. Each strategy has advantages and disadvantages. One such strategy adopted by Dr 
Déchanet-Merville’s laboratory was to attempt to generate blocking antibodies. Antibodies 
were generated in mice immunised with the HT29 human colorectal carcinoma cell line, 
which are recognised effectively by the LES γδ clone and LES JRT3 transfectants. One 
antibody blocked activation of the LES γδ clone by HT29 and other target cell lines as well as 
by CMV-infected fibroblasts, and was designated 2E9 (Willcox et al, 2012, Appendix I). 
Crucially, 2E9 blocking was TCR-specific, since it did not block recognition of HT29 by the 
MAU γδ T cell clone, suggesting 2E9 was not blocking a common costimulatory or NKR 
ligand required for activation of both γδ clones, and instead that 2E9 was highly likely to be 
blocking the ligand of the LES γδ TCR. Interestingly, whereas the 2E9 ligand (2E9L) was 
essential for activation of LES γδ T cells, it did not appear to be sufficient, as some 2E9L+  
cell lines were not productively recognised by the LES clone (Table 3.1). This work 
highlighted 2E9 as a potentially key reagent that may allow identification of the LES γδ TCR 
ligand. 
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Subsequent immunoprecipitation experiments were performed by Dr Carrie Willcox to 
identify 2E9L. 2E9
+
 cell lines were surface biotinylated and lysed, and a protein of 37kDa 
was specifically immunoprecipitated from HeLa cells by 2E9. The band was isolated and 
upon analysis by Fourier transform-ion cyclotron resonance mass spectrometry, four peptides 
derived from endothelial protein C receptor (EPCR) were identified (Willcox et al, 2012). 
EPCR was confirmed as the 2E9L in several ways. A commercial anti-EPCR antibody was 
used to western blot the band specifically immunoprecipitated by 2E9 in HT29 and HeLa 
cells. In addition, a commercial anti-EPCR polyclonal antibody blocked staining of target 
cells by 2E9, and also blocked activation of the LES clone by HT29 target cells to a similar 
degree as 2E9 (see Willcox et al, 2012 Appendix I Figures 2c-e). Finally, BIAcore analyses 
proved that 2E9 specifically bound immobilised EPCR protein with high affinity. 
 
While it was apparent that EPCR was the 2E9L, it had not been confirmed as the ligand for 
the LES γδ TCR. To address this, the cDNA for the ectodomain of EPCR was cloned into the 
pMTBiPHis vector and expressed in the Drosophila expression system (DES). Soluble EPCR 
(sEPCR) was purified (Appendix I, Supplementary Figure 1a) and tested in SPR studies for 
binding to the Drosophila derived LES γδ TCR (described in Chapter 3). Greater binding 
responses were observed following injection of sEPCR over immobilised LES γδ TCR than 
over immobilised MAU γδ TCR or an irrelevant αβ TCR control (Appendix I, Figure 3). This 
confirmed EPCR is a direct ligand for the LES γδ TCR. Equilibrium binding analyses 
revealed an apparent dissociation constant (Kd) of 87μM, which is low but within of the 
range demonstrated for αβ TCR-pMHC interactions (1-100 μM) (Rudolph et al, 2006). 
Notably, EPCR produced in human 293T cells also specifically bound LES γδ TCR with a 
similar affinity. 
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EPCR is a well established component of the protein C anti-coagulation pathway. Protein C 
binds to EPCR on endothelial cells and is cleaved by the thrombin-thrombomodulin complex 
to form activated protein C (APC). APC then inactivates factor V in the coagulation cascade, 
which ultimately results in a decrease in fibrin formation and clotting (Esmon, 2010) (Figure 
4.1). Moreover, EPCR is also required for the anti-inflammatory and endothelial barrier 
protective role of APC. 
 
EPCR is a type I transmembrane protein with approximately 20% sequence homology to 
CD1d. Despite this low sequence homology, the structure of EPCR (Oganesyan et al, 2002) 
highlights a high degree of structural similarity to CD1d (Koch et al, 2005) (Figures 4.2a-b): 
EPCR consists of α1 and α2 helices, positioned above a β-sheet platform, and between the 
two alpha helices is a hydrophobic channel enabling binding of a lipid. In the crystal 
structure, EPCR was shown to bind either Phosphatidylethanolamine (PE) or 
Phosphatidylcholine (PC). However, in contrast with CD1d, EPCR lacks an α3 domain and is 
not associated with β2-microglobulin (β2M). In addition, the lack of a β2M domain 
conceivably enables the α1/α2 domain to be more flexible with respect to the membrane, 
which may facilitate binding to APC (Figures 4.3a-b). 
 
Although EPCR has not previously been recognised as having an immunological function, it 
fulfils the hypothesis that ligands for Vδ2neg cells would be present in both HCMV infection 
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Figure 4.1 Cartoon representation of EPCR-dependent protein C (PC) activation by the 
thrombin (T) – thrombomodulin (TM) complex. Activated protein C (APC) binds to protein S 
(S) and inactivates factor Va, thereby down regulating the downstream coagulation cascade 
(adapted from Esmon, 2010).  
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Figure 4.2 Structural comparison of the lipid binding platform of a) EPCR (Oganesyan et al, 
2002) and b) the α1/α2 domain of CD1d (Koch et al, 2005). In each case the bound lipid 
within the hydrophobic groove is highlighted in stick format.  
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Figure 4.3 Structural comparison of a) EPCR (Oganesyan et al, 2002) and b) CD1d (Koch et 
al, 2005) as each molecule is proposed to be presented on the plasma membrane (side view). 
The α1/α2 platform of CD1d is held parallel to the plasma membrane because of interactions 
between the underside of the b-sheet and the α3 domain/β2M. EPCR is thought to be anchored 
to the membrane by a flexible stalk, allowing it to adopt different conformations, including 
the one shown in which the α1/α2 platform is perpendicular to the plasma membrane. In each 
case the bound lipid within the hydrophobic groove is highlighted in stick format.  
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and cancer; firstly, endothelial cells are a key target for HCMV infection and conceivably 
expression of EPCR on the endothelium might suggest surveillance of this site by γδ T cells. 
In addition, EPCR has been shown to be over-expressed on cancer cell lines and in tissue 
sections of some human cancers (Scheffer et al, 2002), suggesting recognition of EPCR by γδ 
T cells as a possible mechanism of tumour immunosurveillance.  
 
Despite the fact that EPCR is closely related to the CD1 family that present lipid antigens to 
T cells, the mechanism by which EPCR is recognised by LES γδ T cells remains unclear and 
has important implications. It is intriguing that some cell lines stain with 2E9 but do not 
activate the LES γδ clone or JRT-3 transfectant, suggesting that expression of EPCR is 
necessary but not sufficient for recognition by LES T cells (Table 4.1). This could be 
explained by two different mechanisms (Figure 4.4). Firstly, activation by EPCR
+
 cell lines 
could be dependent on EPCR-intrinsic factors, such that EPCR may be expressed in a 
different and more stimulatory form on the surface of activatory cells relative to non-
activatory EPCR
+
 cells. Perhaps most likely, the homology between EPCR and CD1d 
suggests that EPCR may have the ability to present a stress lipid to LES γδ TCR (Figure 
4.4a). A putative stress lipid might only be present on activatory cancer lines (versus non-
activatory EPCR
+
 lines) and might conceivably be upregulated after CMV infection of target 
cells. Alternative discriminatory factors could include differential EPCR glycosylation, which 
could directly affect binding to the TCR; or the distribution of EPCR on the plasma 
membrane, or its association with other proteins on the cell surface, might influence 
recognition of target cells by LES γδ T cells. In contrast, EPCR-extrinsic factors could 
instead determine whether EPCR
+
 cell lines can activate LES γδ T cells (Figure 4.4b). In this 
scenario, EPCR expressed on stimulatory and non-stimulatory EPCR
+
 lines would be 
identical, however EPCR-extrinsic factors such as differential expression of costimulatory 
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Figure 4.4 Models of LES activation by EPCR expressing tumour cells. EPCR is necessary 
but not sufficient for LES activation. The difference in response of the LES clone to 
activating and non-activating target cell lines could be explained by EPCR-intrinsic factors (a) 
or EPCR-extrinsic factors (b). EPCR-intrinsic factors could include presentation of a stress 
lipid which is only expressed by activating cell lines. EPCR-extrinsic factors could indicate 
the requirement for additional costimulatory ligands, present on EPCR
+
 activating cells, but 
not expressed on EPCR
+
 non-activating cells.  
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ligands could render stimulatory EPCR
+ 
cell lines more conducive to productive recognition 
by LES T cells.  
 
Cell Line LES 2E9 EPCR 
expression 
HT29   + 
K562   + 
U937   + 
HUTU80 X X - 
HUH7 X X - 
U373 X  - 
293T X  - 
HeLa EV2 X X - 
HeLa PF X  + 
SKMES X  + 
MRC5 X   
Table 4.1 Staining of cell lines with 2E9 mAb and recognition by LES γδ TCR. List of Cell 
lines which were analysed for recognition by the LES γδ clone or JRT-3 LES transfectants. 
The presence of EPCR on the cell line was also determined and recognition by 2E9 mAb. 
 
Arguably the most compelling of these explanations is that EPCR acts as a presentation 
element, enabling LES T cells to recognise “stress lipids” selectively present on stimulatory 
target cell lines. Importantly, recognition of a stress lipid in EPCR would require TCR 
interaction with the solvent exposed surface of the α1/α2 helices in a fashion analogous to 
that of TCR/CD1 interaction, whereby bound lipids are discriminated directly by the TCR, 
based on their lipid head group (Girardi and Zajonc, 2012). In contrast, a TCR binding site on 
EPCR that was distinct from this face of the α1/α2 platform would effectively exclude direct 
recognition of EPCR-bound lipids. This would suggest that instead of serving as a restriction 
element for stress-regulated lipids, EPCR may act as a stress ligand itself. It would also 
highlight the potential importance of EPCR extrinsic factors such as expression of  
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costimulatory molecules as playing a critical role in activation. Therefore, in order to shed 
light on these issues, the key aim of this chapter was to define the binding mode of the LES 
Vγ4Vδ5 TCR for EPCR. The primary approach adopted was based on direct protein-protein 
binding experiments using SPR, in combination with alanine scanning mutagenesis of the 
EPCR molecule. A second, parallel and complementary strategy was to attempt 
crystallisation of the LES γδ TCR in complex with EPCR.  
 
4.2 Soluble EPCR expression 
The expression of soluble EPCR was developed in the DES, the expression system that was 
initially used to establish the LES TCR directly bound EPCR. In addition, by allowing 
endogenous Drosophila lipids to be loaded into the molecule, it would therefore circumvent 
the difficulty of artificially loading a lipid into E. coli-produced, refolded EPCR. Indeed, 
previous experimental work has shown the intrinsic difficulty of loading lipids into 
artificially refolded protein molecules such as CD1 (M. Salim unpublished observation). The 
cDNA for the ectodomain of EPCR was cloned into the pMTBiP vector containing a BirA 
and His tag by Dr Carrie Willcox. Soluble EPCR was expressed in S2 cells, and then purified 
by nickel chelate chromatography and biotinylated using the BirA enzyme. The purified 
EPCR was shown to bind both the 2E9 anti-EPCR mAb, as well APC, the known ligand for 
EPCR (Appendix I Supplementary Figures 1a-c).  
 
It has already been demonstrated that sEPCR binds immobilised LES γδ TCR (Appendix I 
Figure 3). To confirm this interaction in the reverse orientation soluble TCR was injected 
over a flow cell immobilised with EPCR. As a negative control, biotinylated HLA-A2 was  
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immobilised on a control flow cell. The resulting sensorgrams revealed considerably higher 
responses after injection of soluble LES γδ TCR over immobilised EPCR than over HLA-A2, 
indicating specific binding. Representative binding curves and Scatchard plots are shown in 
Figure 4.5 and multiple equilibrium binding analyses gave an apparent Kd of 91.3μM +/-46.7 
μM (n=30), consistent with the value originally obtained in the reverse orientation (87 μM) 
(Appendix I). To determine whether LES γδ TCR recognised a conformational epitope on 
EPCR, soluble biotinylated EPCR was denatured. Specific binding responses were observed 
to native EPCR but not EPCR pre-treated with DTT at 60°C (Figure 4.6a). To confirm the 
EPCR was completely denatured, 2E9 mAb was injected and specifically interacted with 
native EPCR but binding to denatured EPCR was greatly reduced (by approximately 70%, 
Figure 4.6b). Therefore this confirmed that LES γδ TCR binds a conformational epitope on 
EPCR.  
 
EPCR has four predicted N-linked glycosylation sites (Asn-X-Ser/Thr: N30, N47, N119 and 
N155), and differences in the extent of EPCR glycosylation have been observed in activating 
and non-activating target cell lines by SDS-PAGE and Western blotting (Appendix I Figure 
2), although no obvious correlation between glycosylation state and activity emerged. 
However, it was important to determine whether the glycosylation status of EPCR was 
critical for the binding of LES γδ TCR, particularly as insect cell expressed proteins lack 
complex-type N-glycans present in mammalian proteins and instead consist mainly of high 
mannose structures, and therefore conceivably altered glycosylation status could be an 
important component of recognition. Purified EPCR was treated with peptide N-glycosidase 
F (PNGase F), which cleaves carbohydrate chains from the asparagine residue. Treatment of 
both native and reduced EPCR with PNGase F resulted in an increased mobility of the 
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Figure 4.5 Soluble LES γδ TCR binds EPCR in the reverse orientation. a) Representative 
binding trace of LES γδ TCR (117 mM) injected over immobilised EPCR (1774 RU) or 
control HLA-A2 (1804 RU). b) Equilibrium binding analysis, involving injection of a range 
of LES γδ TCR concentrations (7.3-117 mM), allowed the calculation of an apparent 
dissociation constant (Kd) of 112.1 mM in this experiment. c) A Scatchard plot of the same 
data gave a Kd of 107.5 mM.  This experiment was repeated (n=30), giving an average Kd of 
91.3 +/- 46.7 mM. 
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Figure 4.6 LES γδ TCR binds to EPCR in a conformational manner. a) LES γδ TCR was 
injected over immobilised native EPCR (2405 RU), denatured EPCR (1911 RU) and HLA-A2 
control (2239 RU). To denature EPCR, purified EPCR was treated with 5mM DTT at 60°C 
for 1 hour then treated with 20mM iodoacetamide for 30 minutes in the dark to prevent 
disulphide bonds reforming. b) 2E9 (2 mM) was injected over immobilised native and 
denatured EPCR and control HLA-A2.  
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protein on SDS-PAGE (the major speciesmigrated at ~25 kDa, the predicted molecular mass 
of the EPCR protein backbone) (Figure 4.7a), suggesting the majority of carbohydrates were 
removed under both reducing and non-reducing conditions. Notably, PNGase F treatment of 
native EPCR highlighted that the glycosylation of EPCR did not play a role in LES γδ TCR 
binding, as glycosylated and deglycosylated EPCR bound TCR with similar affinity (Figures 
4.7b-c). Also, PNGase F treatment of EPCR did not affect overall conformation of the 
structure as 2E9 bound deglycosylated EPCR equivalently to native EPCR (Figure 4.7d). 
 
Based on these results, it is clear that the LES γδ TCR binds a conformation-dependent 
protein epitope on EPCR. Therefore, to further probe the binding mode of LES γδ TCR and 
EPCR, and examine whether lipid presentation was critical for TCR recognition, mutagenesis 
of the α1 and α2 helices of EPCR was undertaken. The amino acids selected for alanine 
scanning mutagenesis were solvent exposed, and hence unlikely to be important in stabilising 
the EPCR structure, and more likely to interact with the TCR. This selection process was 
made possible by detailed examination of the EPCR crystal structure (Oganeysan et al, 2002) 
(Figure 4.2). Using this strategy 17 initial EPCR mutant constructs were designed on the α1 
(Figure 4.8a) and α2 (Figure 4.8b) helix (Table 4.2). To gain a more comprehensive profile of 
the LES γδ TCR/EPCR mode of binding, 8 further mutants were generated, in which 
additional regions of the EPCR were examined including the N-terminus and the β-sheet face 
opposite the antigen binding platform (Table 4.2; Figure 4.9).  
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Figure 4.7 a) SDS-PAGE analysis of EPCR after PNGase F treatment. Lane 1 and 2 show 
DTT-reduced EPCR treated with and without PNGase F, respectively; lane 3 shows PNGase 
F-treated native EPCR; a shift in mobility is observed after removal of carbohydrates from the 
protein under both native and reducing conditions. b) SPR profile of LES γδ TCR injected 
over immobilised native EPCR (3300 RU), PNGase F-treated EPCR (3700 RU) and HLA-A2 
control (3100 RU). c) Scatchard plots were generated following injection of LES γδ TCR over 
a range of concentrations (3-96 mM) and the Kd for wtEPCR (126.3μM) and PNGaseF 
treated EPCR (125 mM) were calculated d) 2E9 mAb (2 mM) was injected over native and 
denatured EPCR, and control HLA-A2. 
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Figure 4.8 Lipid binding platform of EPCR, highlighting solvent exposed amino acids. 
Highlighted residues (side chains are shown in green in stick format) on the a1 helix (a) and 
a2 helix (b) were selected for alanine scanning mutagenesis to examine their effect on LES γδ 
TCR binding. Lipid is highlighted in stick format (yellow). 
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Figure 4.9 Underside view of the EPCR molecule highlighting solvent exposed residues on 
the β-sheet and interstrand loops that were targeted for alanine scanning mutagenesis. 
Selected residues are depicted as stick figures in green. Highlighted in yellow is the lipid 
bound to EPCR. Dashed line represents the stalk region of EPCR. 
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α1 helix α2 helix β-sheet 
E58A + E60A T145A L14A + I16A 
R64A F146A R20A 
S67A Q149A W26A 
S71A + L74A Q150A F98A 
Q75A Y154A F113A + E115A 
R81A+ L82A R156A N119A 
Q85A E160A S121A 
E86A + R87A E163A Q138A + V139A + S141A 
 D167A + Q171A + K175A  
Table 4.2 Solvent exposed amino acids mutated on EPCR. Listed are the residues selected 
for alanine scanning mutagenesis. Exposed residues located on the α1 and α2 helices were 
selected, as they are not predicted to stabilise the EPCR molecule and could be in contact 
with the LES γδ TCR, if the TCR binds analogously to αβ TCR/CD1 complex enabling lipid 
discrimination. A number of additional residues were mutated on the opposite face of EPCR. 
 
In these constructs, solvent-exposed amino acids were mutated to alanine residues to 
determine whether these substitutions affected LES γδ TCR binding to EPCR. Many of the 
constructs generated contained a single amino acid mutated to alanine, however several 
constructs were generated in which multiple residues in close proximity were mutated in 
combination, in order to more rapidly identify important residues. If any of these compound 
mutants highlighted a region of interest, then individual mutant EPCR constructs could be 
generated to focus on the residues of interest (Figures 4.8/4.9). In total, twelve amino acids 
on the α1 helix were mutated in eight constructs and eleven amino acids on the α2 helix were 
mutated in nine constructs (Table 4.2). In addition, as the α1/α2 platform of EPCR was 
predicted to be tethered to plasma membrane by a flexible stalk, a number of amino acids on 
the β-sheet or the inter connecting strand loops were also mutated to alanine, as this region 
could be accessible for interaction with the LES γδ TCR. 
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4.3 Site directed mutagenesis of EPCR, transfection and large scale expression  
Wild type EPCR (wtEPCR) in the pMTBiPBirAHis vector was used as the DNA template in 
the Site Directed Mutagenesis (SDM) PCRs. After successful PCR and verification of the 
point mutations by DNA sequencing (Figure 4.10) the mutated constructs were introduced 
into S2 cells by calcium phosphate transfection. S2 transfectants were selected for 
hygromycin resistance as previously described in Chapter 3. Expression of EPCR mutants 
following induction by copper sulphate was confirmed by SDS-PAGE and western blotting 
(Figure 4.11). After verification of mutant EPCR expression by western blot analysis, large 
scale production was undertaken to produce and purify the mutant EPCR proteins, as 
described for the soluble TCRs in Chapter 3. Ni-NTA purified EPCR mutants were 
biotinylated utilising BirA enzyme and free biotin was removed by gel filtration. SDS-PAGE 
analysis of biotinylated protein indicated that the level of purity was sufficient for SPR 
analysis (Figure 4.12). 
 
4.4 Effect of α1/α2 mutations on EPCR recognition 
SPR analysis of EPCR mutants was performed as described in Figure 4.13a. In each 
experiment wtEPCR was immobilised alongside mutant EPCR and an irrelevant control 
protein, HLA-A2. Equilibrium binding responses were measured over a range of LES γδ 
TCR concentrations and the apparent Kd was determined for the wild type and mutant in 
each individual experiment. Representative binding plots are shown for EPCR S67A and 
Q149A compared to wtEPCR in a single experiment (Figure 4.13b). These residues are 
located on the α1 and α2 helix, respectively, and bound to LES γδ TCR with a similar affinity 
as wtEPCR (Figure 4.13c). In addition, both S67A and Q149A mutants bound the 2E9 mAb 
equivalently to wtEPCR (Figure 4.13d). Analysis of other mutants on the α1/α2 helices w
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Figure 4.10 Site-directed mutagenesis of EPCR. a) Gel electrophoresis analysis of the 
products of site-directed mutagenesis PCRs of the α1 and α2 helices of EPCR loaded on a 1% 
agarose gel. Lane 1 loaded with 1Kb DNA ladder, lanes 2 to 18 loaded with all 17 SDMs to 
mutate solvent-exposed residues on both helices. b-d) Sequencher analysis of wtEPCR 
sequence compared to EPCR mutants S67A (b), Q149A (c) and Q150A (d). Nucleotides 
highlighted by black dots indicate the bases that have been changed to introduce the Alanine 
mutation. 
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Figure 4.11 Western blot analysis to test for expression of mutant EPCR constructs. Mutated 
EPCR constructs were transfected into S2 cells and selected for hygromycin resistance. Cells 
were induced to express protein by addition of copper sulphate (0.5 mM), and cell 
supernatants were harvested on the indicated days and analysed by SDS-PAGE and western 
blotting. Expression of His-tagged EPCR mutants was detected by blotting with anti-His tag 
mAb, goat anti-mouse IgG-HRP, and ECL. 
 
 139 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 SDS-PAGE analysis of purified biotinylated wild type and mutant EPCR proteins 
utilised in SPR experiments. wtEPCR and EPCR mutants were purified from S2 cell 
supernatant by nickel chelate chromatography, biotinylated and further purified by size 
exclusion. Purified proteins were analysed by SDS-PAGE and Coomassie staining prior to 
SPR studies. 
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Figure 4.13 Analysis of EPCR mutants using SPR. a) Cartoon of experimental set-up, 
showing biotinylated wild type and mutant EPCR, as well as control HLA-A2, were 
immobilised on a streptavidin-coated CM5 chip and binding of soluble LES γδ TCR was 
measured. b) SPR profile of LES γδ TCR (43 mM) injected over immobilised control (HLA-
A2, red, 4291 RU), wtEPCR (black, 4085 RU), and EPCR mutants S67A (blue, 4089 RU) 
and Q149A (pink, 4047 RU). c) Scatchard plot of the binding data for wtEPCR (Kd=90.9 
mM) and mutants S67A (Kd=97.1 mM) and Q149A (Kd=99.1 mM). d) 2E9 mAb (2 mg/ml) 
was then injected over the same proteins, and response measured. 
 
 141 
performed, and the binding affinity of wtEPCR relative to mutant EPCR was plotted (Figure 
4.14; Table 4.3). All α1/α2 mutants bound LES γδ TCR with similar affinities, with the 
exception of mutations at E86 and R87 which had a marginally higher affinity for the TCR. 
This is particularly interesting as E86A/R87A is present on the α1 helix and is sited at the 
membrane distal region of EPCR, on the assumption that the long axis of the EPCR 
ectodomain (parallel to the α1 and α2 helices) is perpendicular to the plane of the membrane. 
This is consistent with a model whereby LES γδ TCR would dock to the membrane distal 
region on EPCR. However, mutants T145A, F146A and Q149A are also prominent at the 
membrane distal region on the α2 helix and highlighted no change in LES γδ TCR 
recognition. The E86A/R87A mutations substituted large charged side chains for small 
alanine side chains and could have affected the overall structure of EPCR, supported by 
evidence that 2E9 mAb binding to this mutant is decreased. Several other α helical mutations 
revealed reduced binding of 2E9 (Table 4.3), whereas the R81A/L82A mutant combination 
completely abolished 2E9 binding, suggesting these residues are critical for 2E9 recognition.  
 
1 helix 
equilibrium 
Kd mutant 
(μM) 
equilibrium 
Kd wt (μM) 
wt Kd/mutant 
Kd 2E9 binding Error +/- 
E58 & E60 160.2 184.5 1.15 + 19.57 
R64 33 29.5 0.89 + 5.29 
S67 100.5 97.8 0.97 + 32.07 
S71 & L74 109.9 104.6 0.95 + 21.78 
Q75 280.2 279.9 1.00 + 75.91 
R81 & L82 184.4 177.9 0.96 - 12.76 
Q85 157.9 136.1 0.86 +/- 32.5 
E86 & R87 77.2 138.1 1.79 +/- 14.34 
2 helix      
T145 139.4 177.9 1.28 + 10.62 
F146 28.7 29.5 1.03 +/- 3.77 
Q149 105.7 97.8 0.93 + 25.12 
Q150 91.2 83.2 0.91 + 15.76 
Y154 133.5 122.9 0.92 + 26.0 
R156 32.8 28.7 0.88 + 5.86 
E160 135.1 134.4 0.99 + 10.52 
E163 91.7 117.7 1.28 + 6.68 
D167,Q171 & 83.9 105.7 1.26 +/- 30.4 
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Table 4.3 LES γδ TCR binding affinity to EPCR α1/α2 mutants. Point mutations on the α1 
and α2 helices of EPCR were analysed for LES γδ TCR binding by SPR. Equilibrium binding 
analyses were performed for mutant EPCR and wild type EPCR in a single experiment and 
apparent dissociation constants (Kd) were calculated. The ratio of wild type Kd/mutant Kd 
was calculated in each experiment. A ratio of ~1 indicates equivalent binding. Mutations in 
the α-helices of EPCR indicated this region was not involved in LES γδ TCR binding. EPCR 
mutants were also analysed for 2E9 mAb binding to confirm that these mutations did not 
affect overall conformation of EPCR. Where Kd values were recorded, errors in the Kd 
values (ie Kd +/- x µM) were determined from estimates of the standard error from the 
Equilibrium binding as calculated in Origin V3. In each case, the range given (ie +/- x µM) 
represents the largest deviation from the estimated Kd value. Ultimately, determination of the 
binding mode of the LES TCR/EPCR interaction relied entirely on mutations that abolished 
binding, for which Kd estimation was clearly not possible. 
 
Strikingly, these results indicated that it is unlikely LES γδ TCR binds EPCR in a similar 
manner to αβ TCR/CD1 interaction, as lipid discrimination would require interaction with the 
α1/α2 helical residues. However, analysis of the β-sheet mutations highlighted several 
residues which affected TCR binding (Table 4.4). For instance, EPCR mutants N119A and 
S121A failed to bind TCR but interestingly, these residues make up one of the glycosylation 
sites. It is unclear whether the N119A and S121A mutants are locally misfolded due to the 
disruption to the glycosylation motif during protein synthesis and folding in the endoplasmic 
reticulum, as mutant S121A also binds 2E9 mAb with decreased affinity. Furthermore, 
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Figure 4.14 LES γδ TCR binding affinity for EPCR mutants (mutant Kd) with alanine 
substitution of α1 or α2 helix residues relative to EPCR wild type affinity (WT Kd) measured 
in the same experiment (a). Binding affinity for EPCR mutants with alanine substitution on β-
sheet residues relative to EPCR WT (b). Red dashed line indicates an equal binding affinity. 
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double mutant F113A/E115A displayed a four-fold increased TCR binding. The increase in 
TCR binding may have resulted from the longer side chains perturbing the LES γδ TCR-
EPCR interaction. This was particularly interesting as these amino acids were positioned on 
the β-sheet and away from the lipid binding pocket of EPCR, highlighting a novel region on 
the β-sheet (Figure 4.15) as a potential TCR binding site. To further examine this hypothesis, 
additional mutations on the β-sheet surrounding residues 113-121 were generated and 
analysed. 
 
β-sheet 
equilibrium 
Kd mutant 
(μM) 
equilibrium 
Kd wt (μM) 
wt Kd/mut 
Kd 
2E9 
binding 
Error 
+/- 
L14A & I16A 137.3 184.5 1.34 + 66.16 
R20A 34.5 32.4 0.94 ND 1.75 
W26A 32 28.7 0.90 + 5.02 
N119A 0 131.6 0 + 0 
S121A 0 56.3 0 +/- 0 
F98A 88.2 122.9 1.39 + 28.05 
F113A & E115A 27.7 117.7 4.25 + 11.7 
Q138A,V139A & 
S141A 135.1 123.4 0.91 + 12.63 
Table 4.4. β-sheet mutations scanning the platform region of EPCR. Effect of EPCR β-
sheet mutations on LES γδ TCR binding. Equilibrium binding analyses were performed and 
Kd calculated for WT and mutant EPCR in each experiment. The ratio of WT Kd/mutant Kd 
was calculated. A ratio of approximately 1 indicates equivalent binding of LES γδ TCR to WT 
and mutant EPCR. Ratio of >1 indicates increased binding, while 0 indicates no binding was 
observed to mutant EPCR. 2E9 was also used to confirm EPCR structure was not disrupted 
by mutagenesis. Note that 2E9 binding to EPCR-R20A was not determined (ND). 
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Figure 4.15 Amino acid residues on EPCR indicating areas potentially involved in LES γδ 
TCR binding. Highlighted in green sticks are residues F113/E115, mutation of which results 
in a higher affinity for TCR binding, and N119 and S121, mutation of which abrogates LES 
γδ TCR binding. 
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4.5 Identification of key residues involved in LES γδ TCR binding to EPCR 
On examining the EPCR structure to identify solvent exposed amino acids on the β-sheet in 
close proximity to residues 113–121, an additional 27 amino acids were selected for SDM 
analysis (Table 4.5). Firstly, to determine the precise role of F113 and E115 with respect to 
LES TCR binding, each residue was separately mutated to alanine. In addition, the nearby 
residue A117 was mutated to a smaller amino acid, glycine (A117G), as well as a large 
charged residue, aspartic acid (A117D). This would highlight whether the beta sheet residues 
represented a bona fide TCR binding site. Moreover, to determine if S121 was truly involved 
in TCR binding, it was mutated to threonine to preserve the glycosylation site. Finally, to 
assess the limits of the proposed TCR binding site, several amino acids on neighboring β-
strands and loops were mutated to alanine, as single residue mutants or in pairs (Figure 4.16). 
Each mutant was analysed for LES γδ TCR binding by SPR as described earlier, and 
compared directly to wtEPCR in each experiment. A ratio of wild type Kd/mutant Kd was 
calculated and a number of residues emerged which affected TCR binding (Figure 4.17). The 
most striking observation consisted of individual mutants F113A and E115A abolishing LES 
γδ TCR binding, confirming that these residues were of interest. This result was contrary to 
the combined double mutations on EPCR F113A/E115A which displayed a 4-fold increase in 
LES γδ TCR binding. However, one caveat is that for F113A, the lack of LES TCR 
recognition was accompanied by a decrease in 2E9 binding, and the loss in TCR binding by 
this mutation resulted from local misfolding or altered conformation of EPCR. However, 
E115A exhibited a loss in LES γδ TCR binding accompanied by normal levels of 2E9 
binding indicating correct conformation in EPCR, confirming likely involvement in the 
interaction. S121T bound LES γδ TCR but with a slightly decreased affinity, and nearby 
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Figure 4.16 Further amino acids mutated on the β sheet to identify the mode of LES γδ TCR 
binding to EPCR. Highlighted in green sticks are the side chains of solvent exposed residues 
which were most prominent and are therefore potentially involved in TCR binding.  
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Figure 4.17 Analysis of further EPCR β-sheet mutations by SPR, showing the ratio of WT 
LES γδ TCR binding affinity to mutant of solvent exposed mutant constructs. Data plotted by 
normalising affinity of wtEPCR tested against each mutant. Indicated in red are the residues 
mutated which demonstrated a decrease in LES γδ TCR affinity for EPCR. 
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S122A reduced the affinity by 5-fold. The fact that S121T and S122A demonstrate decreased 
affinities despite the preservation of the glycosylation motif, suggests the serine side chains 
themselves, rather than the glycosylation site itself, were important in LES γδ TCR binding. 
The A117 residue seemed also to be involved in binding, as mutagenesis to a larger aspartic 
acid inhibited binding, while mutation to the smaller glycine revealed no effect. A number of 
residues on neighboring β-strands also affected TCR binding, and the majority of these bound 
2E9 mAb equivalently to wtEPCR, suggesting the mutation did not alter the overall structure 
of EPCR. In addition, residue S32 is part of an N linked glycosylation site at N30 and 
substitution to alanine disrupted TCR binding. However, this disruption did not seem to be 
due to absence of the glycosylation site or misfolding in the absence of the glycosylation, as 
the N30A mutant bound LES γδ TCR equivalently to wild type and both bound 2E9 mAb. In 
all, 12 residues on the β-sheet affected binding (Table 4.5), and an extensive binding site 
emerged on the β-sheet face opposite to the lipid binding platform (Figure 4.18). 
2nd round 
mutants 
KD 
equilibrium 
mutant (μM) 
KD 
equilibrium 
wtEPCR 
(μM) 
WT 
Kd/mutant 
Kd 
2E9 
binding 
Error 
+/- 
R10A 0 51.8 0 + 0 
L14A 0 84.8 0 + 0 
Y18A 88.3 91.4 1.04 + 16.17 
D21A/Y23A 59.5 38.5 0.65 +/- 10.76 
N30 102.5 74.5 0.73 + 12.7 
S32A 0 74.5 0 + 10.8 
L37A 64.9 51.8 0.80 + 1.77 
V40A 74.3 83.2 1.12 + 10.63 
E42A 290 138.1 0.48 + 166.14 
N47A 34.6 86.1 2.49 + 6.55 
T49A 75.3 94.6 1.26 + 10.8 
I51A 77.7 75.6 0.97 + 5.29 
L53A 175.3 182.5 1.04 + 28.4 
T94A/R96A 79.6 49 0.62 + 24.88 
F113A 0 105.7 0 +/- 0 
E115A 0 140 0 + 0 
A117G 77.4 86.1 1.11 + 22.11 
A117D 0 67 0 + 0 
S121T 37 22.6 0.61 + 13.74 
 150 
S122A 717 140 0.20 + 166 
S125A/R127A 0 91.4 0 + 0 
S125A 0 84.8 0 + 0 
R127A 0 182.5 0 + 0 
Q134A/D136A 0 49 0 + 0 
N155A 78.1 80.1 1.03 + 15.13 
T157A 59.4 38.5 0.65 + 14.19 
Table 4.5. LES γδ TCR binding affinity data of further selected residues for mutagenesis. 
Highlighted are the affinity of each β-sheet mutation compared to the wtEPCR, 2E9 antibody 
analysis indicates conformation of EPCR. 
 
4.6 2E9 binding site identification 
Binding analyses of the 2E9 antibody to each mutant highlighted several other amino acids 
which affected 2E9 binding. Combined with the previously identified residues on the α1/α2 
helices, it is predicted that the main 2E9 binding site encompasses residues R81, L82, Q85, 
E86, E87 and F146 (Figure 4.19). Further, other residues that may contact 2E9 include D21 
and Y23 which are located on the side of platform. It is unclear how F113A and S121A on 
the underside of the platform can affect 2E9 binding; potentially these mutations could affect 
folding of the molecule, causing a localized change in conformation of EPCR that may have 
an effect on 2E9 binding to other regions of the molecule. Likewise, mutation of 
D167A/Q171A/K175A also demonstrated reduced 2E9 binding. These residues are on the C-
terminal end of the α2 helix, located distal to the putative 2E9 binding site. It is possible that 
mutation of these residues may cause a conformational change in the α2 helix such that it 
affects 2E9 binding (Figure 4.19). 
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Figure 4.18 LES γδ TCR binding mode to EPCR. Depicted in red are the residues which, 
when mutated to alanine, demonstrated decreased LES γδ TCR binding to EPCR. This 
diagram highlights a region on the β-strand platform where the LES γδ TCR may dock to the 
EPCR protein.  
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Figure 4.19 2E9 mAb binding mode to EPCR. Depicted in pink are the residues, which when 
mutated to alanine highlighted a change in 2E9 binding to EPCR. Shown in yellow dotted line 
is the 2E9 binding site. Indicating 2E9 antibody interacts with the α1/α2 helices of EPCR, 
away from the proposed LES γδ TCR docking site on the β-sheet.  
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In summary, the majority of residues which affected 2E9 antibody binding were located on 
one end of the α1/α2 platform of EPCR. The 2E9 binding site was distinct from the LES γδ 
TCR recognition site, suggesting 2E9 did not directly prevent TCR binding in functional 
assays (Figure 4.18). Rather, because 2E9 is a pentameric IgM, binding of 2E9 sterically 
inhibited binding of LES γδ TCR to EPCR. Interestingly, a number of residues which affect 
2E9 binding were identified as critical for APC binding (Oganesyan et al, 2002) suggesting 
2E9 could be a good blocking antibody for the EPCR-APC interaction (Figure 4.20). 
 
4.7 Crystallisation trials of the LES γδ TCR-EPCR complex 
To enable a greater molecular understanding of the LES γδ TCR-EPCR interaction 
crystallization of the complex was attempted. Expression and purification of LES γδ TCR 
and EPCR was performed as described in Chapters 3 and 4. After concentration of the LES 
γδ TCR and EPCR, the purity of the proteins was evaluated by SDS-PAGE analysis (data not 
shown). This highlighted that the proteins were of acceptable purity for subsequent 
crystallisation complex trials. SPR analysis of LES γδ TCR-EPCR interaction revealed that 
the interaction was within the micro-molar range similar to αβ TCR-pMHC affinities (1-100 
M). Despite the low affinity observed for the αβ TCR-pMHC interactions, several of these 
ternary complexes have readily crystallized allowing their structures to be determined 
(Rudolph et al, 2006), thereby suggesting that LES γδ TCR-EPCR complex is a valid 
candidate for structural studies. Initial complex crystallization trials were attempted using the 
hanging drop vapour diffusion method at a concentration of 5.3 mg/ml. These trials were 
unsuccessful presumably due to the fact that the majority of the hanging drops were under-
saturated. 
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Figure 4.20 Crystal structure of EPCR in complex with the Gla domain of Protein C 
(Oganesyan et al, 2002). The Gla domain of protein C (depicted in pink) interacts with the 
α1/α2 helices of EPCR (blue), away from the proposed LES γδ TCR docking site on the β-
sheet. Residues of EPCR that interact with Gla domain are highlighted in ball and stick format 
and labelled. EPCR residues that are circled in red are involved in 2E9 binding, indicating 
2E9 mAb binding may inhibit protein C docking to EPCR.  
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Further attempts for setting up crystallization trials at a higher concentration were limited due 
to problems associated with producing highly concentrated amounts of LES γδ TCR. Also, 
previous structural studies of EPCR demonstrated the region following the α2 helix that links 
EPCR to the transmembrane domain is very flexible. It is possible that this region may have 
prevented efficient crystallisation. To overcome this issue and potentially facilitate 
crystallization of the complex, a new construct was designed by Dr Carrie Willcox which 
lacked the flexible region at the C-terminus of the protein, but still encompassed a His tag for 
purification. Unfortunately, the new complex trials with the shortened EPCR construct also 
revealed a lack of viable crystallization hits. This was attributed to the drops being under-
saturated, despite the fact that the trials were set up at a protein concentration of 10 mg/ml. 
The final strategy involved utilizing a high affinity mutant EPCR construct (F113A/E115A; 
Kd= ~25 M) previously identified by SPR analysis. Notably, the mutant construct also 
lacked the flexible stalk region. It was possible that the increased affinity of the LES γδ TCR-
EPCR complex may facilitate crystal formation. However, the mutant EPCR high affinity 
construct proved to be unstable when concentrating to high levels. To increase the solubility 
of the high affinity EPCR mutant construct, a thermal stability assay was performed, and a 
buffer condition was identified that appeared to increase stability. However, when EPCR was 
then concentrated in this optimized buffer, the stability of the protein, as judged by its 
propensity to aggregate, was observed to be similar in the optimized buffer at high 
concentrations, and only a limited number of crystallization complex trials were set up.  
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4.8 Discussion 
Although several molecules have been proposed to stimulate human γδ T cells, none have 
been demonstrated to bind the γδ TCR in direct binding studies. EPCR has been identified as 
a ligand for human Vγ4Vδ5 TCR derived from a T cell clone which recognized tumour cell 
lines and CMV infected cells. Although the affinity of this interaction is low, it is within the 
range of affinities for αβ TCR-pMHC studied to date (1-100μM) (Rudolph et al, 2006). 
Notably, it is much lower than the only γδ TCR interaction known, that of the murine G8 
TCR for non-classical MHC molecules T10/T22 (0.1 μM) (Adams et al, 2005). It is plausible 
that similar to αβ TCRs, γδ TCRs may display a broad range of affinities for their ligands. 
 
Further SPR analysis revealed LES γδ TCR binds a conformational epitope on EPCR. 
Previous analysis of TCR binding had demonstrated EPCR was necessary but not sufficient 
for activation of the LES γδ T cell clone or the transfected JRT3-LES cell line. This could 
have been due to intrinsic or extrinsic factors associated with EPCR. EPCR-intrinsic factors 
could include effects of glycosylation of the protein, as EPCR contains four N-linked 
glycosylation sites within the primary protein sequence. Indeed, analysis of tumour cell 
lysates indicated EPCR was heavily and differentially glycosylated in different cell lines 
(Willcox et al, 2012). However, there was no obvious correlation between the extent of 
EPCR glycosylation and ability of the cell line to activate LES γδ T cells. To directly address 
this, recombinant EPCR was deglycosylated by treatment with PNGase F. Purified EPCR 
was completely deglycosylated as determined by SDS-PAGE, but still bound LES γδ TCR 
with the same affinity as glycosylated EPCR. Therefore, glycosylation of EPCR is unlikely to 
explain the observed differential reactivity. 
Another EPCR-intrinsic factor could include differential membrane localization of EPCR in 
activating and non-activating cells. The short cytoplasmic tail of EPCR contains a cysteine 
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which can be palmitoylated (Xu et al, 1999). Palmitoylation is a reversible post translational 
modification in which a palmitic acid chain is attached to juxtamembrane cysteine residues 
and affects subcellular trafficking and protein association (Linder and Deschenes, 2007). In 
endothelial cells, palmitoylation of EPCR is thought to result in localization of EPCR to 
caveolae. Cell based studies carried out in our laboratory have shown EPCR staining in 
tumour cell lines to be highly punctuate consistent with localization of EPCR to lipid rafts or 
caveolae (Appendix I, Figure 1d). However, this is observed in both activatory and non-
activatory cell lines, and hence is unlikely to explain the pattern of reactivity to 2E9
+
 cells.  
A third possibility is that EPCR has the capacity to present a stress lipid to the TCR. This is 
supported by the fact that EPCR is structurally related to CD1d, a lipid presenting molecule 
recognized by NKT cells. Strikingly, EPCR has also been demonstrated to possess a lipid 
molecule bound between the helices of the protein. The hypothesis that EPCR presents a lipid 
to the γδ TCR was examined in several ways. Cell lines which activate or fail to activate the 
LES γδ TCR were transduced to express sEPCR, which was purified and analysed for LES γδ 
TCR binding by SPR. No differences in affinity for TCR were observed between sEPCR 
produced in activating (U373) or non-activating (HeLa) cells, or between uninfected and 
CMV infected U251 cells (Appendix I Supplementary Figure 4). However, EPCR molecules 
that lack the transmembrane and cytoplasmic tail may not traffic throughout the cell in the 
same manner as native EPCR and hence are unlikely to enter the correct organelle to be 
loaded with appropriate lipid. Therefore, alanine scanning mutagenesis was used, with the 
intention that mutations on the α1/α2 helices would affect TCR binding if bound lipid was 
being discriminated. However, the α1/α2 helical mutations showed no change in LES γδ TCR 
binding suggesting that the TCR does not to discriminate lipids presented by EPCR. 
Following additional mutational analysis the region of LES γδ TCR binding was identified on 
the β-sheet face beneath the lipid binding platform of EPCR. This region would be accessible 
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for TCR binding as the EPCR structure predicted the α1/α2 platform as being attached to a 
flexible stalk, rather than tethered in a horizontal position like class I MHC or CD1d by 
interactions with α3 and β2M. This flexibility may allow the LES γδ TCR direct access to the 
binding site on the β-sheet platform. Therefore, the difference in recognition of activatory and 
non-activatory cell lines does not seem to be related to an EPCR-intrinsic factor. Instead, LES 
clone and Jurkat transfectant recognition of activating tumour lines and CMV infected cells 
has been shown to be highly dependent on costimulatory signals including CD58-CD2 and 
CD54-CD11a. Despite these observations, blocking these interactions led to incomplete 
inhibition of activation (Appendix I Figure 7), suggesting other yet to be identified 
costimulatory complexes may be involved.  
Several alloreactive murine γδ clones have been identified which recognize classical MHC or 
MHC-like molecules (Crowley et al, 2000; Hampl et al, 1999, Schild et al, 1994), but the two 
clones which have been studied extensively have been shown to interact with residues on the 
α1/α2 helices, similar to αβ TCR-pMHC interactions. The unique binding mode of LES γδ 
TCR for EPCR may be indicative of γδ T cells ability to recognize intact self stress antigens 
in an antibody-like manner. This is reminiscent of CD4/CD8/MHC-I
-
/II
-
 deficient mice, in 
which αβ T cells are not MHC-restricted, but recognized intact self antigen (Tikhonova et al, 
2012).  
To gain greater molecular insights into the LES γδ TCR-EPCR interaction, co-crystallisation 
of the two proteins was attempted, but has thus far been unsuccessful. To overcome 
intransigent LES γδ TCR-EPCR complex crystallization, a number of strategies used in 
previous structural studies could be attempted. These involve decreasing the level of protein 
glycosylation by expressing proteins in the presence of tunicamycin (Adams et al, 2005), or 
treatment of purified sEPCR and LES γδ TCR with PNGase F or endoglycosidase H to 
remove N-linked glycosylations. One could also try to increase the concentration of LES γδ 
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TCR and EPCR in complex crystal trials to enhance protein nucleation. Furthermore, 
introduction of an additional domain to the complex may encourage crystallization, by 
altering crystal contacts. This could include addition of an Ig-domain to the C-terminus of 
EPCR, or addition of APC to the complex trials. 
Structural analysis of the LES γδ TCR-EPCR complex will undoubtedly complement the 
mutational studies and help validate the proposed binding site identified in this chapter. In 
addition, the complex structure may elucidate other residues on EPCR which interact with 
LES γδ TCR, as well as determine which regions of the TCR are vital for EPCR binding. It 
will be interesting to evaluate the contribution of each CDR loop to EPCR binding. It is 
already evident from TCR chain swap experiments that the Vγ4 CDR3 loop is essential for 
EPCR binding (Willcox et al, 2012). Antibody-antigen binding usually involves all 6 CDR 
loops, while the G8 γδ TCR-T22 interaction is completely dependent on the CDR-3 loop of 
the δ chain (Adams et al, 2005). In addition, since the LES Vδ5 chain sequence contains 
many N-nucleotide additions, it is likely to result from a rare recombination event, suggesting 
it may be restricted to a minority of individuals. Dependence on such CDR loop sequences 
could explain why EPCR reactivity is a seemingly rare event. Since other EPCR reactive 
cells have not to date been identified, this may suggest all CDR loops may be required for 
binding. To address these issues, structural analysis of LES γδ TCR in complex with EPCR 
may give valuable insight into which CDR regions are important for ligand recognition.  
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CHAPTER 5 – 
 STRUCTURAL DETERMINATION OF SKINT-1
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Chapter 5: Structural Determination of Skint-1 
5.1 Introduction 
Arguably one of the best studied γδ T cells subsets is the intraepithelial γδ TCR+ cell subset 
found in the skin of mice. These cells have a characteristic dendritic morphology and are 
therefore known as dendritic epidermal T cells (DETC). DETCs are the first T cells to 
develop in the foetal mouse thymus, from embryonic day 13-17, and are subsequently only 
found in adult skin (Havran and Allison, 1990). Unlike αβ T cells and circulating γδ T cells, 
which utilise TCR V(D)J gene rearrangement and N-nucleotide addition by terminal 
deoxynucleotide transferase (TdT) to generate diversity in their TCRs, more than 90% of 
DETCs express a monomorphic Vγ5Vδ1 TCR, which is specifically recognised by the 
conformation-dependent 17D1 mAb. It is unclear whether the limited diversity of the 
canonical DETC TCR results from biased recombination of the gene segments used by DETC 
combined with the lack of TdT expression in the embryonic thymus during DETC 
development, or whether the lack of diversity is a result of positive selection. Early evidence 
favoured the biased recombination hypothesis, as the majority of thymocytes from mice 
expressing a Vγ5 gene segment containing a premature stop codon showed canonical 
rearrangements, even in the absence of TCR expression and hence positive selection. 
However, other experiments supported the idea of positive selection of DETC cells: in mice 
over-expressing TdT throughout embryonic development, more than 50% of in-frame TCR 
joins were canonical (Zhang et al, 1995). Further evidence for positive selection was obtained 
by disruption of the Vγ5 gene segment, which led to a replacement Vγ1 chain being utilised. 
Replacement Vγ1Vδ1 cells were still recognised by the 17D1 antibody, suggesting that the 
selection of a particular TCR conformation during their maturation in the thymus is important 
(Mallick-Wood et al, 1998).  
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DETCs, like the majority of γδ T cells, do not recognise classical peptide-MHC complexes. 
Instead, they appear to be activated by signals from adjacent damaged or stressed 
keratinocytes (Havran et al, 1991). These signals can include known ligands for the activating 
receptor NKG2D expressed by DETCs, as well as unidentified signals through the TCR. Once 
activated, whether through the TCR or NKG2D, DETCs are involved in regulating 
inflammation, modulating downstream immune responses, and maintaining epithelial 
integrity. Mice deficient in DETC display spontaneous ear inflammation that can be rescued 
by adoptive transfer of foetal Vγ5+ cells (Girardi et al, 2002). DETCs are also crucial in 
wound healing: mice lacking DETCs are slower to heal full-thickness skin wounds than wild 
type mice (Jameson et al, 2002). Following wounding, DETC near the wound lose their 
dendritic morphology, and produce growth factors such as FGF-7 and FGF-10 to encourage 
the regulated proliferation of keratinocytes around the wound site (Boismenu et al, 1994). 
Activated DETC also make chemokines that include MIP-1a/MIP-1b/RANTES, which attract 
monocytes and lymphotactin to T cells at the site of the wound (Boismenu et al, 1996), as 
well as pro-inflammatory cytokines IFN-γ and TNFα (Jameson et al, 2002). Other forms of 
keratinocyte damage, such as that generated in vivo or in vitro by exposure to contact 
sensitizers, also induce DETC proliferation in vitro (Huber et al, 1995). This has been shown 
to be mediated by the γδ TCR because anti-CD3 mAb effectively blocked activation of the 
DETC. Further studies using a doxycycline-inducible Rae-1 transgenic system examined the 
ability of DETC to organise downstream immune responses in the skin following activation 
through NKG2D but in the absence of an obvious TCR signal: induced Rae-1 caused DETC 
rounding, changes in the skin Langerhans cells, and recruitment of unconventional αβ T cells 
(Strid et al, 2008). However, recent intravital microscopy studies have suggested that even in 
the absence of stress stimuli, the γδ TCR of DETC is preferentially localised in contacts to 
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keratinocytes and provides steady state signalling to the DETC, suggestive of interaction with 
constitutively expressed ligands on keratinocytes (Chodaczek et al, 2012).  
 
DETCs also play a role in protection against epithelial tumourigenesis. TCRδ-/- mice showed 
increased susceptibility to several cutaneous chemical carcinogenesis regimes in the FVB/N 
strain (Girardi et al, 2001). This effect was shown to be specifically due to the lack of DETC 
by using mice deficient for both the Vγ5 and Vδ1 gene segments in the same models (Strid et 
al, 2008). Mice lacking either the Vγ5 or Vδ1 gene segments had DETCs which expressed 
“replacement” receptors that stained with 17D1 to some degree, and these cells protected 
against malignancy to the same degree as wild type DETC (Strid et al, 2008). DETC
-/-
 mice 
showed increased incidence of papilloma formation compared to wild type mice, as well as 
increased progression from papilloma to carcinoma (Girardi et al, 2001; Strid et al, 2008), 
suggesting a role for DETC at very early stages of immunosurveillance. Ligands for the 
NKG2D receptor have been shown to be upregulated in murine skin within 24 hours of 
treatment with carcinogen (Girardi et al, 2001). In these models of tumourigenesis, it is likely 
DETCs are activated at least partly by signals through NKG2D, however γδ TCR ligands may 
also contribute, as supported by recent imaging studies (Chodaczek et al, 2012).  
 
Despite extensive studies on DETCs, the ligand for the DETC TCR in the skin remains 
unclear, as does the identity of a positively selecting ligand in the thymus. However, a 
potential breakthrough came whilst using FVB/N mice from a new breeding colony at 
Taconic Farms (FVBtac) as a control in the abovementioned tumour immunosurveillance 
studies (Girardi et al, 2001). Lewis, et al (2006) serendipitously found these FVBtac mice had 
normal numbers of DETCs, but these cells expressed diverse TCRs and not the normal 
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monomorphic Vγ5Vδ1 TCR. These mice also displayed spontaneous cutaneous inflammation 
similar to δ-/- mice. Backcrossing FVBtac x FVBJax mice suggested an autosomal dominant 
gene was responsible for the selection of DETCs and genetic mapping ultimately identified a 
single substitution between FVBtac and FVBJax mice, consisting of a mutation in the 
LOC384040 gene, which was characterised and named Skint-1 (for selection and upkeep of 
intraepithelial T cells 1).  
 
Skint-1 encodes a 364 amino acid protein which contains two Ig-like domains (one IgV-like 
and one IgC-like domain), three transmembrane domains and a short cytoplasmic tail at the C 
terminus (Figure 5.1). Skint-1 mRNA was only expressed in thymic epithelial cells, and also 
constitutively in keratinocytes (Boyden et al, 2008), consistent with a possible role in thymic 
selection of DETC as well as activation of mature DETC in the periphery. Expression of full-
length skint1Jax rescues the development of mature Vγ5Vδ1 DETC in reaggregate thymic 
organ culture (RTOC), and FVBtac mice which over-express transgenic wild type skint1 have 
normal numbers of DETCs in the skin (Boyden et al, 2008; Barbee et al, 2011). Therefore, it 
appears that Skint-1 expression in the thymus is essential for the selection of the DETC subset 
and homing to the epidermis, as the immature DETC which developed in FVBtac mice were 
found to home to sites other than the skin and acquire a different functional phenotype 
(Turchinovich and Hayday, 2011). Over-expression of Skint-1 under the control of a β-actin 
promoter did not result in negative selection of DETC, or alterations in other γδ subsets 
(Barbee et al, 2011), suggesting DETCs do not undergo negative selection in the same 
manner as αβ T cells. 
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Figure 5.1 Schematic diagram of Skint-1 as expressed on the surface of thymic cells (Boyden 
et al., 2008). Membrane-distal variable domain (IgV) is displayed in green and the 
membrane-proximal constant-like domain (IgC) shown in blue. Mutation identified in FVB/N 
mouse strain (generated by Taconic laboratories) that results in the selective deficiency for 
epidermal Vγ5Vδ1 T cells is highlighted.  
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In order to learn more about Skint-1, which clearly plays a key role in thymic selection of 
DETCs but is also a candidate ligand in the skin, I expressed Skint-1 and carried out structural 
studies on the recombinantly expressed protein. Recombinant production of soluble Skint-1 
was undertaken in several expression systems, providing sufficient levels of protein, for 
downstream structural studies with X-ray Crystallography and NMR. 
 
5.2 Production of Skint-1 ectodomain 
5.2.1 Cloning and Expression 
The mouse Skint-1 cDNA was kindly donated by the Hayday laboratory. The Skint-1 
ectodomain construct consisting of the IgV and IgC regions (incorporating residues 1-224) 
was successfully amplified using Pfu Stratagene polymerase into a prokaryotic expression 
vector pET23a. Confirmation of the correct Skint-1 sequence cloning was verified using the 
Big Dye terminator kit from Functional Genomics. This expression vector was subsequently 
transformed into BL21 (DE3)pLYS E. coli cells and test expression for the Skint-1 IgV-IgC 
construct (in 5ml cultures) revealed a distinct band induced at ~31 kDa (data not shown). This 
highlighted that the Skint-1 protein was migrating non-ideally on the SDS-PAGE gel given 
that the predicted sequence derived molecular weight of the Skint-1 ectodomain is ~25.5 kDa. 
To obtain high yields of recombinant Skint-1, initial expression conditions were replicated on 
a large scale to a volume of 2L. Consistent with other Ig-domain containing proteins, 
centrifugation of lysed cultures of Skint-1 resulted in a large pellet of insoluble inclusion body 
material. Inclusion bodies were purified as described previously (Willcox et al, 1999) and 
finally solubilised in a denaturing buffer containing 8M urea. Generally, ~120 mg/litre of 
recombinant inclusion protein were obtained. SDS–PAGE analysis of purified inclusion body 
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pellets confirmed the presence of Skint-1 (Figure 5.2) at relatively high purity and sufficient 
levels for renaturation.  
 
5.2.2 In vitro refolding of Skint-1 IgV-IgC 
Initial attempts for renaturation of the Skint-1 ectodomain consisted of slowly removing the 
denaturant by dilution, a method that has proven successful for many other Ig-like domain-
containing proteins (Allison et al, 2001 Garner et al, 2005). Renaturation was carried out in 
the presence of glutathione redox components to allow formation/breakage of disulphide 
bonds. In addition, an alkaline pH was maintained to promote formation of the active 
glutathione thiolate anion and hence disulphide exchange. Furthermore, L-arginine, an 
additive widely used to enhance in vitro protein refolding (Choi et al, 2012), was incorporated 
into the refolding buffer, to suppress protein aggregation. To reduce concentration-dependent 
aggregation effects, 60 mgs of Skint-1 IgV-IgC inclusion bodies were added in pulses to the 
refolding mixture over several days. Despite these provisions, the size exclusion profile of the 
refolded mixture revealed no prominent peak suggesting that the Skint-1 IgV-IgC protein was 
refractory to refolding (data not shown). 
 
Further attempts at refolding the Skint-1 ectodomain comprised of supplementing the refold 
mixture with a denaturant, a strategy that has proven successful for renaturing TCRs (Willcox 
et al, 1999). The denaturant, in this case 5M urea, was included in the renaturation buffer for 
several days to prevent protein aggregation and then dialysed out. This strategy allowed the 
Skint-1 ectodomain to fold into its native state, as demonstrated by the size exclusion profile 
following purification on the Superdex 200 column (Figure 5.3). However, the recovery yield 
of the Skint-1 IgV-IgC was extremely inefficient (0.008%), suggesting that the levels of 
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Figure 5.2 SDS-PAGE analysis of the Skint-1 ectodomain expressed as inclusion bodies in E. 
coli. Molecular weight standards are shown in the first lane and inclusion body preparations 
in the second lane. Band corresponding to Skint-1 IgV-IgC (black arrow; Mw 26 kDa) has 
migrated close to the 31 kDa standard. Full-length Skint-1 inclusion body preparations were 
relatively pure (>80%) and contained high levels of protein (120 mg/L). 
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Figure 5.3 Elution profile for Skint-1 IgV-IgC ectodomain following purification by size 
exclusion chromatography using the Superdex 200 column. Skint-1 ectodomain elutes at 225 
ml consistent with the Skint-1 ectodomain existing as a monomer in solution (26kDa). From a 
60 mg Skint-1 pulsed refold a peak of 5 mAu is observed which is unfeasible for downstream 
structural studies. 
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correctly refolded protein was inadequate for downstream structural studies. One possibility 
for enhancing recovery yields consisted of scaling up the refold mixture and pulsing with 
increased concentrations of inclusion bodies. However, given that the levels of protein 
required for structural and binding studies are relatively high, this approach was deemed to be 
impractical, expensive and time-consuming.  
 
5.3 Recombinant Production of Skint-1 IgV domain 
 
5.3.1 Cloning, expression and inclusion body preparation 
Given that the Skint-1 ectodomain was intransigent to refolding and therefore an unsuitable 
candidate for structural analyses, a new approach was employed which consisted of producing 
a single immunoglobulin variable (IgV) domain of Skint-1. Notably, a previous member of 
the Willcox group having encountered similar renaturation problems with the LILRB4 
ectodomain (Domains 1 and 2), successfully refolded LILRB4 IgV-like domain in amounts 
sufficient for crystallisation trials (PhD Thesis, L.I. Garner, 2011). To generate the Skint-1 
IgV construct, a stop codon (TAA) was introduced at the C-terminal end of the IgV domain 
(residue 119T) in the pET23a expression construct. The domain boundary for the Skint-1 IgV 
domain was determined using a combination of secondary structure predictions and structural 
homologues. Following verification of the Skint-1 IgV sequence by DNA sequencing, small-
scale test expressions (in 5 ml cultures) were performed and analysed by SDS-PAGE. This 
revealed an over-expressed protein band at ~13.5 kDa in the induced sample relative to the 
un-induced cells (Figure 5.4a), consistent with the expression of the Skint-1 IgV domain. The 
single IgV domain was subsequently expressed as inclusion bodies on a large scale (in 2L 
cultures), with estimated yields of 136 mg/L based on the Bradford assay. Analysis of the 
Skint-1 IgV inclusion body preparations by SDS-PAGE demonstrated high quality protein for 
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Figure 5.4 SDS–PAGE analysis of Skint-1 IgV domain test expression and inclusion body 
preparation in BL21 E. coli cells. a) Test expression analysis reveals Skint-1 IgV over-
expression in post-induction sample (Lane 3) relative to pre-induced sample (Lane 2). b) 
Skint-1 IgV inclusion body material solubilised in 8M urea (IB). Molecular weight standards 
are shown in the first lane, masses indicated in kDa. 
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renaturation studies (Figure 5.4b). In addition, analysis of purified inclusion bodies using the 
SALDI-TOF mass spectrometer revealed a 13.5 kDa peak, consistent with the sequence 
derived molecular weight of the Skint-1 IgV domain (Figure 5.5). 
 
5.3.2 Renaturation and purification of Skint-1 IgV 
The Skint-1 IgV inclusion bodies were refolded using the oxidative in vitro dilution method 
(Willcox et al., 1999). Confirmation of correctly refolded protein was assessed by size 
exclusion chromatography and SDS-PAGE. The size exclusion elution profile revealed a 
large peak (245 mAu) eluting at 235 ml in 20 mM Tris pH 8 and 50 mM NaCl (Figure 5.6), 
consistent with Skint-1 IgV existing as a monomeric form in solution. Importantly, the refold 
yield for the IgV domain was considerably improved relative to the IgV-IgC ectodomain (5 
mAu). Moreover, SDS-PAGE analysis of the Skint-1 IgV peak fraction revealed sufficient 
levels of purity for subsequent crystallisation trials (Figure 5.7). 
 
5.4 Structural studies of Skint-1 IgV domain using X-ray Crystallography 
5.4.1 Crystallisation trials of Skint-1 IgV  
Purified Skint-1 IgV was concentrated down to 5-15 mg/ml and subjected to crystallisation 
trials using the hanging drop vapour diffusion method with the Mosquito nanolitre 
crystallisation robot. Initial crystallisation trials were carried out using the commercial sparse 
matrix kits with the hanging drop vapour diffusion method. Using this approach two potential 
nanocrystal hits were observed in drops equilibrated against the PACT screen condition 1-14 
(0.1M MIB buffer pH5, 25% w/v PEG 1500) and 1-41 (0.1M MMT buffer pH8, 25% w/v 
PEG 1500) (Figure 5.8 a-b). However, these hits were exceedingly difficult to reproduce and 
subsequent optimisation trials involving adjustments in the pH and variations in the protein 
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Figure 5.5 Mass spectrometry analysis of Skint-1 IgV inclusion bodies. Sample was analysed 
by SALDI TOF mass spectrometer. Top and bottom spectrograms correspond to replicate 
samples of Skint-1 IgV with the size of the protein demonstrated to be ~13.5 kDa. 
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Figure 5.6 Elution profile for Skint-1 IgV following purification by size exclusion 
chromatography using the Superdex 200 column. Skint-1 IgV domain elutes at 235 ml 
consistent with existing as a monomer in solution (14kDa). From a 30 mg pulsed refold a 
peak of 245 mAu is observed which was sufficient for downstream structural studies.   
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Figure 5.7 SDS-PAGE analysis of refolded Skint-1 IgV domain. Skint-1 IgV was renatured 
and purified by size exclusion chromatography using the Superdex 200 column. Molecular 
weight standards are shown in the first lane, masses indicated in kDa. Lanes 2, 3 and 4 show 
inclusion body (IB), reduced and non-reduced samples of Skint-1 IgV, respectively.  
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Figure 5.8 Micro-crystals of Skint-1 IgV grown using the hanging drop vapour diffusion 
method. a) The drop was set up by mixing Skint-1 IgV (10mg/ml in 50mM NaCl/20mM Tris 
pH8) with an equal volume of reservoir buffer (PACT screen condition number 1-14, 0.1M 
MIB pH5,25% w/v PEG 1500). b) The drop was set up by mixing Skint-1 IgV (10mg/ml in 
buffer) with an equal volume of reservoir solution (PACT screen condition number P1-41, 
0.1M MMT pH8, 25% w/v PEG 1500). In each case the crystals (black arrow) appeared after 
7 days at room temperature. 
 
b) 
a) 
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and precipitant concentration led to no further improvement in crystal size or morphology. As 
a result, the Skint-1 IgV protein was subjected to additional crystallisation screening trials. 
Based on these extended trials, preliminary crystallisation hits were identified in 2M 
ammonium sulphate and 0.1M Tris pH 8 (Figure 5.9a). Strikingly, these trials when repeated 
in the absence of protein revealed no crystals thereby considerably reducing the possibility 
that these crystals were derived from salt. However, this particular crystallisation condition 
proved to be equally challenging for generating diffraction-grade Skint-1 IgV crystals. Hence, 
further optimisation trials were performed with the detergent screen to improve the size and 
morphology of the crystals. The most favourable results were gained from the addition of 
BigCHAPS (1.4mM) to the existing condition (2M ammonium sulphate and 0.1M Tris pH 8) 
at room temperature and 4°C (Figure 5.9b). Although, this condition significantly improved 
the size of these crystals, their morphology was unsuitable for X-ray diffraction experiments. 
Hence, further optimisation trials with the additive screen were carried out to improve the 
morphology of the Skint-1 IgV crystals. Using this approach, PEG 400 was identified as a 
highly promising additive that promoted formation of large diamond shaped crystals (Figure 
5.10a). The final optimised condition for reproducibly generating Skint-1 IgV crystals for 
crystallographic analysis consisted of 2M ammonium sulphate, 0.1M Tris pH 8, 1.4 mM 
BigCHAPS and 5% PEG 400. These crystals were grown manually on a large scale (2µl + 2μl 
drops), favouring growth at 4°C and appearance of crystals after 1-2 weeks (Figure 5.10b). 
 
5.4.2 X-ray diffraction studies of Skint-1 IgV  
Single Skint-1 IgV crystals were soaked in mother liquor supplemented with increasing 
concentrations of either ethylene glycol (5-23%) or glycerol (5-20%) and flash cooled in 
liquid nitrogen. X-ray diffraction studies were carried out using an ‘in house’ rotating anode 
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Figure 5.9 Generation and optimisation of Skint-1 IgV crystals. a) Micro-crystals of Skint-1 
IgV were identified using the ProPlex Screen. The drop was set up by mixing Skint-1 IgV 
(10mg/ml in 50mM NaCl/20mM Tris pH8 buffer) with an equal volume of reservoir solution 
(condition number 76, 2M NH2SO4/0.1M Tris pH8). b) Optimisation of Skint-1 IgV crystals 
were carried out using the Detergent screen. The best crystals were grown by incorporating 
1.4mM BigCHAPS to the existing crystallisation condition (2M NH2SO4/0.1M Tris pH8). 
The crystals (black arrow) were grown using the hanging drop vapour diffusion method and 
appeared after 7 days at room temperature and 4°C. 
a) 
b) 
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Figure 5.10 Generation of diffraction-grade Skint-1 IgV crystals. a) Optimisation of Skint-1 
IgV crystals were carried out using the additive screen. Diamond shaped crystals of Skint-1 
IgV were grown by incorporating 5% PEG 400 to the existing crystallisation condition (2M 
NH2SO4, 0.1M Tris pH8 and 1.4 mM BigCHAPS). The drop was set up by mixing 300 nl of 
Skint-1 IgV (10mg/ml in 50mM NaCl/20mM Tris pH8 buffer) with an equal volume of 
crystallisation solution. b) Large-scale Skint-1 IgV crystals were grown in 2µl + 2µl drops 
using crystallisation conditions described in the left panel. The crystals were grown using the 
hanging drop vapour diffusion method and appeared after 5 days at room temperature and 
4°C. 
a) 
b) 
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Rigaku X-ray generator and a Saturn CCD detector. All X-ray diffraction experiments were 
performed at 100K. An initial Skint-1 IgV crystal pre-soaked in 23% ethylene glycol for 1 
hour diffracted X-rays to 4.5Å resolution (data not shown). However, crystals soaked in 20% 
glycerol for longer intervals (up to 30-40 minutes) diffracted to a higher resolution (Figure 
5.11).  
 
The best Skint-1 IgV crystal diffracted to a resolution of 4Å and crystallised in the 
trigonal/hexagonal space group with unit cell parameters a=73.8=b=73.8Å, c=140.7 Å, 
α=β=90°, γ=120°. The data collection strategy was calculated using the CrystalClear software. 
A total of 720 images each covering an oscillation angle of 0.5°, were collected with an 
exposure time of 15s per frame and a crystal to detector distance of 100 mm. Intensity data 
from the Skint-1 IgV crystal were scaled and merged using programs of the XDS suite. The 
relevant data processing statistics for Skint-1 IgV are listed in Table 5.1. 
Resolution Limits 20-4Å 
Unit Cell Dimensions a=b=73.8 Å c=140.7Å α=β=90° γ=120° 
Space Group P622 
Total Observations 43923 (2874) 
Unique Observations 2038 (127) 
Multiplicity 21.5 (22.6) 
Completeness (%) 98.4 (97.7) 
Rmerge (%) 9.5 (76.8) 
I/σI 31.1 (6.1) 
Redundancy 21.6 (22.6) 
Table 5.1. Data processing statistics for Skint-1 IgV. X-ray data were processed using 
programs of the XDS suite. Numbers in parentheses correspond to statistics in the highest 
resolution shell. The data processing statistics were acceptable for subsequent structural 
determination analysis.  
In order to overcome space group ambiguity (trigonal/hexagonal), the data were processed in 
the lower symmetry trigonal space group, P3, and input into POINTLESS (Winn et al, 2011). 
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Figure 5.11 A 0.5° oscillation image of Skint-1 IgV crystal collected at 100K with a Saturn 
CCD detector using a rotating anode Rigaku X-ray generator. The crystal was soaked in 
mother liquor supplemented with 23% glycerol. The crystal diffracted X-rays to a resolution 
of 4Å and crystallises in the hexagonal space group P622.  
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The output from POINTLESS indicated that the best possible space group solution was P622. 
However, unequivocal space group determination could only be made following a correct 
translation function solution during molecular replacement. 
 
5.4.3 Determination of phase information with Molecular Replacement 
Assuming the Skint-1 IgV crystals have two molecules per asymmetric unit, a solvent content 
of 40% was calculated (Kantardjieff KA and Rupp B, 2003). Following the submission of the 
Skint-1 IgV sequence to BLAST, a putative structural homologue, murine myelin 
oligodendrocyte (MOG) (PDB code 1PY9), was identified. The homologue shared 47% 
sequence identity to Skint-1 IgV, and unsurprisingly, the overall fold of MOG conformed to 
the classical IgV type fold. However, no significant rotation function solutions were found 
using MOG as the phasing model. The lack of success in determining phase information with 
molecular replacement may have been due to the low quality of the X-ray diffraction data or 
that the phasing model possessed regions that were structurally different to Skint-1. It was 
theoretically possible to calculate phase information by alternative methods such as MAD or 
MIR. However, both techniques were deemed unfeasible due to poorly diffracting Skint-1 
IgV crystals. Based on these considerations, it prompted the idea of determining the solution 
structure of Skint-1 IgV using nuclear magnetic resonance (NMR). 
 
5.5 Structural studies of Skint-1 IgV domain using NMR 
5.5.1 Production of Labelled Skint-1 IgV for NMR analysis 
The X-ray diffraction studies of Skint-1 IgV crystals yielded low resolution data that 
prevented structure determination using the molecular replacement technique. Hence, to 
elucidate the detailed structural features of Skint-1 IgV domain, attempts were made to 
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determine the solution structure of this protein with NMR. Experiments and analysis were 
performed in collaboration with Dr Timothy J Knowles (University of Birmingham). To 
assess the potential of utilising the E. coli derived Skint-1 IgV material for NMR analysis, the 
sample was initially buffer exchanged into 0.1M MES pH 6.5 to reduce amide exchange 
effects that occur at higher pH levels, and was subjected to one dimensional (1D) 1H-NMR 
spectroscopy. Buffer exchange was required as the higher exchange rate with solvent at basic 
pH leads to a significant loss of signal. Analysis of the resulting 1D 1H-NMR spectrum 
(Figure 5.12) demonstrated that the Skint-1 protein was folded and provided a good signal-to-
noise ratio. This was demonstrated by good dispersion of peaks, especially in the methyl 
region with peaks clearly observed down to -1ppm as well as in the amide and aromatic 
region with signal dispersed from 6–10 ppm. Based on these considerations, the Skint-1 IgV 
domain represented a highly promising candidate for structural determination by NMR 
spectroscopy.  
 
In order to conduct further analysis, isotope labelling of Skint-1 IgV was required. Briefly, 
single labelled (
15
N) Skint-1 IgV was grown in M9 media, renatured by dilution refolding and 
purified by size exclusion chromatography as described in Chapter 2. Based on the size 
exclusion elution profile, 
15
N Skint-1 IgV eluted as a monomer at approximately 240 ml 
similar to the unlabelled protein (Figure 5.13a). Similar results were obtained for the double 
labelled 
13
C/
15
N Skint-1 IgV protein (Figure 5.13b). Notably, the recovery yield for the 
labelled proteins was as efficient as the unlabelled sample. SDS-PAGE analysis of the 
labelled recombinant proteins demonstrated that the sample was homogeneous and thus ideal 
for NMR analysis (Figure 5.14a-b).  
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Figure 5.12 One dimensional 
1
H spectrum profile of Skint-1 IgV. The Spectrum profile 
indicates that Skint-1 IgV domain data (50mM NaCl/20mM MES pH6.5) is amenable to 
NMR analysis. Chemical shift peaks are observed down to -1ppm in the proton scale (x axis), 
that are sharp and dispersed peaks and clearly visible in the CH3 region, down to 9.5ppm. 
 
 
 
H2O region 
α region CH3 region 
CH2 region 
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Figure 5.13 a) Elution profile for 
15
N labelled Skint-1 IgV following purification by size 
exclusion chromatography using the Superdex 200 column. Single labelled Skint-1 IgV elutes 
at 235 ml consistent with existing as a monomer in solution (~14kDa). From a 60 mg pulsed 
refold a peak of 173 mAu is observed. b) Elution profile for 
15
N/
13
C labelled Skint-1 IgV 
following purification by size exclusion chromatography using the Superdex 200 column. 
Double labelled Skint-1 IgV elutes at 235 ml consistent with existing as a monomer in 
solution (~14kDa). From a 60 mg pulsed refold a peak of 815 mAu is observed.   
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Figure 5.14 SDS-PAGE analysis of refolded and size exclusion purified labelled Skint-1 IgV. 
a) 
15
N labelled protein. b) 
15
N/
13
C labelled protein in 50mM NaCl and 20mM MES pH 6.5 
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5.5.2 HSQC analysis 
The heteronuclear single quantum coherence (HSQC) experiment provides a heteronuclear 
two dimensional spectrum by detecting a correlation between protons and attached hetero 
nuclear atoms either 
13
C/
15
N. For the purpose of this thesis only the 
1
H 
15
N HSQC was 
utilised. This experiment highlights the one bond correlation between protons and directly 
attached nitrogen’s, which in a protein are the amides present in the backbone and amines 
present in the side chains of Asparagine and Glutamine predominantly. The proton dimension 
is described in the x-axis and the nitrogen dimension is highlighted in the y-axis (Figure 5.15) 
 
15
N Skint-1 IgV was analysed at a concentration of 19 mg/ml in 20 mM MES pH 6.5 and 50 
mM NaCl. The HSQC spectrum for 
15
N Skint-1 IgV domain demonstrated that the protein 
was stable and gave an ideal, well dispersed spectrum showing the protein was folded (Figure 
5.15). The HSQC data set shows 93 clearly defined amide peaks out of a potential 114 
resonances which could be observed (excluding 5 unobservable proline residues), suggesting 
81% of the protein could be clearly resolved. Hence, the Skint-1 IgV domain was an ideal 
candidate for assignment and structure calculation using NMR spectroscopy. 
 
5.5.3 Backbone assignments 
To interpret the data recovered from NMR experiments, it is important to assign the 
resonances. In proteins, the most expedient method is to assign the backbone. This can be 
achieved by linking the atoms to their sequential neighbours, correlating via the amides and in 
essence walking along the protein backbone. The individual experiments listed allowed this 
walk along the protein. Backbone assignments were derived from BEST versions of 
1
H-
15
N-
HSQC, HNCACB, HN(CO)CACB, HNCA, HN(CO)CA, HNCO and HN(CA)CO 
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Figure 5.15 Two dimensional HSQC spectrum of 
15
N labelled Skint-1 IgV. The Spectrum was 
recorded at 303 K on a Varian Inova 600 MHz NMR spectrometer equipped with triple 
resonance cryogenic probe and z-axis pulse field gradients. Skint-1 IgV was at 19mg/ml 
(50mM NaCl/20mM MES pH6.5). This spectrum profile indicates the protein is folded and 
has dispersion of signals from 5 to 9 ppm, with little signal overlap of each peak which 
represents an amide in the protein backbone. Peaks joined by lines correspond to amine side 
chain peaks of Asparagine and Glutamine.   
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experiments (Muhandiram DR 1994) (Figure 5.16). The description of the HNCA experiment 
correlates the proton and nitrogen of the backbone amide of residue i with its carbon α 
resonance and that for i-1 for a particular residue (Figure 5.16). This provided both intra-
residue and inter-residue data and therefore enabled a walk along the backbone of Skint-1 
IgV. The HN(CO)CA experiment is similar to the HNCA experiment but this correlates only 
the HN and N resonances for residue i and that of the Cα residue of i-1 (Figure 5.17), so 
distinguishing between the two resonances observed in the carbon dimension of the HNCA 
(Figure 5.17). By matching the i-1 Cα resonance associated with one HN, with the i Cα 
resonance associated with another HN, it was possible to identify the subsequent amino acid 
in the backbone chain and thus move along it. The remaining experiments were undertaken to 
overcome the difficulty of overlapping Cα signals in more complex larger proteins by 
utilising Cβ and CO inter-residue links as well, the HNCACB and HN(CO)CACB 
experiments provide the Cβ chemical shift, whilst the HNCO and HN(CA)CO provides the 
carbonyl.(Figure 5.17) 
 
The 
1
H 
15
N HSQC of the Skint-1 IgV domain is shown in Figure 5.18. In collaboration with 
Dr. Timothy J Knowles, backbone assignments were completed for all non proline 
1
H, 
13
C 
and 
15
N backbone resonances except for the amides of M1, H37, G57, S66, and those in the 
regions 44 to 52 and 69 to 71, presumably due to the dynamic nature of these residues (Table 
5.2).  
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Figure 5.16 NMR experiments that were utilised to assign the backbone structure of Skint-1 
IgV. Highlighted by blue boxes are the pairs of experiments that facilitated the construction of 
the backbone residues, atoms in red indicate those residues for which chemical shift data was 
recorded. Shown by the HNCA experiment in black boxes are the intra (i) and inter (i-1) 
residue signals that allow for pairing of residue assignments. The arrows represent the 
direction of magnetic transfer. 
 
 
CC
O R
C
OH
N
N
H
C
R
C
O
N
H
HNCA
ii-1
CC
O R
C
OH
N
N
H
C
R
C
O
N
H
HN(CO)CA
CC
O CR3
C
OH
N
N
H
C
CR3
C
O
N
H
HNCACB
CC
O C
C
OH
N
N
H
C
R
C
O
N
H
HH
R
H
CBCA(CO)NH
CC
O R
C
OH
N
N
H
C
R
C
O
N
H
HNCO
CC
O R
C
OH
N
N
H
C
R
C
O
N
H
HN(CO)CA
 
 
    
 191 
                          
 
 
Figure 5.17 Strip plots from residues 104 to 107 highlighting the proton and carbon planes 
taken from the HNCA and HN(CO)CA. Shown in dashed lines are resonances associated with 
each residue and highlight the interaction between residue i and i-1. The amide proton 
chemical shift is displayed in the x axis and the Cα chemical shift is in the y axis. The 
nitrogen chemical shifts are taken from variable z axis's as displayed at the upper section of 
the strip plots. The dotted lines represent the inter-chain walk through of the protein backbone 
assignments. 
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Figure 5.18 
1
H 
15
N-HSQC spectrum of Skint-1 IgV. A standard 
1
H 
15
N-HSQC displaying all 
assigned backbone amide residues for Skint 1 IgV. Spectrum recorded on a varian Inova 800 
MHz spectrometer and processed using NMRPipe (Delaglio F 1995) and analysed using 
SPARKY (Goddard TD 2004).  
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Residue 
Number 
Residue 
type 
Chemical Shift (ppm) 
HN N Co Cα Cβ 
1 Met - - 177.2 - - 
2 Ser 8.322 121.6 174.9 58.57 63.72 
3 Ser 8.412 117.9 174 58.37 63.73 
4 Glu 8.319 122.9 174.5 54.36 29.77 
5 Pro - - 175.9 64.04 32.27 
6 Phe 6.322 113.7 174.1 55.35 41.34 
7 Iso 8.579 113.3 174.4 60.17 41.42 
8 Val 8.711 121.9 174.5 61.63 33.52 
9 Asn 8.944 125.4 174.2 50.92 41.92 
10 Gly 7.379 104.4 172.3 46.17 - 
11 Leu 8.418 120.6 178.8 55.12 42.15 
12 Glu 9.011 124.9 178.2 58.02 30.18 
13 Gly 8.479 108 178.1 44.27 - 
14 Pro - - 176.2 61.8 34.09 
15 Val 9.38 128.2 174.3 62.65 33.06 
16 Leu 8.451 128.2 177 53.91 42.11 
17 Ala 8.542 125.6 175.3 50.58 22.71 
18 Ser 8.387 116.1 174.2 57.17 64.89 
19 Leu 8.518 124.7 178.5 57.01 42.16 
20 Gly 9.215 115.7 174.7 45.41 - 
21 Gly 8.304 109.8 171.4 44.02 - 
22 Asn 8.39 115.6 174.8 51.32 40.07 
23 Leu 8.91 124.2 174.2 53.56 46.6 
24 Glu 8.16 123.9 174.8 54.68 32.01 
25 Leu 8.724 122.9 174.9 53.1 46.9 
26 Ser 7.881 114.3 173.7 57.26 65.94 
27 Cys 8.751 120 172.4 55.15 50.61 
28 Gln 8.917 117.6 174 53.65 31.93 
29 Leu 8.012 122.2 177.8 54.63 44.54 
30 Ser 8.525 115 173.2 54.86 64.72 
31 Pro - - - 64.11 31.71 
32 Pro - - 176.2 64.32 32.2 
33 Gln 6.8 115.4 172.2 54.16 31.79 
34 Gln 8.276 117.7 177.2 57.42 30.29 
35 Ala 7.934 123.9 178.4 51.04 21.1 
36 Gln 9.65 120 177.6 59.44 27.83 
37 His - - 175.5 56.58 30.2 
38 Met 7.48 121.6 174.4 57.4 32.61 
39 Glu 8.535 120.2 175.3 54.91 31.96 
40 Iso 9.391 127.7 174.8 60.13 40.69 
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41 Arg 9.164 129.4 173.8 54.26 36.04 
42 Trp 8.94 124.4 176.9 54.57 31.81 
43 Phe 8.839 118.2 171.8 56.63 41.32 
53 Leu - - 171.3 54.98 45.97 
54 Tyr 9.179 131.2 173.5 55.81 42.26 
55 Arg 8.637 125.9 174.7 56.09 33.58 
56 Asp 8.73 125.8 175.9 55.26 40.03 
57 Gly - - 174.1 45.29 - 
58 Lys 7.337 119.8 174.4 54.57 35.94 
59 Asp 8.469 121.9 176.1 54.85 42.13 
60 Met 8.658 125.1 176.7 52.36 29.62 
61 Phe 7.621 119.7 177.8 61 39.29 
62 Gly 8.961 106.5 174.7 46.25 - 
63 Glu 7.647 117.4 175.6 55.8 31.09 
64 Iso 6.984 118.7 176.2 61.2 38.75 
65 Iso 7.777 120.6 178.2 62.39 38.35 
66 Ser - - 176.5 62.16 62.95 
67 Lys 7.938 118.8 176.3 58.25 33.16 
68 Tyr 8.174 115.5 176.3 60.04 40.77 
70 Glu - - 176.9 57.88 - 
71 Arg 7.991 116 174.3 56.34 32.98 
72 Thr 7.85 108.5 174.6 59.5 72.56 
73 Glu 8.631 119.7 172.6 55.55 34.32 
74 Leu 8.905 126.7 175.7 52.62 43.72 
75 Leu 9.586 130.6 179.7 55.6 40.64 
76 Lys 9.067 122.9 177.7 56.85 33.26 
77 Asp 8.705 122.1 177.1 57.53 40.22 
78 Gly 9.095 107.1 177.2 45.51 - 
79 Iso 7.81 125 177.5 66.3 39.62 
80 Gly 9.09 113.2 174.1 46.05 - 
81 Glu 7.74 116.6 177.4 55.2 30.98 
82 Gly 7.897 111.3 172.1 47.11 - 
83 Lys 7.713 120.9 176.7 55.07 35.52 
84 Val 8.656 114.6 173.8 59.93 36.27 
85 Thr 7.156 117.2 171.6 61.25 72.1 
86 Leu 9.298 130.5 173.5 53.17 43.2 
87 Arg 8.902 127.3 174.3 54.03 33.23 
88 Iso 8.637 123.2 175.4 59.79 40.45 
89 Phe 8.586 125 176.1 56.82 41.1 
90 Asn 8.23 118.3 174.7 53.57 36.73 
91 Val 8.647 114.6 177.3 62.95 32.98 
92 Thr 9.448 116.1 175.6 59.75 72.72 
93 Val 8.355 116 177 65.09 31.61 
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94 Asp 7.724 118.3 176.1 55.35 41.08 
95 Asp 7.88 116.6 176.2 55.01 41.51 
96 Asp 7.641 121.3 175.7 55.04 42.31 
97 Gly 8.448 107.8 172.8 45.17 - 
98 Ser 8.484 116.4 174.4 58.11 63.23 
99 Tyr 9.226 124.3 175.9 58.28 41.05 
100 His 9.476 123.3 173.6 53.43 29.12 
101 Cys 8.681 118.3 172 53.24 40.92 
102 Val 9.113 124 175 60.73 35.13 
103 Phe 8.662 126.4 173.9 56.52 41.27 
104 Lys 9.44 123.3 175 54.85 37.5 
105 Asp 9.49 129.5 176.2 52.47 43 
106 Gly 8.825 115.4 174.6 47.23 - 
107 Asp 8.886 126.1 175.7 54.96 41.32 
108 Phe 7.914 121.8 173.3 58.24 41.43 
109 Tyr 7.147 123 172.6 55.85 41.44 
110 Glu 8.52 121.1 174.4 55.54 36.5 
111 Glu 9.241 116.7 174.7 54.31 36.29 
112 His 8.18 117.6 172.1 55.28 31.55 
113 Iso 7.912 128.6 174.3 60.79 39.78 
114 Thr 8.804 122.9 173.1 61.99 71.75 
115 Glu 8.703 128.4 175.1 56.47 30.98 
116 Val 9.196 126.1 175.9 61.3 35.2 
117 Lys 9.009 129.5 174 54.44 35.56 
118 Iso 9.167 126.6 176.5 58.98 37.62 
119 Thr 8.491 125.9 178.7 62.76 71.37 
121 Val - - 175.8 63.44 32.07 
 
Table 5.2 Chemical shift assignments for Skint-1 IgV. Chemical shifts were recorded from 
the HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH, HNCO and HN(CA)CO experiments with 
15
N/
13
C labelled Skint-1 IgV protein. 
 
5.5.4 Assignment of Skint-1 IgV side chains 
The majority of the side chain resonances of the Skint-1 IgV protein were identified by the 
analysis of the HCCH-TOCSY, (H)CCH-TOCSY, HCCONH, CCONH and 
13
C-edited 
aromatic NOESY spectrum. The HCCONH and CCONH experiments provided a lower 
resolution map of resonance assignments in the side chain correlated to the backbone amide 
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(Figure 5.19). This provided a key starting point for the assignment of the more complex but 
high resolution TOCSY experiments which allowed the assignment of the aliphatic side 
chains (Figure 5.20). The NOESY spectrum provided through space interactions within 5Å 
and was predominantly used for confirming assignment locations and aromatic side chains 
allowing correlation back to the side chain aliphatic residues in close proximity to the 
aromatic moiety.  
 
In total 84.9% of H
α
, H
β
, H
γ
, H
δ
 and H
ε
, 89.9% of C
α
, 80.7% of C
β
, 73.5% of C
γ
, 85.7% of C
δ
, 
and 100% of C
ε 
aliphatic resonances were assigned. The 
1
H and 
15
N resonances for the NH2 
side chains for 3 out of 4 Asparagine and 4 Glutamine were assigned completely. No 
assignments were made for the labile guanidine moiety of Arginine, the side chain NH3
+
 of 
Lysine, and the side chain carboxyl groups of Aspartate and Glutamate (see Appendix II). 
 
5.5.5 Secondary structure predictions 
The secondary structure of the Skint-1 IgV domain was predicted using the chemical shift 
difference method between measured values and random-coil values of C
α
, C
β
 and (ΔCα - 
ΔCβ) based on the TALOS (Cornilescu et al, 1999) and CSI (Wishart and Sykes, 1994) 
protocols. The comparisons between folded and random coil chemical shifts show that Cα 
resonances tend to shift upfield in β-sheets and extended stands, but tend to shift downfield in 
α-helices. The reverse is true for the Cβ resonances. As the Cα and Cβ secondary shifts are of 
similar magnitude and opposite sign for both helices and shifts, subtraction of the Cα and Cβ 
secondary shifts (ΔCα - ΔCβ) enhances the correlation between the secondary structural 
elements and the secondary shifts. The ΔCα - ΔCβ and TALOS plots represent an empirical 
prediction of a protein’s phi and psi backbone torsion angles using HN, HA, CA, CB, CO and 
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Figure 5.19 HCCONH and CCONH strip plots at a 
15
N chemical shift of 127.0 ppm showing 
the side chain assignments for residue Leucine 86. The Spectra were recorded at 303 K on a 
Varian Inova 800 MHz NMR spectrometer equipped with triple resonance cryogenic probe 
and z-axis pulse field gradients 
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Figure 5.20 CD1-MD1 TOCSY and NOESY interactions for I65 displayed in two strip plots. Protons up to 
the Hγ can be identified and intra residue NOE’s and inter residue NOE’s are visible and allow for the 
sequential assignment and structure determination of the protein. The red arrows in the HCCH-TOCSY 
show the through bond direction of magnetism. The green arrows in the NOESY-HSQC show the through 
space direction of magnetism displaying the possible inter-residue assignments to within a distance of 5Å. 
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N chemical shift assignments for a given residue (Figure 5.21). The CSI program for 
determining secondary structure in proteins from the chemical shift indices of 
1
H and 
13
C 
nuclei plot indicated the presence of 3 α-helices and 8 β-strands of at least 3 amino acids in 
length (Figure 5.21); the α-helices were estimated to encompass residues I64 to Y68, D77 to 
E81 and T92 to G97 whilst the β-strands span residues V7 to G9, V15 to A17, G21 to Q28, 
E39 to F43 and L53 to R55, T72 to L75, K83 to F89, S98 to D105 and F108 to I118. The 
assignments and secondary structure prediction of the Skint-1 IgV domain provided the basis 
for the characterisation of its three dimensional structure and interaction with other cellular 
molecules. 
 
5.5.6 Hydrogen deuterium (H-D) exchange 
The Hydrogen deuterium (H-D) exchange method provides data regarding hydrogen bonding 
and the solvent accessibility of different parts of the protein, and thus provides key restraints 
for structure determination. The principle is based on measuring the rate of exchange of a 
protonated protein with that of a deuterated solvent. For example, an amide which contributes 
to an intramolecular hydrogen bond will exchange very slowly, whereas an amide located on 
the surface of protein will exchange more rapidly. In addition, amides buried from the solvent 
but not mediating hydrogen bonding interactions may also exhibit slower exchange rates. 
Therefore, when a protein is transferred from a protonated to a deuterated solvent, only 
signals from residues protected from the solvent, remain. 
Since the nuclei of hydrogen and deuterium exhibit significantly different magnetic properties 
it is possible to discriminate between them using NMR spectroscopy. Generally, HSQC 
spectra are measured at a number of time intervals during which the H-D exchange is taking 
place. As the HSQC experiment is specific for hydrogen, the signal decays exponentially as 
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Figure 5.21 Summary of secondary structural predictions of Skint 1 IgV. (ΔCα - ΔCβ) 
highlights the enhanced correlation between the secondary structural elements and the 
secondary shifts, CSI and TALOS results plotted. In the consensus CSI, the values ‘1’ 
represents the β-strand tendency, while ‘-1’ represents α -helical tendency, the lack of α 
helices maybe due to their size being only 3
10
 helices and undetectable by CSI. Backbone 
dihedral angles (phi, psi) were calculated using TALOS. Phi (/) and psi (w) angles are shown 
in black and red, respectively. Predicted secondary structure elements are indicated using 
rectangles for β-strands and arrows for α-helices 
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the hydrogen exchanges. This experiment provides amino acid-specific data for all the 
residues in the protein simultaneously. To establish which Skint-1 IgV residues were buried 
or participating in hydrogen bonding interactions, HSQC experiments were carried out with 
samples before and one hour after incubation with deuterium oxide (Figure 5.22). The 
resulting HSQC spectrum demonstrated that ~63% of the residues in the protein exchanged 
hydrogen for the deuterated solvent. This indicates that the remaining 37% (42 residues) are 
protected from exchange and hence are either completely buried or most likely involved in 
hydrogen bonding (Table 5.3). 
Residue 
number 
Amino 
acid 
 Residue 
number 
Amino 
acid 
17 Ala 85 Thr 
23 Leu 86 Leu 
25 Leu 87 Arg 
27 Cys 88 Ile 
29 Leu 89 Phe 
38 Met 90 Asn 
39 Glu 96 Asp 
40 Ile 99 Tyr 
41 Arg 100 His 
43 Phe 101 Cys 
54 Tyr 102 Val 
55 Arg 103 Phe 
73 Glu 104 Lys 
75 Leu 105 Asp 
79 Ile 110 Glu 
81 Glu 112 His 
82 Gly 114 Thr 
83 Lys 116 Val 
84 Val 117 Lys 
 
Table 5.3 Hydrogen-deuterium (H-D) exchanged residues. Highlighted are the amides 
involved in hydrogen deuterium exchange. These residues were protected from the hydrogen 
deuterium exchange process therefore indicating that they are either involved in hydrogen 
bonding or buried in the core of the protein. 
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Figure 5.22 Skint-1 IgV H/D exchange analysis. 
15
N Skint-1 IgV in 20mM MES pH 6.5, 
50mM NaCl in 100% H2O buffer (Black) and following 1 hour incubation in 100% D2O 
buffer (Red). Those resonances remaining after 1 hour are labelled. 
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5.5.7 Structure calculation 
 
The 3D structure of Skint-1 IgV domain was determined using the CANDID/CYANA 
package with automated NOE cross peak assignment and structure calculation with torsion-
angle dynamics implemented (Güntert, 2004). Three NOE spectra were used to provide 
restraints, the 
15
N-edited NOESY-HSQC, the 
13
C-NOESY-HSQC and the 
13
C-aromatic-
NOESY-HSQC, together with dihedral angles calculated using TALOS. The protocol 
consisted of seven iterative cycles of NOE assignment and structure calculation. The first 
cycle started from 100 random conformers with 10000 torsion angle dynamic steps performed 
per conformer in each cycle and the results inputted into the next cycle. 20 conformers with 
the lowest CYANA target function were selected as representative. Using the initial structure 
as a template together with the H/D exchange data, hydrogen bonds were mapped and the 
structure was further refined.  
 
A total of 894 NOEs, 38 hydrogen bonds and 182 dihedral angle restraints were used in the 
final calculation. Structures were analysed using PROCHECK-NMR. The RMSD of the 20 
lowest energy structures was calculated using MOLMOL. The quality parameters of the 
Skint-1 IgV structure ensemble are listed in Table 5.4. Despite a significant number of peaks 
lacking from the 
1
H-
15
N-HSQC spectrum, almost complete resonance assignment of the side 
chain signals was attained. Hence the structure determination of Skint-1 IgV was successful 
and produced a high quality structure. All distance restraint violations fall under 0.2Å. On 
average also the dihedral angle violations are small: in 20 substructures only two violations 
exceed 10°. Both backbone and heavy atom RMSD values of the structure family are very 
low and coordinate precision is uniform throughout the structure. There are 1.3% residues in 
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the disallowed regions of the Ramachandran plot. The 20 structures for the Skint-1 IgV 
molecule were visualised utilizing PyMol (Figure 5.23) 
 
 
Number of restraints  
NOE  
  Total 894 
  Intraresidue (i=j) 117 
  Sequential (|i-j|)=1 194 
Medium range (1 < |i-j|≤4) 140 
Long range (|i-j| > 4) 443 
Hydrogen bond restraints 38 
Dihedral-angle restraints 182 
RMSD from distance restraints (Å) 0.018 ± 0.002 
RMSD from covalent geometry  
  Bond lengths (Å) 0.004 ± 0.000 
  Angles (°) 0.509 ± 0.019 
  Impropers (°) 1.517 ± 0.123 
Ramachandran plot (%)  
  Most favoured regions    80.5 
  Additionally allowed regions 16.5 
  Generously allowed regions 1.6 
  Disallowed regions 1.3 
RMSD (Å)  
  Backbone (residues 8-118) 1.42 
  Backbone (Absent undefined regions 8-14 & 44-71) 0.83 
  Heavy atoms (residues 8-118) 2.28 
  Heavy atoms (Absent undefined regions 8-14 & 44-71) 1.58 
 
Table 5.4 Structural statistics for Skint-1 IgV (20 structures). The statistics for the Skint-1 
IgV ensemble were calculated using PROCHECK-NMR. 
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Figure 5.23 Solution structure of mouse Skint-1 IgV domain highlighting the 20 lowest 
energy states derived from NMR spectroscopic analysis. The lowest energy state is depicted 
in green (cartoon form).  
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5.6 Discussion 
The structure determination of the Skint-1 ectodomain could provide a greater molecular 
understanding of its role in selection of the DETC subset, and also potentially antigen 
recognition by DETC resident in the skin. Unfortunately, the prokaryotic derived Skint-1 
ectodomain inclusion body material proved intransigent to refolding, despite extensive 
attempts with conventional oxidative in vitro refolding strategies. This is particularly 
surprising given that there are a considerable number of studies highlighting the use of similar 
strategies to refold proteins encompassing two tandem Ig domains in sufficient levels for 
structural studies (Willcox et al, 2002; Nicholls et al, 2009 and Simpson et al 2011). There 
are several possible explanations for why the Skint-1 IgV-IgC construct proved resistant to 
refolding. Firstly, the constituents of the refolding mixture are most likely sub-optimal for 
efficient renaturation of the Skint-1 IgV-IgC domains. It is possible that the refolding 
efficiency of the Skint-1 ectodomain could be enhanced by varying constituents of the 
refolding buffer. This could involve pulsing with smaller quantities of inclusion body protein, 
sampling different denaturant buffers and varying the ratio of oxidised and reduced 
glutathione. Secondly, SDS-PAGE analysis of the Skint-1 IgV-IgC inclusion bodies 
demonstrated a high level of background proteins which may have interfered with the 
refolding process. Indeed, previous experiments have also demonstrated that impurities within 
the inclusion body material have detrimental effects on protein renaturation and to 
successfully overcome intransigent refolding additional purification of the inclusion bodies 
were required (Ouellette et al, 2003). A similar strategy could be employed for the Skint-1 
IgV-IgC inclusion bodies to improve purity and enhance the efficiency of the renaturation 
process. However, one of the major problems associated with this approach is that the 
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recovery yield of the inclusion body material following additional purification steps is often 
extremely poor (~ < 10%) for subsequent refolding.  
 
Finally, the domain boundaries selected for the Skint-1 ectodomain construct may have 
inadvertently affected the renaturation step. As mentioned previously, the secondary structure 
predictions of the Skint-1 molecule revealed three distinct domains; a membrane distal IgV 
domain followed by an IgC-like domain which then leads to a transmembrane spanning 
domain. The Skint-1 ectodomain construct used for structural studies encompassed the two 
tandem Ig domains but lacked the transmembrane spanning region. It was envisaged that by 
removing the transmembrane sequence it may promote Skint-1 crystallisation. However, it is 
possible that the transmembrane region is important for stabilising the IgC-like domain, and 
in its absence it led to inefficient refolding or yielded over-expressed protein that was very 
unstable. Indeed, previous secondary structure predictions have revealed that elements of the 
transmembrane region protrude outwards on the extracellular side. It is possible that some of 
these protruded regions may play a key role in stabilising the IgC domain. Hence, future 
Skint-1 constructs should factor into account the inclusion of the transmembrane spanning 
region. Alternatively, the IgV-IgC construct may be too long such that the residues at the C-
terminal end prevent efficient refolding of the Skint-1 ectodomain. Future cloning strategies 
could involve utilising truncated versions of the IgV-IgC construct, whereby residues at the 
C-terminal end are systematically removed. 
 
Since the Skint-1 IgV-IgC construct was intransigent to oxidative refolding, an alternative 
strategy involved shortening the construct in order to refold each domain independently. It 
was envisaged that of the two domains the Skint-1 IgV domain was most likely to play a 
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functionally significant role in selecting the DETC cells and hence was chosen for further 
characterisation. As demonstrated with LILRB4 (PhD Thesis, L.I. Garner, 2011), the single 
Skint-1 IgV domain construct was successfully refolded in sufficient quantities for structural 
characterisation. 
 
Initial attempts at determining the three dimensional structure of Skint-1 IgV domain involved 
using X-ray crystallography. Following extensive crystallisation screening and optimisation 
process, suitably sized Skint-1 IgV crystals were grown. These crystals were reproducibly 
generated allowing multiple attempts to determine the optimum cryoprotectant conditions 
prior to X-ray data collection. Although the final optimised Skint-1 IgV crystals were of 
reasonable size, they diffracted X-rays to 4Å resolution with the ‘in house’ rotating anode 
generator. The data processing statistics calculated for the Skint-1 IgV crystal were deemed 
acceptable and did not highlight major causes for concern. Nevertheless, attempts at solving 
the Skint-1 IgV structure with molecular replacement using MOG as the search model proved 
to be unsuccessful despite the relatively high sequence homology between the two proteins. It 
was possible, but unlikely, that higher resolution data obtained from a synchrotron radiation 
source may enhance the likelihood of determining the crystal structure of Skint-1 IgV. Since 
molecular replacement failed to provide meaningful phase information it was theoretically 
possible to experimentally calculate phases using MAD or MIR. However, as both approaches 
were time-consuming and given that the native crystals diffracted to a low resolution, a new 
strategy was employed in which the Skint-1 IgV was subjected to NMR analysis. Indeed, 
previous studies have demonstrated that proteins encompassing Ig domain architecture were 
amenable to structural characterisation by NMR spectroscopy (Gallagher et al, 1994).  
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Preliminary assessment of the Skint-1 IgV domain suggested that the protein exhibited the 
necessary properties for structure determination using NMR spectroscopy. In particular, the 
highly concentrated Skint-1 protein was relatively stable for long periods of time at room 
temperature. Initial analysis revealed that although 80% of the backbone assignments could be 
assigned the remaining could not due to lack of chemical shift resonances. This had 
significant ramifications in terms of resolving the overall Skint-1 structure as the backbone 
experiments were expected to provide information regarding the overall basic fold of the 
molecule. To supplement these data, further experiments involving 
15
N-edited HCCH-
TOCSY, (H)CCH-TOCSY, HCCONH, CCONH were performed to allow side chain 
assignments to be resolved, thereby decreasing the level of unassigned residues to 
approximately 15%. Despite these efforts, there still remained a significant proportion of 
residues that were unassigned most likely due to these residues conforming to a less stable 
and dynamic structure. In future to overcome the lack of resonances in this region the residues 
could be mutated, thus stabilising this region, therefore allowing chemical shift data to be 
recorded. However given the large proportion of unassigned residues, this approach could be 
problematic as it may affect functionally important regions of the Skint-1 IgV domain. 
Alternatively, stabilising compounds such as trimethylamine n-oxide (TMAO), a naturally 
occurring osmolyte that stabilizes proteins, could be utilised to enhance the rigidity and 
facilitate the stabilisation of the dynamic region. It is possible that these highly flexible 
regions prevented tight packing within the Skint-1 IgV crystal lattice, which contributed to the 
Skint-1 IgV crystals providing relatively low resolution X-ray data.  
 
Since the structure of the Skint-1 IgV domain has successfully been determined with NMR, it 
opens up the possibility of using a similar strategy to resolve the structure of the IgC-like 
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domain. This would then allow for a model of the IgV-IgC structure to be constructed and 
may provide a more comprehensive understanding of Skint-1 ligand binding sites and/or 
partners. The analysis of the Skint-1 IgV structure is presented in significant detail in Chapter 
6. 
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Chapter 6: Solution structure analysis of the Skint-1 IgV domain 
 
 
6.1 Overall Structure of Skint-1 IgV 
NMR derived structure calculations produced 20 solution models for the structure of the 
mouse Skint-1 Immunoglobulin variable (IgV) domain (Figure 6.1). The final structural 
ensemble is well-defined, yielding a mean backbone root-mean-square deviation (RMSD) of 
0.83 Å for the structured regions. Structural analysis reveals the Skint-1 IgV domain adopts 
an immunoglobulin (Ig) fold, consisting of nine β stands, with three 310 α helices that are 
positioned between the C’-D, D-E and E-F strands (see Table 6.1). 
Residue 
number 
Secondary 
structure 
Residue 
number 
Secondary 
structure 
S1 to I6 Random coil V69 - R71 Random coil 
V7 to G9 β Strand A T72 to L75 β Strand D 
L10 to P14 Random coil K76 Random coil 
V15 to A17 β Strand A' D77 to E81 310 helix 2 
S18 to G20 Random coil G82 Random coil 
G21 to Q28 β Strand B K83 to F89 β Strand E 
L29 to M38 Random coil N90 - V91 Random coil 
E39 to R44 β Strand C T92 to G97 310 helix 3 
N45 to H52 Random coil S98 to D105 β Strand F 
L53 to R55 β Strand C' G106 - D107 Random coil 
D56 to F63 Random coil F108 to I118 β Strand G 
I64 to Y68 3
10
 helix 1 T119 Random coil 
Table 6.1. Secondary structure assignments for the Skint-1 IgV domain derived from the 
solution structure 
Consistent with its homology to Ig variable-type domains, the Skint-1 IgV structure adopts a 
compact beta sandwich domain comprising two anti-parallel sheets (one consisting of strands 
A, A’, B, D, E, the second C, C’, F, G), with the N and C termini at opposite ends of the 
molecule (Figure 6.2). A large hydrophobic core, formed by in-pointing hydrophobic residues 
from the B (L23, L25 and L29) and E (V84 and L86) strands in sheet 1 and residues from the 
C (I40, W42 and F43) and F (Y99 and F103) strands in sheet 2, contributes to stabilising the 
interior of the IgV domain (Figure 6.3). The Skint-1 IgV domain is further stabilised by an 
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Figure 6.1 20 NMR structure solutions of the membrane-distal Skint-1 IgV domain with each 
state displayed in a simple ribbon (in purple). The lowest energy state is highlighted as a 
cartoon (in green) and was used in the subsequent structural analysis. 
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Figure 6.2  Ribbon representation of the lowest energy NMR structure of Skint1 IgV. The 
strands highlighted in red represent the core region of a typical IgV-type fold. Helices are 
shown in yellow. The β-strands are labelled according to the IgV-type fold described by Bork 
et al, 1994. 
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Figure 6.3 Stabilisation of the Skint-1 IgV core. The beta sheets are stabilised by a inter-chain 
disulphide bond (mediated by C27 & C101; shown in pink), an invariant tryptophan residue 
(W42; depicted in blue) and multiple non-polar interactions mediated by hydrophobic 
residues (shown as black sticks) from the core B, E, F and C strands (highlighted in red).  
Helices are shown in yellow. 
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intra-chain disulphide bond formed between strands B and F (mediated by residues C27 and 
C101) (Figure 6.3). This prominent feature, which connects the beta sheets, is similar to other 
IgV-like domain containing proteins and is a structural hallmark of Ig-folds (Lesk & Chothia, 
1982). Also, there are 74 residues found between the conserved disulphide bond in Skint-1 
IgV, which is reminiscent of previously reported variable and variable-related domain 
structures (65-75 residues) (Williams and Barclay, 1988). As reported with other Ig domains, 
the internal core region of the Skint-1 IgV domain is additionally stabilised by an invariant 
tryptophan residue (W42) packing against the disulphide bond (Figure 6.3).  
 
The hydrogen-deuterium exchange analysis demonstrates that although the A to A’ strand 
region is structurally defined via NOE restraints, it is weakly associated with the structure, as 
no protection of exchangeable amides was noted. In addition, the A, A’, C and C’ β-sheet 
regions show reduced conformational rigidity resulting from a lack of NOE restraints, most 
likely due to dynamics present within these regions, consistent with previous observations of 
IgV-domain structures (Kabsch and Sander, 1983). 
 
6.2 Comparisons of Skint-1 with structural homologues 
Automated structural comparisons using the DALI software revealed that the Skint-1 IgV 
structure is closely related to other IgV domains, in particular murine myelin oligodendrocyte 
(MOG) (PDB code 1PY9) and human Programmed Death-1 Ligand 1 (PD-L1) (PDB code 
3FN3), with Z scores (corresponding to strength of structural similarity) of 13.8 and 12.7, 
respectively. 
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MOG is a type I transmembrane myelin protein of unknown function which is highly 
conserved between mouse and human, and is expressed in the Central Nervous System 
myelin. An autoantigen linked to pathogenesis of multiple sclerosis (MS) and experimental 
autoimmune encephalomyelitis (EAE), MOG is a minor component of the myelin sheath. In 
animal models, immunisation with MOG or MOG-specific T cells or even autoantibodies 
against MOG can lead to the development of neurological disease that mimics MS disease 
(Clements et al, 2003). Furthermore, MOG is commonly used to induce a demeylinating 
antibody response in mice with EAE as a model for MS (Breithaupt et al, 2008; Clements et 
al, 2003). 
 
PD-L1 is a type I transmembrane protein that plays a major role in suppressing the immune 
system. The receptor for PDL-1 has been identified as Programmed Death 1 (PD-1) which is 
expressed on activated T cells and is a member of the CD28/CTLA-4 family. The formation 
of the PD-1/PD-L1 ligand complex is responsible for delivering an inhibitory signal which 
down-regulates T cell function, and maintains central and peripheral tolerance (Keir et al, 
2008; Chen et al, 2010). 
 
The primary amino acid sequences of murine Skint-1, murine MOG and human PD-L1 IgV 
domains were aligned with ClustalW2 (Figure 6.4). The alignments between murine Skint-1 
and MOG demonstrated moderate levels of sequence conservation (sequence identity of 47% 
and overall sequence homology of 73%). In contrast, comparison of sequences between 
murine Skint-1 and human PD-L1 highlighted considerably less sequence conservation with a 
sequence identity of 24% (sequence homology of 45%). Notably, despite displaying modest 
to low levels of sequence conservation, both structural homologues adopt an IgV-type fold 
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Figure 6.4 Multiple sequence alignment of the IgV domains of murine Skint-1, murine MOG 
and human PD-L1. Sequences of IgV domains were downloaded from the Uniprot database 
and aligned with ClustalW2. *Indicates residues that fully conserved, represents conservation 
between groups of strongly similar properties and indicates conservation between groups of 
weakly similar properties. Amino acids shaded in colour based on their chemical properties; 
red (small and hydrophobic), blue (acidic), magenta (basic) and green (hydroxyl, sulphydryl 
and amine). 
 219 
 (Clements et al, 2003 and Chen et al, 2010) and the structure of each can be superimposed 
onto Skint-1 IgV, resulting in an RMSD of 2Å (over 103 Cα aligned atoms) for MOG and 
2.75Å for PD-L1 (over 92 Cα aligned atoms) (Figures 6.5-6.6). Furthermore, the majority of 
the internal facing non-polar residues that stabilize the Skint-1 Ig-V core are highly conserved 
in MOG and PD-L1.  
 
6.3 Structural comparison of Skint-1 with MOG and PD-L1  
Comparisons of the Skint-1 IgV domain with MOG demonstrates moderate levels of 
structural similarity as reflected by the RMSD value of 2Å (Figure 6.5). Unsurprisingly, 
regions that are most structurally compatible between MOG and Skint-1, particularly the 
strands that contribute to stabilising the IgV core, correlate with high levels of amino acid 
sequence identity (Figure 6.4). The majority of the strands, especially the A and B strands, are 
comparable in length between Skint-1 and MOG. Moreover, there are three additional 
segments that are highly conserved, both in terms of sequence and secondary structure, 
namely the C-C’ loop (which adopts a random coil) and strands D and E (Figure 6.5). 
 
Despite these similarities there are several topological differences observed between the 
Skint-1 and MOG IgV domains (Figure 6.5). With the exception of the loops connecting the 
strands, the most distinct structural features are restricted to two areas. Firstly, both the C and 
C’ strands of MOG (E36-S42 and V48-Y51, respectively) are longer relative to Skint-1 (E39-
R44 and L53-R55, respectively) (Figure 6.5). As a result, the interconnecting C-C’ loop is 
considerably larger in Skint-1 relative to MOG and this may adversely affect the potential of 
Skint-1 to dimerise (more details below). Secondly, there are structural differences following 
the C’ region, which in MOG includes a short β strand termed C’’ (N55-D56), and two 310 
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Figure 6.5 Comparison of the lowest energy NMR structure of Skint-1 IgV with mouse 
myelin oligodendrocyte glycoprotein (MOG). The IgV domain of MOG (teal; PDB ID 1PY9, 
Clements et al, 2003) was superimposed onto Skint-1 (green) using align with a RMSD of 2Å 
(over 103 Cα aligned atoms). Secondary structural elements that differ between Skint-1 and 
MOG are labelled in red. 
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Figure 6.6 Comparison of the lowest energy NMR structure of Skint-1 IgV with human PD-
L1. The IgV domain of PD-L1 (red; PDB ID 3FN3; Chen et al, 2010) was superimposed onto 
Skint-1 (green) using align with a RMSD of 2.75Å (over 92 Cα aligned atoms). Secondary 
structural elements that differ between Skint-1 and PD-L1 are labelled in black. 
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helical sections. In contrast, in Skint-1, the corresponding region lacks the C’’ strand, and 
retains only one 3
10
 helix which may contribute to the increased flexibility observed relative 
to MOG. The lack of the C’’ strand in Skint-1 is particularly surprising given the fact that, in 
this region, the primary amino acid sequence is relatively conserved with MOG (Figure 6.4). 
 
Indeed, a paucity of NOE restraints for residues R44 to H52 of Skint-1 IgV provides further 
evidence for additional flexibility in this area. Moreover, temperature factor analysis of MOG 
highlights that the region following the C’’ strand including the tandem 310 helices are 
uniformly rigid. In addition, this region in MOG does not participate in any crystal contacts, 
suggesting that it is genuinely inflexible. One possible explanation for these differing 
observations may be attributed to the fact that the MOG structure represents a lower energy 
state relative to Skint-1, as MOG was resolved from a crystal at 100K by X-ray 
Crystallography, whereas the structure of Skint-1 IgV was determined in solution at 293K 
using NMR.  
 
Despite the low amino acid sequence identity between PD-L1 and Skint-1 (24%), the 
structures of these domains possess remarkably similar conformations, particularly in the IgV 
core strands (Figure 6.6). Regardless of these structural similarities, there are several 
distinctive features that separate Skint-1 from PD-L1. Notably the PD-L1 IgV-like molecule 
contains 5 α helical regions, three of which are conserved in the Skint-1 domain; the 
additional α helical segments are located between the B-C (L50-A52) and C’’-D (E72-A85) 
strands (Chen et al, 2010 and Figure 6.6). The equivalent regions in Skint-1 encompass 
random loop conformations and demonstrate considerable flexibility. Further topological 
differences include a shorter strand A in the PD-L1 structure relative to Skint-1. Moreover, 
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the A’ (L27-E31) and C’ (K62-F67) strands in PD-L1 are longer than the corresponding 
regions of Skint-1 (V15-A17 and L53-R55, respectively). However, strands B and D in PD-
L1 (M36-K41, D85-L87) were found to be shorter relative to the equivalent regions of Skint-
1 (G21-Q28, R71-L75) (Figure 6.6). 
 
It is possible that these structural differences observed between Skint-1 and PD-L1 correlate 
with their unique biological function. However, this appears not to be the case based on 
detailed examination of the PD-1/PD-L1 complex structure. Indeed, the majority of PD-L1 
regions that are critical for binding to and stabilising the PD-1 interface include the A, C, F 
and G strands (Lin et al, 2008). Strikingly, the majority of PD-L1 residues that mediate 
contacts to PD-1 are non-conserved in the corresponding regions of Skint-1, thereby 
providing a molecular basis for the non redundant roles of PD-L1 and Skint-1 despite 
adopting similar IgV folds. 
 
6.3.1 Skint-1 shows radical alterations in the dimer interface region of MOG and PD-
L1 
Interestingly both structural homologues of Skint-1, MOG and PD-L1, exist as a dimeric 
species based on extensive biochemical and structural evidence (Clements et al, 2003 and 
Chen et al, 2010). Indeed, native MOG has previously been documented to exist as a mixture 
of monomeric and dimeric species (Clements et al, 2003). SDS-PAGE and Western blot 
analysis of myelin-derived proteins using a MOG-specific antibody resulted in detection of 
both monomeric and dimeric MOG protein (Clements et al, 2003). In addition, cross linking 
experiments with increasing concentrations of primary amine-coupling agent 3,3’-
dithiobis[sulfosuccinimidylpropionate] (DTSSP), resulted in the detection of a MOG species 
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with a relative molecular mass equivalent to a dimer. Also, MOG adopted a head-to-tail dimer 
in the crystal lattice despite the size exclusion elution profile of renatured MOG 
demonstrating a predominantly monomeric species (Clements et al, 2003). This dimer 
interface is extensive, burying 1,800 Å
2
 of surface area. Furthermore, the dimer interface 
exhibits a shape complementarity index of 0.7, consistent with a value that has been 
previously reported for antibody–antigen interactions (Clements et al, 2003). Taken together, 
this suggests that the crystallographic MOG dimer may represent a physiologically relevant 
MOG dimer (Clements et al, 2003). 
 
Similarly to MOG, the PD-L1 structure also highlighted a dimer in the crystal lattice, with 
cross linking analysis performed on in vitro refolded protein confirming dimer formation 
(Chen et al, 2010). In contrast, the Skint-1 IgV domain behaves as a monomer in solution, as 
assessed by size exclusion chromatography, which highlighted an elution volume comparable 
to other known IgV-like monomeric proteins, such as β2-microglobulin (See Chapter 5 Figure 
5.6). Furthermore, the solution structure of Skint-1 IgV determined by NMR revealed a stable 
monomeric protein.  
 
Detailed structural analysis of MOG and PD-L1 has enabled identification of key residues that 
contribute to stabilising the dimer interface. For MOG, the dimer interface runs along the long 
axis of the protein, involving the A-A’ loop, the C-C’ loop and the F-G β hairpin (Figure 
6.7a). More specifically, the MOG dimer interface is stabilised predominantly by van der 
Waal’s and hydrogen bonding interactions mediated by G9, P11, S45, T97, Q106, E107, 
E108, A109, A110 and E112. Notably, whereas P11, E107, E108 and E112 of MOG are 
identical in Skint-1 IgV (P14, E110, E111, E115), the majority of the remaining amino acids 
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Figure 6.7 a) Interactions at the MOG dimer interface. Secondary structural elements that 
highlighted in pink are involved in stabilising the dimer interface (Clements et al, 2003). 
Monomers that form the dimer are labelled A and B, respectively. b) Putative Skint-1 dimer 
interface generated using the MOG dimer as a template. The longer C-C’ loop in Skint-1 
(depicted in blue) prevents dimer formation presumably due to major steric clashes with the 
opposing monomer.    
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contributing to the dimer interface are semi-conservatively altered (S45, T97, Q106 and A110 
in MOG is replaced with T48, H100, Y109 and I113 in Skint-1). Moreover, in MOG, G9 
stabilises the dimer interface by mediating a hydrogen bonding interaction with E107 of the 
opposing monomer via its backbone carbonyl group. In contrast, in Skint-1 a non-
conservative substitution to E12 is unlikely to interfere with dimer formation as the backbone 
carbonyl group is predicted to interact with E110. Consequently, there is no obvious reason 
for why Skint-1 fails to adopt the mode of dimerisation observed for MOG. 
 
To examine this further, a potential model of the Skint-1 dimer was generated based on using 
the MOG dimer as a template. In MOG, the C-C’ loop of each monomer contributes 
significantly to stabilizing the dimer interface. However, modelling of the Skint-1 IgV dimer 
demonstrates that the C-C’ loop, which is considerably greater in length compared to MOG, is 
orientated at a perpendicular angle that protrudes out of the β sheet, resulting in major steric 
clashes with the corresponding C-C’ loop of the opposing Skint-1 monomer (Figure 6.7b). As 
a result, it is predicted that due to steric hindrance, the mode of dimerisation observed for 
MOG is structurally incompatible with Skint-1 IgV.  
 
Similarly to MOG, the dimer interface of the PD-L1 IgV domains is stabilised predominantly 
by multiple hydrogen-bonding interactions (Figure 6.8a), albeit with a significantly reduced 
buried surface area (PD-L1=859Å
2
; MOG=1800Å
2
). The regions that contribute to stabilising 
the PD-L1 dimer interface include strand A (T22), strand B (E39 and K41), B-C loop (V44) 
and α helix 4 (Q91). Superimposition of the Skint-1 IgV domain onto the PD-L1 dimer has 
enabled the generation of a putative Skint-1 dimer model (Figure 6.8b). Interestingly, the 
majority of residues highlighted to be important for contributing to stabilising the PD-L1 
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Figure 6.8 a) PD-L1 dimer with a close-up view of the interactions that contribute to 
stabilising the interface (Chen et al, 2010). Monomers A and B are coloured in burgandy and 
red, respectively. Contacting residues are shown in ball-and-stick format, and hydrogen bonds 
are represented by black dashed lines. b) Putative Skint-1 dimer interface generated using PD-
L1 dimer as template. The close-up view demonstrates clashes and loss of interactions at the 
proposed Skint-1 dimer interface. Monomers A and B are coloured cyan and green, 
respectively.  
 
K4
1 
V44 
Q91 T22 
E39 
K41 
Q9 
P31 
G78 
S26 
Q9 
N28 
 
 
a) 
b) 
A                    B 
A                    B 
 
 228 
dimer interface are non-conservatively substituted in Skint-1. Consequently, the molecular 
contacts present at the PD-L1 dimer interface are likely to be absent for Skint-1. For instance, 
whereas in PD-L1, E39 forms a salt bridge contact to K41 (on the corresponding monomer), 
non-conservative substitutions to S26 and Q28 would result in loss of this interaction (Figures 
6.8a/b). Similarly, whereas in PD-L1 the Q91 side chain hydrogen bonds with the hydroxyl 
moiety of T22 (opposing Skint-1 monomer), introduction of the G78 and N9 at the equivalent 
positions in Skint-1 would abolish this interaction (Figures 6.8a/b). Finally, whereas K41 of 
PD-L1 forms hydrogen bonding interactions with the backbone carbonyl of V44 (on the 
second PD-L1 monomer), in Skint-1 non-conservative substitutions to Q28 and P31 would 
result in a loss of this contact as well as introduce major steric clashes (Figures 6.8a/b). 
Collectively, these observations explain why the Skint-1 IgV domain is unlikely to conform to 
the dimerisation mode of PD-L1.  
 
6.4 Comparison of Electrostatics surface potential of Skint-1 with MOG 
To identify putative ligand binding sites for Skint-1, a molecular surface electrostatic potential 
map was calculated using DELPHI. Comparison of the molecular electrostatic potential 
surfaces for Skint-1 IgV and MOG revealed striking dissimilarities in the surface charges. In 
particular, crystallographic analysis of MOG revealed a striking electronegative strip that runs 
approximately half the length of the molecule, terminating at a small patch of electropositive 
charge (R4, R25 and K80) (Figure 6.9). This electronegative strip is dominated by residues 
from the N-terminal part of strand B (D18, E19 and E21) with minor contributions made from 
strands D (E74) and G (E116). Notably, this distinctive electrostatic pattern, which has been 
proposed as a putative ligand binding site for MOG (Clements et al, 2003), is not shared in 
the corresponding regions of Skint-1, owing to several non-conservative amino acid 
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Figure 6.9 Molecular surface representation of the MOG IgV domain. a) Electrostatic 
potential, highlighting the electronegative strip that terminates at the electropositive patch. b) 
Residues contributing to these features are labeled and shown in the same orientation as the 
left panel (Clements et al, 2003).  
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substitutions (Figure 6.10). Further analysis of the Skint-1 IgV molecular electrostatic surface 
revealed an electronegative strip broadly similar in length to that of MOG, however its 
location is quite different, positioned on the loop preceding the strand A as well as C, C’, G β 
strands (E4, E39, D59, E110 and E111), and oriented approximately perpendicular to the long 
axis of the G, F and C strands, relatively close to the membrane-distal region of the domain 
(Figure 6.11). In addition, Skint-1 IgV exhibits two small electrostatic patches that are absent 
in MOG. Firstly, an electropositive patch is located slightly above the electronegative strip, 
generated by R53 and K104 (Figure 6.11). Secondly, an electronegative patch is found in the 
membrane-distal region of the IgV domain that is generated by the presence of two aspartic 
residues (D105 and D107). Taken together, these observations suggest that MOG and Skint-1 
most likely recognize distinct ligands. 
 
6.4.1 Comparison of Solvent-Exposed Hydrophobic Patches of Skint-1 and MOG 
Generally, solvent-accessible hydrophobic surfaces are not energetically favourable and are 
therefore likely to represent potential protein–protein or protein-ligand binding sites. Indeed, 
there exists a high correlation between surface exposed hydrophobicity and protein-protein 
interactions. In this vein, MOG exhibits a number of solvent-exposed hydrophobic residues, 
including three aromatics: Y10, F44, and F90 (Figure 6.12). The equivalent residues in Skint-
1 are semi-conservatively substituted at two of these positions (Y47 and V93). In Skint-1, 
Y47 and V93 are located at the membrane-proximal region of the Skint-1 molecule and 
therefore ideally placed to mediate inter-domain interface stabilizing interactions with 
residues from the IgC domain. Other notable solvent-exposed non-polar side chains located in 
the membrane-proximal portion of Skint-1 include L19, Y68, V69, F89 and V93, and these 
may also function in stabilizing the IgV-IgC inter-domain interface. Indeed, since these 
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Figure 6.10 Molecular surface representation of the Skint-1 IgV domain. a) Electrostatic 
potential map highlighting the lack of electronegative strip and electropositive patches near 
strands B, D and G of MOG. b) Residues contributing to these features are labeled and shown 
in the same orientation as the top panel.  
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Figure 6.11 Molecular surface representation of the Skint-1 IgV domain.  a) Electrostatic 
potential, highlighting a novel electronegative strip running approximately perpendicular to 
strands C, F and G. b) Residues contributing to these features are labeled and shown in the 
same orientation as panel a.  
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Figure 6.12 a) Putative ligand binding site for MOG. Solvent-exposed aromatic side chains 
that may be involved in ligand binding are drawn in ball-and-stick format (Clements et al, 
2003). b) Solvent-exposed non-polar side chains in Skint-1. Residues located at the C-
terminal region are most likely involved in stabilising the IgV-IgC interdomain interface.  
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residues are highly conserved across the Skint gene family, they most likely represent a 
common structural and functional feature. Strikingly, there are several solvent-exposed 
aromatic side chains located in the membrane-distal end of Skint-1 IgV (Figure 6.12), which 
will be discussed in greater detail in the subsequent section.  
 
6.4.2 Characterisation of the CDR-like loops of Skint-1 with MOG 
Determination of the Skint-1 IgV structure has allowed detailed characterisation of potentially 
functionally significant regions of the Skint-1 molecule. In particular, the three loops at the 
membrane distal end of Skint-1 that connect the B-C (Q28-M38), C-D (D56-I64) and F-G 
(K104-Y109) strands have been termed CDR1/2/3 like loops, respectively (Figure 6.13). 
These CDR-like loops are in the equivalent positions to the Complementarity Determining 
Regions (CDRs 1, 2, and 3, respectively) of IgV domains present in T cell receptor or B cell 
receptor chains. Intriguingly, at the membrane-distal end of Skint-1, there is a small 
hydrophobic patch in and around CDR3 like loop, comprised of three solvent exposed 
aromatic rings (F6, Y108 and Y109) (Figure 6.13). It is possible that the recently identified 
functionally relevant F-G loop (personal communication with Professor Hayday laboratory) in 
combination with this trio of solvent-exposed hydrophobes form a potential protein-protein 
docking site. Interestingly, the equivalent region in MOG is largely conserved with F3, Y105 
and Q106, suggesting that this area may also be important for ligand docking (Figure 6.13).  
 
Comparison of the CDR-like loops between Skint-1 and MOG highlights several striking 
differences in their overall sequence, length and conformation. In MOG, the three loops 
combine to form a polar and essentially uncharged featureless molecular surface (Figure 
6.14). In contrast, in Skint-1 the membrane-distal loops collectively form an undulating and 
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Figure 6.13 Key features of the membrane-distal regions of Skint-1 and MOG. a) Skint-1 
loops that connect B-C (CDR1-like), C-D (CDR2-like) and F-G (CDR3-like) strands are 
coloured in red, blue and pink, respectively. Trio of solvent-exposed aromatic side chains are 
located in and around the CDR3-like loop. b) MOG loops that connect B-C (CDR1-like), C-D 
(CDR2-like) and F-G (CDR3-like) strands are highlighted in red, blue and pink, respectively 
(Clements et al, 2003). Note that two of the solvent exposed aromatic residues in Skint-1 are 
conserved in MOG, indicating a common putative protein binding site. 
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Figure 6.14 Key molecular features associated with MOG CDR-like loops. a) Residues from 
CDR-like loops that are found in highly prominent positions are highlighted in ball-and-stick 
format. The second residue in the CDR3-like loop is occupied by H103 which strains the 
conformation of the type II β-turn. MOG CDR-like loops are highlighted in red, blue and 
pink, respectively. b) Electrostatic potential map for membrane-distal region of MOG 
(orientation as in panel a). The three CDR-like loops combine to form essentially a flat and 
uncharged molecular surface (Clements et al, 2003). 
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charged molecular surface (Figure 6.15). The CDR1-like loop in Skint-1 
(28QLSPPQQAQHM38) is relatively similar in length to MOG (27SPGKNATGME36). 
However, whereas in MOG the B-C loop forms a flat and indistinctive surface, in the 
corresponding region of Skint-1 the side chains of Q33, Q34 and H37 protrude prominently to 
form an undulating polar surface (Figure 6.15). In addition, there are significant differences 
observed between the CDR2-like loop of Skint-1 (56DGKDMFGEI64) and MOG 
(51YRNG54). Firstly, the CDR-like loop in Skint-1 is considerably longer in length as it lacks 
the C’’ region found in the equivalent region of MOG. Secondly, whereas in MOG the loop is 
comprised of mainly non-polar and charged residues, in Skint-1 the loop displays amphipathic 
properties, containing both hydrophobic and hydrophilic residues. Finally, in Skint-1 the side 
chain moieties of D56 and K58 are highly solvent exposed thereby providing a charged 
molecular patch that is potentially available for ligand binding (Figure 6.15).  
 
In both homologues, the CDR3-like loop is located in a highly prominent position of the IgV 
domain, forming a hairpin loop that adopts a type II β-turn. However, there are several 
distinctive features evident in Skint-1 that are absent in MOG. In MOG, the second residue of 
the F-G loop is occupied by a non-canonical H103, whereas in Skint-1 a glycine is present, 
consistent with what is usually expected for a type II β-turn (Sibanda, B. L. & Thornton, J. 
M.1985). As a result, the dihedral angles of H103 are found in disallowed regions of the 
Ramachandran plot, allowing MOG to adopt a strained loop conformation. It is well 
documented that residues with strained conformations are often positioned at functionally 
important sites in proteins. This coupled with the fact that the side chains of H103 and 
neighbouring S104 protrude from the tip of CDR3-like loop, suggest that this region 
represents a putative ligand binding site for MOG (Figure 6.14). Indeed, the crystal structure 
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Figure 6.15 Key molecular features associated with Skint-1 CDR-like loops. a) Residues from 
CDR-like loops that are found in highly prominent positions are highlighted in ball-and-stick 
format. The second residue in the CDR3-like loop is occupied by canonical G106 which 
allows the type II β-turn to adopt a more flexible conformation relative to MOG. Skint-1 
CDR-like loops are highlighted in red, blue and pink, respectively. b) Electrostatic potential 
map for membrane-distal region of Skint-1 (orientation as in panel a). The three CDR-like 
loops combine to form a charged and undulating molecular surface. 
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of the extracellular domain of MOG in complex with the antigen-binding fragment (Fab) of 
the MOG-specific demyelinating monoclonal antibody, 8-18C5, has provided further insights 
into the molecular determinants of MOG ligand binding (Breithaupt et al, 2003). The 8-18C5 
antibody binds to the three CDR-like loops located at the upper membrane-distal end of MOG 
with a significant contribution mediated by the G strand and the preceding F-G loop 
(encompassing residues R101–E108), a region that is unique for MOG (Figure 6.16). In 
comparison, in Skint-1 the second residue in the type II β-turn is occupied by a canonical 
glycine, and as a result adopts an unstrained conformation relative to MOG. Furthermore, the 
CDR3-like loop encompasses several solvent exposed and highly prominent residues that are 
essentially polar and charged (K104, D107 and Y109) (Figure 6.15). Collectively, based on 
these structural differences in the CDR-like loop regions this may account for the functional 
differences between Skint-1 and MOG.  
 
6.5 Comparison of Skint-1 IgV with other Skint gene family members 
The IgV domains of the Skint family proteins can be divided into three subfamilies based on 
the degree of sequence identity to Skint-1 (Figure 6.17). Firstly, Skint family members 2-6 
share 74-81% sequence identity to Skint-1, with the highest levels of conservation found with 
Skint-3 closely followed by Skint-2. In contrast, the second subgroup consists of Skint-7 and 
8 which share moderate degrees of sequence conservation with the Skint-1 IgV domain at 43-
45% sequence identity. Finally, the subgroup that exhibits the lowest levels of sequence 
conservation to Skint-1 contains Skint-9 and Skint-10, with sequence identities ranging from 
19-20% (alignments not shown).  
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Figure 6.16 Overall structure of MOG in complex with MOG-specific demyelinating 
monoclonal antibody, 8-18C5 (left; Breithaupt et al, 2003). Close up view of the MOG-8-
18C5 Fab binding interface (right panel). Majority of the contacts to the Fab heavy chain are 
mediated by the CDR3-like loop of MOG. CDR-like loops of MOG are highlighted in red, 
blue and pink, respectively. 
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Figure 6.17 Multiple sequence alignment of the IgV domains of Skint gene family. Sequences 
of IgV domains were downloaded from the Uniprot database and aligned with ClustalW2. 
*Indicates residues that fully conserved,: represents conservation between groups of strongly 
similar properties and . Indicates conservation between groups of weakly similar properties. 
Amino acids shaded in colour based on their chemical properties; red (small and 
hydrophobic), blue (acidic), magenta (basic) and green (hydroxyl, sulphydryl and amine). 
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Detailed analyses of aligned sequences for the IgV domains of Skint-1-6 highlighted that 
many of the regions are highly conserved. In particular, the Hayday group raised a polyclonal 
antibody against one of these conserved regions, KYVERTELL, located between the first 3
10
 
helix and strand D (Figure 6.17). This polyclonal antibody has enabled functional assays to be 
performed in an effort to dissect the role of Skint-1 in mice DETC maturation. As expected, 
when mapping the highly conserved segments onto the Skint-1 structure they correspond to 
core secondary structural elements that contribute to formation and stabilisation of the 
classical IgV domain. Furthermore, the least conserved regions are restricted to the loops that 
interconnect the beta strands, particularly the CDR3-like loop, which has recently been 
identified as playing a pivotal role in the biological activity of Skint-1. The remainder of the 
structural analysis is limited to characterising the differences between Skint-1, Skint-2 and 
Skint-7, the only Skint family members to be expressed in mice. 
 
6.5.1 Comparison of Skint-1 Electrostatic molecular surface properties with Skint-2  
A model of Skint-2 was generated with PHYRE using the Skint-1 structure as a modelling 
template. As expected, the high level of sequence identity between Skint-1 and Skint-2 (80%) 
correlates with an extremely large degree of structural similarity between these mouse Skint 
gene family members. In total there are 20 amino acid substitutions found in Skint-2, the 
majority of which, when mapped onto the Skint-1 structure, are located on the surface (Figure 
6.18). Notably, nine of these alterations represent non-conservative amino acid substitutions. 
As a result, the high level of sequence diversity observed in solvent accessible positions 
presumably reflects the functional specificity of Skint-1. To assess this further, an 
electrostatic potential map for the Skint-2-PHYRE generated model was calculated with 
DELPHI. Comparison of the surface electrostatics between Skint-1 and Skint-2 show a 
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Figure 6.18 Model of Skint-2 IgV domain generated using Phyre.  Residues that differ from 
Skint-1 are highlighted in ball-and-stick format. The Skint-2 CDR-like loops are highlighted 
in red, blue and pink, respectively. 
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remarkably similar electronegative strip that runs perpendicular to the long axis of the G, F 
and C strands, relatively close to the membrane-distal region of the domain. There is a high 
degree of sequence identity for these negatively charged residues across the Skint family 
members 1-6, and to a lesser extent Skint-7, suggesting that the electronegative strip is not 
likely to be critically important in the non-redundant function of Skint-1. Strikingly, of the 
nine non-conservative amino acid alterations between Skint-1 and Skint-2, six lead to the 
insertion of a positively charged residue (K5, R13, R46, R48, K81 and K90) which results in 
Skint-2 exhibiting a higher number of electropositive surface patches (Figure 6.19). It is 
possible that these patches may represent a potential ligand binding site that is unique to 
mouse Skint-2, given that only two of these positively charged residues are conserved in 
Skint-7.  
 
6.5.2 Comparison of Electrostatic molecular surface between Skint-1 and Skint-7 
The Skint-1 IgV structure was used as a template to generate a first-order model for the most 
divergent Skint family member in mouse, Skint-7, using PHYRE. Despite the lower sequence 
identity observed between Skint-1 and Skint-7 (44%), the overall structure of Skint-1 is very 
homologous to the PHYRE generated Skint-7 model. Interestingly, similarly to Skint-2, the 
least conserved residues between Skint-7 and Skint-1 are located in the solvent exposed 
regions of the protein. The solvent exposed non-conservative amino acid substitutions in 
Skint-7 have resulted in marked differences in the electrostatic molecular surface when 
compared to Skint-1. Firstly, Skint-7 does not possess the extensive electronegative zone 
running perpendicular to the long axis of the G, F and C strands as found in Skint-1 and 
Skint-2, owing to several amino acid alterations (D59K and E111A) (Figure 6.20). Secondly, 
there are additional electropositive patches found in Skint-7, relative to Skint-1, due to the 
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Figure 6.19 Comparison of electrostatic molecular surfaces between the IgV domains of 
Skint-1 (a) and Skint-2 Phyre generated model (b). Solvent-exposed non-conservative residue 
substitutions leads to an increased number of electropositive patches in Skint-2 relative to 
Skint-1. The orientation for each structure is as shown in Figure 6.18.  
 
 
a) b) 
                     Skint-1                                              Skint-2 Model 
 246 
 
 
 
 
 
 
 
 
 
 
Figure 6.20 Comparison of electrostatic molecular surfaces between the IgV domains of 
Skint-1 (a) and Skint-7 Phyre generated model (b). The electronegative strip runs 
discontinuously in Skint-7 (bottom, left) relative to Skint-1 (top, left). The CDR-like loops in 
Skint-7 (bottom, right) combine to form a featureless and less charged surface relative to 
Skint-1 (top, right). These changes in the molecular surface may account for differences in 
ligand binding.   
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presence of R7, R13 and K56. Finally, the membrane-distal portion of the Ig domain in Skint-
7 is essentially uncharged and featureless compared to Skint-1 (Figure 6.20). Given these 
changes, coupled with the low sequence identity observed between Skint-7 and Skint-1, it 
provides a possible molecular explanation for the unique role of Skint-1 relative to Skint-7  
 
6.6 Characterization of the CDR-like loops of Skint-1 with Skint-2 and Skint-7  
As mentioned previously, the activity of Skint-1 is truly non-redundant as in RTOC 
experiments involving substitution with other Skint family members, Skint-2 (the closest 
family member to Skint-1 in mouse) and Skint-7 both failed to rescue DETC progenitor 
maturation. Moreover, although the Skint-1/Skint2 domain-swap chimeras (involving the IgV, 
IgC and TM regions) were equivalently expressed as protein, none recapitulated the activity 
of Skint-1 when expressed in FVB.Tac RTOC, suggesting that each discrete domain of Skint-
1 was essential for its physiological function (Barbee et al, 2011). More recently, to pinpoint 
which regions of Skint-1 are biologically important in the positive selection and development 
of DETC γδ, Skint-1/Skint-2 CDR3-like loop swap chimeras were generated and expressed in 
FVB.Tac RTOC. The Skint-1 chimeras incorporating CDR1 and CDR2-like loops of Skint-2 
had no diminishing affect on the DETC γδ maturation process. However, replacement of 
CDR3-like loop of Skint-1 (104KDGDFY109) with the equivalent region of Skint-2 
(KVGEFY) negated the positive selection of DETC γδ cells (unpublished data; Professor 
Adrian Hayday’s group). Comparison of the CDR3-like loop between Skint-1 and Skint-2 
identified single non-conservative (D105 in Skint-1 is replaced by V105 in Skint-2) and 
conservative (D107 in Skint-1 is replaced by E107 in Skint-2) substitutions that contribute to 
the unique biological activity of Skint-1. Notably, individual site directed mutants of D105 
and D107 with alanine substitutions prevented the development of DETC γδ cells, thereby 
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confirming the functional significance of each negatively charged moiety. Strikingly, the side 
chain of D107 is extremely prominently exposed on the membrane-distal end of Skint-1, and 
therefore may directly interact with an as yet unidentified ligand (Figure 6.21), a process that I 
hypothesise is essential for the positive selection of DETC γδ cells within the thymus. One 
possibility is that the selection and development of DETC γδ and subsequent thymic egress 
and homing to the epidermis may stem from a direct interaction between Skint-1 and the 
DETC Vγ5Vδ1 TCR. In Skint-2, the corresponding residue at this position is conservatively 
altered to glutamic acid (E107). Although this change preserves the charge relative to Skint-1, 
introduction of the longer side chain in Skint-2 may sterically clash with the molecule on the 
surface of DETC (Figure 6.22). Therefore, steric hindrance presumably perturbs binding to 
the unidentified ligand on DETCs rather than any discernible changes to the conformation of 
CDR3-like loop. Furthermore, in Skint-1 Ig, V105 is partially buried in a hydrophobic 
environment, forming van der Waals interactions with the aliphatic groups of P30, M38 (from 
CDR2-like loop) and F108 (CDR3-like loop) (Figure 6.21). Hence, it is possible that the 
introduction of a charged residue at position 105, in what is a predominantly a non-polar 
environment, affects the conformation of the CDR3-like loop such that it permits binding to 
the unidentified receptor on DETCs. In comparison, in the equivalent region of Skint-2, a 
non-conservative amino acid alteration (D/V105) could allow the valine side chain to mediate 
extensive hydrophobic interactions with nearby non-polar side chains of P30, M38 and F108 
(Figure 6.22). Consequently, the more favourable interactions mediated by the valine side 
chain in Skint-2 may induce the CDR3-like loop to adopt a contrasting conformation to Skint-
1, such that it precludes binding to the DETC receptor (Figure 6.22), a hypothesis that could 
be resolved by determining the three dimensional structure of Skint-2. In comparison, the 
CDR3-like loop in Skint-7 (104NGSGFI109) possesses two non-conservative modifications 
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Figure 6.21 Putative Skint-1 binding site for the DETC selecting ligand. Mutations to D105 
and D107 prevent the selection and development of DETC. D107 is extremely prominently 
located suggesting a direct interaction with DETC selecting ligand. D105 is found in an 
unusual hydrophobic environment (interacting with CDR2-like loop residues P32 and M38) 
which may allow the CDR3-like loop to adopt a strained conformation such that it permits 
binding to the DETC selecting ligand. Also, residue P5, unique among Skint gene family, 
may change the direction of main chain away from the putative binding site permitting ligand 
binding. Residues that are potentially important in ligand binding are drawn as ball-and-stick 
format. The CDR-like loops are highlighted in red, blue and pink, respectively.  
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Figure 6.22 Membrane-distal regions of Skint-2. Skint-1/Skint-2 CDR3-like loop swap 
chimeras prevent the selection and development of DETC. There are 3 possible mechanisms 
for Skint-2 failing to reconstitute DETC in FVB.Tac RTOC. Firstly, the longer E107 side 
chain may directly interfere Skint-2 ligand binding. Secondly, V105 mediates multiple 
hydrophobic interactions with CDR2-like loop residues (M32 and P38) which may affect the 
conformation of the CDR3-like loop, such that it prevents binding to the DETC receptor. 
Finally, K5 at the N-terminus may also interfere with ligand binding. Residues are represented 
as ball-and-stick format. CDR-like loops are highlighted in red, blue and pink, respectively.  
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at positions that are critically important for Skint-1 activity. In both instances, the negatively 
charged residues are replaced with glycine (D/G105 and D/G107) and as a result Skint-7 is 
likely to present a highly flexible and featureless CDR3-like loop which may perturb binding 
to the DETC selecting ligand (Figure 6.23). Finally, in Skint-2 and Skint-7, there is a 
positively charged residue (K5) that protrudes from the N-terminus and is located near the 
vicinity of the CDR3-like loop and the trio of solvent-exposed hydrophobes (distance of ~7Å) 
(Figures 6.22-23). It is postulated that this long and positively charged side-chain may also 
perturb ligand binding in Skint-2 and Skint-7. In contrast, in Skint-1 the corresponding region 
contains a Proline residue which is less prominent and unlikely to interfere with ligand 
binding. In addition, the Proline side chain reverses the direction of the Skint-1 main-chain 
away from the putative ligand binding site (Figure 6.21). Intriguingly, given that P5 is not 
conserved across the Skint gene family members (Figure 6.17), it provides additional 
circumstantial evidence in support of this residue being important for contributing to the non-
redundant role of Skint-1. Collectively, these structural observations provide three putative 
molecular mechanisms that may ultimately prove critical in the non-redundant role of Skint-1 
in facilitating the positive selection and development of DETC γδ cells.  
 
6.7 Identification of Skint-1 Ligand Binding Sites using de novo prediction servers 
Using the SPPIDER server attempts were made to predict putative Skint-1 IgV protein-
protein binding sites. The prediction of potential binding sites was based on integrating 
solvent accessibility predictions with high resolution Skint-1 IgV structural data. Intriguingly, 
the in silico based predictions highlighted several regions, predominantly at the membrane-
proximal end of the Skint-1 IgV module, as possible sites for protein-protein binding. 
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Figure 6.23 Membrane-distal regions of Skint-7.  Skint-1 residues implicated in DETC 
selecting ligand binding (D105 and E107) are altered in Skint-7 (G105 and G107). It is 
envisaged that such changes provide a featureless and more flexible CDR3-like loop 
conformation relative to Skint-1 and prevents ligand binding. Also, K5 at the N-terminus may 
also interfere with ligand binding. Membrane distal residues are represented as ball-and-stick 
format. CDR-like loops are highlighted in red, blue and pink, respectively. 
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However, the location of these putative ligand binding residues suggests that the software 
program has predicted residues that may contribute to stabilising the inter-domain IgV-IgC 
interface (Figure 6.24). Interestingly, Barbee et al highlighted the initial ten amino acids of 
the IgC domain from Skint-1 as playing a role in selecting DETCs, and these results may add 
credence to the SPPIDER predicted residues mapped onto the IgV domain. Further attempts 
with prediction servers ODA and PINUP failed to identify any novel protein-ligand 
interaction sites, highlighting the difficulties associated with the prediction of protein-protein 
docking sites. 
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Figure 6.24 Putative ligand binding sites for Skint-1 IgV calculated by SPIDDER. The 
regions highlighted in red represent potential residues implicated in protein-protein 
interactions. The majority of residues found in the membrane-proximal region most likely 
represent regions involved in stabilising the Skint-1 IgV-IgC interface. 
 
 
 
N 
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6.8 Discussion 
The molecular interactions regulating the selection and maturation of the DETC subset, which 
expresses the Vγ5Vδ1 TCR, are poorly defined. However, substantial evidence now suggests 
that DETC development is linked to a molecule expressed by thymic stroma, identified as 
Skint-1 (Lewis et al, 2006). Here, the solution structure of the Skint-1 IgV domain has been 
determined allowing detailed analysis with the ultimate aim of establishing an in-depth 
molecular understanding of the non-redundant role of Skint-1 in the positive selection of 
DETCs. 
 
Initial structural determination studies of the Skint-1 IgV domain using X-ray crystallography 
proved to be unsuccessful due to a combination of issues. Firstly, Skint-1 IgV crystals 
diffracted X-rays poorly, despite exhibiting excellent morphology and size. A second problem 
associated with resolving the crystal structure of Skint-1 is the lack of molecular replacement 
derived phase information. This was unexpected given that the phasing model consisted of 
MOG, which, similar to Skint-1 secondary structure predictions, adopts an Ig fold and shares 
significant levels of sequence similarity to Skint-1. The NMR-derived Skint-1 IgV structure 
has provided insights into the problems encountered during attempts at resolving the crystal 
structure of the DETC selecting molecule. Initial analysis of the Skint-1 IgV domain revealed 
insufficient chemical shift data for two distinct regions (S1 to A17 and R44 to F63), 
suggesting that these areas are extremely flexible. It is possible that, during the crystallisation 
process, these dynamic regions may have prevented close packing of the protein molecules 
and hence gave rise to Skint-1 IgV crystals that diffracted X-rays poorly and provided low 
resolution data (4Å). Comparison of the NMR derived Skint-1 IgV domain structure with the 
crystal structure of MOG indicated a possible explanation into the failure of molecular 
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replacement to determine initial phase information whilst using MOG as the phasing model. 
Indeed, in addition to the two flexible regions (S1-A17 and R44-F63), substantial differences 
in the conformation of several loops as well as secondary structural elements were observed, 
which may have interfered with the superimposition process and hence prevented structure 
determination using molecular replacement. 
 
One of the more remarkable features associated with proteins containing Ig domains is their 
significant variation in function, despite these proteins exhibiting a similar overall tertiary 
fold. Indeed, this also appears to be the case for Skint-1 when compared with its closest 
structural homologue, MOG. These comparisons have revealed several distinct structural 
features consistent with the fact that the biological role of MOG differs from Skint-1. Firstly, 
the crystal structure of MOG reveals a physiologically relevant dimeric species, consistent 
with previous biochemical evidence (Clements et al, 2003). In contrast, for Skint-1 the 
extension of C-C’ loop prevents the mode of dimerisation adopted by MOG, confirming that 
Skint-1 IgV domain exists as a monomeric form in solution as highlighted by the size 
exclusion profiles during purification. Secondly, comparison of surface electrostatic patterns 
of the IgV modules of Skint-1 and MOG highlighted several regions encompassing distinctive 
electronegative patches. Finally, in MOG the CDR-like loop regions combine to form a flat 
and uncharged surface, whereas an undulating and charged surface is formed in the equivalent 
region of Skint-1. Taken together, these diverse structural features reflect the unique 
biological function of Skint-1 relative to MOG. However, these observations are subject to 
one noteworthy caveat in that the MOG structure was resolved from a crystal structure 
(Clements et al, 2003) whereas the Skint-1 structure was derived from solution NMR data. 
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Recent data has indicated that Skint-1 plays a unique role in the positive selection and 
maturation of DETC progenitors. This is somewhat surprising since Skint-1 belongs to a 
family of genes of which there are currently 10 members that have been identified in the 
mouse genome. In addition, sequence alignment comparisons have revealed that a few of 
these family members bear a high degree (~80%) of sequence homology to Skint-1, namely 
Skint-2 and Skint-3. Initial experiments to assess whether Skint-2 or Skint-7 could substitute 
for Skint-1 activity in FVB.Tac RTOC revealed that neither family member could restore 
DETC progenitor maturation. Hence, Skint-1 has a unique and non-redundant role relative to 
Skint-2 and Skint-7. To determine regions that are essential for the non-redundant biological 
function of Skint-1 in mice, in vitro experiments involving domain swapping chimeras using 
Skint-1 and Skint-2 were performed (Barbee et al, 2011). Skint-2 was used in the domain 
swap chimeras because this gene is highly homologous to Skint-1 (~80%). These functional 
studies confirmed that each domain of Skint-1 was indispensable for conferring the 
maturation of the DETC subset. Further functional experiments in FVB.Tac RTOC with 
Skint-1 and Skint-2 chimeras highlighted that the amino terminal ten residues of the Skint-1 
IgC domain played a pivotal role in DETC progenitor maturation. (Barbee et al, 2011).  
 
To elucidate the molecular basis for a differential mode of ligand recognition between the 
Skint gene family members, I generated structural models of Skint-2 and Skint-7 using the 
solution structure of Skint-1 IgV as a template. Interestingly, the majority of the non-
conserved residues between these molecules were restricted to the surface of the IgV 
molecule. In addition, Skint-2 and Skint-7 exhibited a series of distinctive electropositive 
patches that were absent in Skint-1. Collectively, based on these observations it was 
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envisaged that Skint-2 and Skint-7 are not likely to bind the same ligands as Skint1 and hence 
perform distinct functions. 
 
More recently, an exciting prospect has involved attempting to further pinpoint the Skint-1 
ligand binding site. Indeed, functional assessment of Skint-1/Skint-2 CDR3-like loop swap 
chimeras in FVB.Tac RTOC have unequivocally demonstrated that the CDR3-like loop of 
Skint-1 is essential for conferring DETC selection (Personal communication Martin 
Woodward, Hayday laboratory). Notably, the CDR3-like regions of Skint-1 and Skint-2 are 
highly conserved with the exception of two residues at positions 105 and 107. In Skint-1, a 
pair of aspartic acid residues occupies positions 105 and 107, whereas in the corresponding 
region of Skint-2 there is a valine and glutamic acid. The solution structure of the Skint-1 IgV 
domain has shed light on the proposed role of D107 in conferring the unique biological 
function of Skint-1. Intriguingly, D107 in Skint-1 is highly prominent and solvent exposed, 
strongly suggestive of direct contact with its counter-receptor on the surface of DETCs. In 
contrast, the equivalent residue in Skint-2 is occupied by a longer side chain, E107, which 
presumably disrupts binding to a membrane bound receptor on the surface of DETCs. Based 
on my results, I therefore hypothesise this change in residue at position 107 could impact 
receptor docking. In addition, since Skint-7 encompasses two glycine residues at these critical 
positions, it is envisaged that the membrane-distal end of the IgV domain portrays a 
featureless surface to the counter receptor expressed on DETCs. Interestingly, there are 
several solvent exposed aromatic hydrophobic residues (F6, Y108 and Y109) in close 
proximity to the functionally significant CDR3-like region in Skint-1. Given that in most 
proteins hydrophobic residues are buried within the molecule, it raises the possibility that this 
group of solvent-accessible hydrophobes are functionally relevant. It is envisaged that these 
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non-polar aromatics together with the CDR3-like region could form a unique ligand binding 
site on Skint-1, as they are only present on Skint-1. To systematically evaluate whether any of 
these potential ligand binding residues are important in the selection of γδ DETCs, a series of 
Skint-1 variants each incorporating a specific point mutation could be generated and 
functionally assessed in FVB.Tac RTOC. This analysis would identify and define the limits of 
such functionally important ‘hot spot’ regions, and in doing so provide further insights into 
how Skint-1 recognition of an unidentified receptor(s) leads to the positive selection of 
DETCs. 
 
Another potentially striking structural feature of Skint-1 is the location and role of P5. This 
residue, which is present in the loop preceding the A strand, is in close proximity to the 
CDR3-like loop and the trio of solvent-exposed aromatic hydrophobes. It is hypothesised that 
the P5 in Skint-1 plays a critical structural role by changing the direction of the main chain 
away from the proposed ligand binding site. Notably, since the Proline residue is non-
conservatively substituted in the remaining members of the Skint family mouse genome, it 
provides a possible second mechanism underlying the non-redundant functionality of Skint-1. 
Hence, the lack of P5 in Skint-2 may allow the N-terminal loop to adopt a conformation such 
that it perturbs binding to the Skint-1 ligand binding partner on DETCs. To address the 
functional significance of P5 in Skint-1, there are several lines of investigation that could be 
undertaken. One possible approach is to generate a Skint-1 mutant construct at P5 and assess 
whether this mutation has an impact on the maturation of DETCs in FVB.Tac RTOC. 
However, it is important to consider that the generation of a construct encompassing a point 
mutation of this nature may alter the mechanical stability of the immunoglobulin module 
resulting in partial or total mis-folding of the protein. An alternative strategy is to determine 
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the solution structure of the Skint-2 IgV domain and compare the conformation of the loop 
preceding the A strand with the equivalent region of Skint-1. This type of approach would 
unequivocally address whether there are significant structural deviations within this region in 
other family members. In either event, these experiments would highlight whether P5 in 
Skint-1 promotes a distinct biological conformation, with obvious relevance for its role in the 
positive selection and maturation of DETCs. 
 
Unfortunately, it was not possible to validate the proposed ligand binding site, identified from 
the solution structure of IgV module, using several in silico protein prediction computational 
programmes. This underlines the overwhelming challenge in identifying ligand binding sites 
based solely on in silico prediction methods, despite the availability of a plethora of web-
based software programs. Nevertheless, the prediction program SPPIDER identified several 
additional regions as putative ligand binding sites. However, the majority of these were 
located close to the membrane-proximal region and most likely involved in stabilising the 
IgV-IgC domain interface. Intriguingly, previous functional experiments with FVB.Tac 
RTOC have demonstrated that the N-terminal amino acids of IgC are essential for DETC 
selection. With this in mind, it is conceivable that the regions identified by SPPIDER are 
critical for binding to the amino terminal 10 residue motif on the IgC domain.  
 
In summary, the solution structure of Skint-1 has identified a putative ligand binding site 
relevant to its function, however the receptor on the DETC surface that binds Skint-1 is yet to 
be defined. Strikingly, an obvious candidate that is repeatedly suggested is the Vγ5Vδ1 TCR 
expressed on the DETC subset. However, at present, this notion is unsupported by any direct 
evidence. To evaluate this hypothesis, direct protein-protein binding assays could be 
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performed using surface plasmon resonance or alpha screen technology. The alpha screen is a 
bead-based assay that has proven to be particularly useful for detection of weak bimolecular 
interaction between molecules. Although the question of whether the TCR is the receptor for 
Skint-1 remains ambiguous, the target molecule of Skint-1 is most likely unique to progenitor 
DETCs (Barbee et al, 2011). 
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Discussion 
The aim of this thesis was to carry out studies on both human Vδ2-negative TCRs, and also 
on the mouse candidate γδ TCR ligand Skint-1 molecule, in order to gain understanding on 
the molecular basis of γδ T cell recognition. In particular, the key human TCR that I focused 
on (LES, using Vγ4Vδ5) was derived from a T cell clone that expanded to high levels in a 
CMV-infected lung transplant patient. In Chapter 3, I successfully produced human 
recombinant γδ TCRs in an insect cell expression system. In contrast to attempts in E. coli, 
expression of the proteins as TCR-zipper proteins in Drosophila was highly successful, 
resulting in high quality recombinant receptor that was correctly folded. This step was crucial 
in enabling downstream BIAcore approaches to verify interaction with EPCR ligand, and also 
to determine the ligand binding mode. In addition, the yield of LES γδ receptor from the 
Drosophila system (~2mg/litre) was substantially higher than in previous work using mouse 
γδ TCRs. Although the reason for this is unclear, broadly similar yields were obtained for a 
second human Vδ2-negative receptor from the MAU clone, and this should in principle 
facilitate structural studies that can require large quantities of protein. Overall, it seems the 
Drosophila expression system is therefore likely to prove a highly useful system for obtaining 
recombinant TCRs to test interaction with candidate ligands, determine binding modes, and 
also potentially structural studies.  
 
Structural studies of γδ TCR/ligand interactions are a major aim in the field, and could 
establish the regions of the γ and δ chains that are involved in ligand binding (e.g. CDR1/2 
versus CDR3), which conceivably could help predict which portion of the γδ T cell repertoire 
is able to recognize specific ligands. My attempts to produce crystals of either the LES γδ 
TCR in isolation or in complex with EPCR, although unsuccessful, confirmed the yields of 
  264 
protein recovered for each protein from the Drosophila expression system were sufficient for 
numerous crystallization attempts. It is unclear why these crystal trials failed to reproducibly 
yield crystals, however several suggestions could be made for future attempts. In principle, 
glycosylation sites may inhibit crystallization, and these (either on EPCR or LES γδ TCR) 
could be mutated. Alternatively, crystallization “rescue” approaches (e.g. lysine methylation) 
have previously been employed to crystallise intransigent proteins (Walter et al, 2006), and 
these could be attempted. Conceivably the low affinity of the LES/EPCR interaction may 
hamper TCR/ligand complex crystallization. Use of high affinity EPCR mutants (as identified 
in Chapter 4) in crystal trials with native sequence LES γδ TCR might circumvent this issue, 
however unfortunately to date such forms of EPCR have proven less soluble than wild-type 
EPCR. Finally, alterations in crystal packing could potentially aid crystallization. This could 
involve either addition of an antibody against one of the proteins, or engineering additional 
domains (e.g. onto EPCR) to facilitate crystal packing. Clearly these attempts could 
collectively represent a major undertaking, but potentially the level of information gained 
about the LES/EPCR interaction could be very substantial. 
 
In principle, the use of recombinant γδ TCRs could also be extended beyond the uses 
mentioned above to ligand identification itself. By comparison, a range of cell surface 
receptors (e.g. CD48 family members, Podoplanin, other C-lectin receptors) have been used 
directly to help identify counter-ligands on the surface of target cells (Brown et al, 1998; 
Christou et al, 2008; Sancho et al, 2009) Conceivably, specific γδ TCRs could be produced in 
tetrameric/multimeric forms and stained against a panel of cell lines for which in-depth 
transcriptional analyses have been carried out. In principle, this could provide a direct read-
out for ligand expression, which could then be correlated with transcriptional data to derive a 
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set of candidate ligands for each TCR, to be subsequently confirmed or excluded by direct 
binding analyses. While this strategy is likely to be attempted in collaboration with Professor 
Simon Davis, several indications highlight it is likely to be technically challenging. In 
addition to the fact it has never been carried out before, as an example, the LES γδ TCR has 
proven impossible to use successfully in tetrameric/multimeric form for staining of EPCR-
expressing target cells. One potential reason for this could be the rather low affinity of the 
LES γδ TCR/EPCR interaction (see below). It is unclear whether this low affinity is unusual 
or not for human γδ TCR interactions. Moreover, the density of target γδ TCR antigen on 
target cells is likely to be variable, and low density ligands are likely to prove extremely 
challenging for TCR staining approaches, even though their expression might be sufficient for 
TCR activation, since T cells can be extremely sensitive to low levels of antigen. In my view, 
these attempts at direct recombinant TCR-based ligand identification are worthwhile but 
likely to be difficult, and alternative approaches such as blocking antibody generation (as for 
EPCR) (Willcox et al, 2012), and transcriptional approaches combined with activation assays 
of target cell recognition may be more productive routes forward.  
 
In Chapter 4, I focussed on determining the binding mode of the LES γδ TCR/EPCR 
interaction, following on from parallel work in the Willcox laboratory by Dr Carrie Willcox 
that identified EPCR as a direct LES γδ TCR ligand (Willcox et al, 2012). One of the reasons 
for investigating this was the observation that EPCR expression on the target cell surface was 
necessary but not sufficient for productive LES T cell recognition. Since EPCR can bind 
lipids in an analogous fashion to CD1 molecules (Oganesyan et al, 2002), a possible 
explanation for this was that EPCR acted as an antigen presentation molecule for LES γδ T 
cells, with relevant “stress lipids” only presented in sufficient quantities on activatory cells. 
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Despite the fact that analogous changes in sphingolipid metabolism have been noted in both 
CMV infection and transformation (Machesky et al, 2008; Oskouian et al, 2007; Oskouian et 
al, 2006)the results in Chapter 4 defined LES/EPCR interaction as independent of the EPCR-
bound lipid moiety. In addition they confirmed that, the interaction is independent of 
glycosylation but dependent on the conformation of the EPCR molecule (Willcox et al, 2012). 
These results suggest that rather than being recognized as an antigen presentation molecule, 
EPCR recognition by LES (and the activatory status of target cells) is dependent on the level 
of EPCR expression in combination with other factors extrinsic to EPCR. Of interest, the 
EPCR expression level on fibroblasts is unaffected by CMV infection, however experiments 
by Dr Déchanet-Merville’s laboratory confirmed that CMV infection does upregulate certain 
adhesion/costimulatory molecules, including in particular ICAM-1, and that these stimulate 
LES T cell recognition. In the context of cellular transformation, while EPCR was again 
necessary for productive LES T cell recognition, the level of EPCR expression did not 
correlate well with activatory status. However, a range of publications have highlighted 
upregulation of EPCR on transformed epithelial cells (Scheffer et al, 2002; Tsuneyoshi et al, 
2001; Anton et al, 2012) and unpublished data from the Willcox laboratory indicate 
upregulation in primary tumour tissue from a range of different cancers, suggesting increases 
in EPCR levels on tumours could be relevant to γδ T cell responses against tumours. 
 
While the antigenic specificity of the LES T cell clone appears to be relatively rare (since it 
has not been observed in other patients, although it was expanded to high levels in the patient 
from which it derived), it is tempting to speculate what the findings outlined above mean for 
γδ T cell responses in general. Firstly, the observation that EPCR is an endothelial protein 
suggests Vδ2-negative T cells, which expand considerably in CMV-infected patients, might 
  267 
use proteins such as EPCR to carry out immunosurveillance of the endothelium, which is a 
key site of CMV infection. For LES, it appears that the TCR ligand, EPCR, is constitutively 
present on endothelium, whereas altered expression of costimulatory molecules is crucial for 
stimulating γδ T cell effector responses. In this particular case, EPCR could therefore be 
viewed as just one part of a “multimolecular stress signature”. This raises many questions, 
including in particular whether other Vδ2-negative γδ T cells utilise a similar mechanism 
(involving TCR recognition of self-antigens) to survey the endothelium for signs of viral 
infection. If so, LES γδ TCR could potentially provide a paradigm for many other γδ TCR 
reactivities used in CMV infection, even if the target antigens may be different, and possibly 
diverse. In keeping with  with my  observations and with this suggestion, are findings from a 
number of studies in mice, that indicate γδ T cells do not undergo stringent negative selection 
during thymic development (unlike αβ T cells), consistent with the possibility of self-antigen 
recognition in the periphery (Crowley et al, 2000) An alternative to this model of self-antigen 
recognition might be that during CMV infection, a portion of the γδ T cell repertoire could 
make responses to infected cells by directly recognizing viral proteins expressed at the 
surface, using their γδ TCR. While such responses would not help explain the observed dual 
reactivity of CMV-reactive Vδ2-negative T cells to tumour cells, consistent with this 
suggestion is a recent study by Chien and colleagues, who explored γδ T cell recognition of 
an algal protein (phycoerythrin, PE), concluding that specific CDR3 sequences in both the γ 
and δ chain can confer reactivity to PE, in the context of multiple different Vγ and Vδ regions 
(Zeng et al, 2012). Clearly many further studies are required to shed light on both of these 
potential models. However, irrespective of the molecular targets recognized by their TCRs, 
the potent effector functions of Vδ2-negative γδ T cells suggest they may play an important 
role in controlling CMV infection in vivo, particularly when αβ responses are compromised. 
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Defining the costimulatory ligands involved in stimulating γδ T cells in such contexts is also 
an area for additional study, although the experiments mentioned in Chapter 4 by Dr 
Déchanet’s laboratory have already highlighted ICAM-1 as potentially important.  
 
In addition to CMV infection, it is interesting to speculate on the specific and general 
relevance of EPCR recognition by LES in the context of anti-tumour immune responses. 
Previous work from Dr Déchanet-Merville’s laboratory highlighted that renal transplant 
patients with CMV-induced expansions of the Vδ2-negative repertoire have significantly 
lower rates of post-transplant skin cancer, suggesting a possible role in tumour 
immunosurveillance (Couzi et al, 2010). In this context, the range of cellular targets 
recognized by γδ T cells, and their relationship to tumourigenesis, is of major interest. 
Conceivably EPCR might simply play a role for the immune system in this context, by 
analogy to NKG2D ligands to which it is homologous. However, its widespread upregulation 
in a number of tumours suggests its aberrant expression on tumour cells might be helpful to 
the tumour in some way. Of relevance is the normal physiological role of EPCR on 
endothelium, which is not only to suppress coagulation (by binding to Activated Protein C), 
but also to protect the endothelium from insults, such as p53-mediated apoptosis induced by 
hypoxia (Cheng et al, 2003). Given this, it is possible that aberrant EPCR expression on 
tumour cells enables them to evade apoptosis, and possibly to circumvent key stresses in the 
tumour microenvironment – such as pro-hypoxic stimuli. These ideas are the subject of 
ongoing work in the Willcox laboratory. 
 
In Chapters 5 and 6, I attempted structural studies on Skint-1, the prototypic member of a 
multiprotein family that bears homology to both the butyrophilin and B7 families. Skint-1, the 
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gene for which was discovered following its serendipitous mutation in strains of Tacoma 
mice, was found to play a critical role in the selection of mouse Vγ5Vδ1 intraepithelial 
lymphocytes, typically referred to as Dendritic Epidermal T cells (DETC), whereas selection 
of other γδ T cell subsets was independent of Skint-1 (Boyden et al, 2008). In addition, since 
other Skint family members cannot substitute for Skint-1 expression in RTOC models of 
DETC maturation, it appears that the role of Skint-1 is non-redundant (Barbee et al, 2011). 
These data, together with its essential expression in the thymus on epithelium, and presence in 
the periphery on keratinocytes, establish Skint-1 is a candidate ligand for the Vγ5Vδ1 TCR. 
Moreover, recent studies suggest that the Vγ5Vδ1 TCR expressed on DETC may be involved 
in engagement of ligands constitutively expressed on the surface of keratinocytes prior to 
stress induction, consistent with the properties of Skint-1 (Chodaczek et al, 2012). The aim of 
Chapters 5 and 6 was to start to define the molecular features of Skint-1, with a view to 
understanding its functions at a molecular level. Although a structure determination of the two 
immunoglobulin-like ectodomains of Skint-1 proved impossible, experiments in Chapter 5 
indicated that the membrane-distal Ig variable-like domain (IgV) could be produced in 
quantities sufficient for structural studies using X-ray crystallography and Nuclear Magnetic 
Resonance (NMR). Despite crystallizing the Skint-1 IgV domain, the crystals diffracted to 
low resolution (4Å), preventing structure determination using X-ray Crystallography.  
However, the structure of the membrane-distal domain of Skint-1 was successfully 
determined in solution using NMR.  
 
While the solution structure of Skint-1 IgV inevitably only provides quite limited information, 
a few key conclusions can be drawn from this study. Firstly, the structure reveals several 
differences compared to homologues, a key comparison being with Myelin Oligodendrocyte 
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Glycoprotein (MOG), itself a homolog of the butyrophilins. This revealed two sizeable 
regions of high flexibility, as well as secondary structural differences, including a loop that is 
important in mediating dimerisation of MOG, but whose conformation in Skint-1 prevents 
dimerisation, consistent with size exclusion experiments that indicate the Skint-1 IgV domain  
is monomeric in solution. Secondly, comparisons with key family members provided two key 
insights. An initial point is that most of the amino acid differences between Skint-1, 2 and 7 
are located at solvent-exposed residues. Consequently, the structure of Skint-1 IgV represents 
a first order mode of the IgV domain of both Skint-2  and Skint-7. However, an additional 
point is that despite a similar overall architecture for these domains, the nature of the solvent 
exposed changes suggested highly distinct electrostatic surfaces, with Skint-1 far less 
electropositive than these other two family members. A third key outcome of these structural 
studies, based on the fact that some residues identified from RTOC experiments as critical to 
Skint-1 function are entirely solvent exposed, is the identification of a putative binding site on 
the Skint-1 surface. Consistent with the non-redundant role of Skint-1 in mediating DETC 
maturation, the region involved contained several Skint-1-specific features, including a 
critical amino acid (D107), a distinctive hydrophobic patch, and a key proline residue. While 
not conclusive, these features are highly suggestive of a Skint-1-specific interaction with a 
counter-receptor.  
 
While these data are interesting, and outline molecular features that may in time prove key to 
Skint-1’s non-redundant function, they inevitably leave our picture of Skint-1 incomplete. 
This is emphasized partly by the results of RTOC experiments that highlight several other 
regions of the Skint-1 molecule (including the IgC-like domain, and the region just N-
terminal of it) as critical to its function (Barbee et al, 2011). Undoubtedly lacking is a clear 
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understanding of the mechanism whereby Skint-1 mediates maturation of the DETC subset; a 
significant advance would be to know if Skint-1 is the ligand for the Vγ5Vδ1 TCR. Although 
this was beyond the scope of this thesis due to time constraints, these experiments are 
ongoing, using both BIAcore and Alphascreen approaches, and TCR expression methods 
similar to those described in Chapter 3. In addition, other questions, such as whether Skint-1 
functions alone or in a multimolecular complex, also remain unresolved. DETC remain a 
highly intriguing example of tissue-resident γδ T cells, and their apparently constitutive 
recognition of TCR ligands on the surface of keratinocytes potentially represents a novel 
paradigm in γδ recognition of cellular stress. Clearly many further studies are required to 
outline the molecular details involved, and how these processes compare with human γδ T 
cell stress surveillance.  
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Appendix II 
Residue  
Number 
Chemical Shift (ppm) 
CD CD1 CD2 CE CE1 CE2 CE3 CG CG1 CG2 CH2 CZ CZ3 
M1 - - - - - - - - - - - - - 
S2 - - - - - - - - - - - - - 
S3 - - - - - - - - - - - - - 
E4 - - - - - - - - - - - - - 
P5 50.08 - - - - - - 27.46 - - - - - 
F6 - 133.3 133.3 - 131.5 131.6 - - - - - 130.2 - 
I7 - 14.04 - - - - - - 26.9 18.6 - - - 
V8 - - - - - - - - 24.46 22.22 - - - 
N9 - - - - - - - - - - - - - 
G10 - - - - - - - - - - - - - 
L11 - 26.08 22.78 - - - - - - - - - - 
E12 - - - - - - - 36.4 - - - - - 
G13 - - - - - - - - - - - - - 
P14 50.52 - - - - - - 25.3 - - - - - 
V15 - - - - - - - - 22.5 21.1 - - - 
L16 - 25.04 23.86 - - - - 27.78 - - - - - 
A17 - - - - - - - - - - - - - 
S18 - - - - - - - - - - - - - 
L19 24.94 25.18 25.09 - - - - 26.87 - - - - - 
G20 - - - - - - - - - - - - - 
G21 - - - - - - - - - - - - - 
N22 - - - - - - - - - - - - - 
L23 - 24.11 26.84 - - - - - - - - - - 
E24 - - - - - - - 37.14 - - - - - 
L25 - 24.22 26.31 - - - - 26.72 - - - - - 
S26 - - - - - - - - - - - - - 
C27 - - - - - - - - - - - - - 
Q28 - - - - - - - 32.97 - - - - - 
L29 - 23.01 26.25 - - - - 25.52 - - - - - 
S30 - - - - - - - - - - - - - 
P31 48.95 - - - - - - 26.46 - - - - - 
P32 50.6 - - - - - - 27.88 - - - - - 
Q33 - - - - - - - 33.33 - - - - - 
Q34 - - - - - - - 34.63 - - - - - 
A35 - - - - - - - - - - - - - 
Q36 - - - - - - - - - - - - - 
H37 - - - - - - - - - - - - - 
M38 - - - - - - - - - - - - - 
E39 - - - - - - - 37.98 - - - - - 
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I40 - 26.23 - - - - - - 14.75 15.9 - - - 
R41 42.91 - - - - - - 28.33 - - - - - 
W42 - 127.9 - - - - 120.1 - - - 122.4 - 122.5 
F43 - 132.2 132.2 - 129.8 129.8 - - - - - 128.4 - 
L53 - 24.05 26.15 - - - - 27.86 - - - - - 
Y54 - 133.9 133.8 - 117.8 117.8 - - - - - - - 
R55 43.9 - - - - - - 27.67 - - - - - 
D56 - - - - - - - - - - - - - 
G57 - - - - - - - - - - - - - 
K58 29.08 - - 42.14 - - - 24.01 - - - - - 
D59 - - - - - - - - - - - - - 
M60 - - - - - - - - - - - - - 
F61 - - - - - - - - - - - - - 
G62 - - - - - - - - - - - - - 
E63 - - - - - - - 36.78 - - - - - 
I64 - 13.78 - - - - - - - 17.57 - - - 
I65 - 13.98 - - - - - - 26.5 18.34 - - - 
S66 - - - - - - - - - - - - - 
K67 29.31 - - 42.14 - - - 24.91 - - - - - 
Y68 - 132.6 132.6 - 119.7 119.7 - - - - - - - 
E70 - - - - - - - - - - - - - 
R71 - - - - - - - - - - - - - 
T72 - - - - - - - - - 22.88 - - - 
E73 - - - - - - - 35.96 - - - - - 
L74 - 26.08 24.21 - - - - 26.96 - - - - - 
L75 - 23.17 24.53 - - - - 27.44 - - - - - 
K76 29.24 - - 42.43 - - - 24.69 - - - - - 
D77 - - - - - - - - - - - - - 
G78 - - - - - - - - - - - - - 
I79 - 14.39 - - - - - - 31.75 17.45 - - - 
G80 - - - - - - - - - - - - - 
E81 - - - - - - - 36.67 - - - - - 
G82 - - - - - - - - - - - - - 
K83 29.77 - - 42.3 - - - 25.36 - - - - - 
V84 - - - - - - - - 19.36 22.59 - - - 
T85 - - - - - - - - - 20.77 - - - 
L86 - 25.25 26.06 - - - - 23.51 - - - - - 
R87 44.3 - - - - - - 27.07 - - - - - 
I88 - 14.64 - - - - - - 27.33 17.55 - - - 
F89 - - - - - - - - - - - - - 
N90 - - - - - - - - - - - - - 
V91 - - - - - - - - 22.78 20.63 - - - 
T92 - - - - - - - - - 21.44 - - - 
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V93 - - - - - - - - 21.49 20.32 - - - 
D94 - - - - - - - - - - - - - 
D95 - - - - - - - - - - - - - 
D96 - - - - - - - - - - - - - 
G97 - - - - - - - - - - - - - 
S98 - - - - - - - - - - - - - 
Y99 - 132 132 - 117.2 117.2 - - - - - - - 
H100 - - - - - - - - - - - - - 
C101 - - - - - - - - - - - - - 
V102 - - - - - - - - 22.18 21.73 - - - 
F103 - 133.1 133.1 - 132.9 132.9 - - - - - - - 
K104 30.41 - - 42.52 - - - 25.1 - - - - - 
D105 - - - - - - - - - - - - - 
G106 - - - - - - - - - - - - - 
D107 - - - - - - - - - - - - - 
F108 - 131.9 131.9 - 131.9 131.9 - - - - - - - 
Y109 - - - - - - - - - - - - - 
E110 - - - - - - - 37.55 - - - - - 
E111 - - - - - - - 34.14 - - - - - 
H112 - - - - - - - - - - - - - 
I113 - 14.56 - - - - - - 27.46 17.84 - - - 
T114 - - - - - - - - - 21.91 - - - 
E115 - - - - - - - 35.76 - - - - - 
V116 - - - - - - - - 22.23 24.31 - - - 
K117 28.88 - - 42.15 - - - 24.84 - - - - - 
I118 - 12.3 - - - - - - 28.27 18.03 - - - 
T119 - - - - - - - - - 22.1 - - - 
V121 - - - - - - - - - - - - - 
Chemical shift data from all assignment experiments for the backbone and sidechain residues 
of Skint1 IgV 
